Page last updated: 2024-10-24

celecoxib and Edema

celecoxib has been researched along with Edema in 178 studies

Edema: Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.

Research Excerpts

Excerpt	Relevance	Reference
" The aim of this study was to compare the efficacy and safety profiles of pelubiprofen with those of celecoxib in patients with rheumatoid arthritis."	9.19	Comparison of the efficacy and safety profiles of a pelubiprofen versus celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, phase III, non-inferiority clinical trial. ( Baek, HJ; Cho, CS; Choi, IA; Chung, WT; Kang, SW; Kim, HA; Lee, J; Lee, SS; Lee, YA; Lee, YJ; Park, YB; Park, YE; Song, JS; Song, YW; Yoo, WH, 2014)
" This study evaluated the effects of celecoxib 200 mg/day and rofecoxib 25 mg/day on blood pressure (BP) and edema in a 6-week, randomized, parallel-group, double-blind study in patients > or =65 years of age with osteoarthritis who were treated with fixed antihypertensive regimens."	9.10	Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. ( Bello, AE; Fort, JG; Puma, JA; Whelton, A; White, WB, 2002)
" In the present study, we report the nanoconjugates of mercaptopropionic acid- (MPA-) capped CdTe quantum dots (QDs) and Celecoxib for bio-imaging in carrageenan-induced mouse paw edema model of inflammation."	7.88	Synthesis, Characterization, and Biodistribution of Quantum Dot-Celecoxib Conjugate in Mouse Paw Edema Model. ( Jain, S; Kalangi, SK; Narayana Rao, D; Reddanna, P; Sathyavathi, R; Swarnakar, NK, 2018)
"Lornoxicam exhibits strong analgesic but weak antipyretic effects in rats with paw inflammation."	7.75	The importance of brain PGE2 inhibition versus paw PGE2 inhibition as a mechanism for the separation of analgesic and antipyretic effects of lornoxicam in rats with paw inflammation. ( Arai, I; Futaki, N; Harada, M; Hashimoto, Y; Honma, Y; Hoshi, K; Nakaike, S; Sugimoto, M, 2009)
"NAF and plasma samples were collected before, 2 weeks after taking celecoxib 400 mg bid, and two weeks after washout from 26 women who were at increased breast cancer risk."	7.73	Celecoxib decreases prostaglandin E2 concentrations in nipple aspirate fluid from high risk postmenopausal women and women with breast cancer. ( Flynn, JT; Hewett, JE; Qin, W; Sauter, ER; Schlatter, L, 2006)
"Rofecoxib, but not celecoxib and NS NSAID, is associated with an increased risk of edema and blood pressure increase compared to nonusers of NSAID."	7.72	Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. ( Pettitt, D; Wolfe, F; Zhao, S, 2004)
"For a 100,000-member Medicare Choice population, an estimated 25,630 persons would have OA and hypertension (stages I-III), and an estimated 5126 of these patients would use celecoxib or rofecoxib."	7.72	A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population. ( Becker, RV; Burke, TA; McCoy, MA; Trotter, JP, 2003)
"This study evaluates the action of celecoxib and rofecoxib, two selective cyclooxygenase-2 (COX-2) inhibitors in two acute models of inflammation, carrageenan (Cg)-induced rat pleurisy, and paw oedema formation."	7.71	Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation. ( Calixto, JB; Pinheiro, RM, 2002)
" The aim of this study was to compare the efficacy and safety profiles of pelubiprofen with those of celecoxib in patients with rheumatoid arthritis."	5.19	Comparison of the efficacy and safety profiles of a pelubiprofen versus celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, phase III, non-inferiority clinical trial. ( Baek, HJ; Cho, CS; Choi, IA; Chung, WT; Kang, SW; Kim, HA; Lee, J; Lee, SS; Lee, YA; Lee, YJ; Park, YB; Park, YE; Song, JS; Song, YW; Yoo, WH, 2014)
"The cardiorenal safety database from the Celecoxib Long-term Arthritis Safety Study (CLASS) was analyzed to examine whether supratherapeutic doses of celecoxib are associated with decreased renal function and blood pressure (BP) effects compared with standard doses of diclofenac and ibuprofen in osteoarthritis (OA) and rheumatoid arthritis (RA) patients."	5.12	Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen. ( Lefkowith, JL; Verburg, KM; West, CR; Whelton, A, 2006)
" This study evaluated the effects of celecoxib 200 mg/day and rofecoxib 25 mg/day on blood pressure (BP) and edema in a 6-week, randomized, parallel-group, double-blind study in patients > or =65 years of age with osteoarthritis who were treated with fixed antihypertensive regimens."	5.10	Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. ( Bello, AE; Fort, JG; Puma, JA; Whelton, A; White, WB, 2002)
"The novel cyclooxygenase- (COX)-2 inhibitor celecoxib is an effective treatment for the signs and symptoms of osteoarthritis and rheumatoid arthritis."	4.80	Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. ( Geis, GS; Maurath, CJ; Verburg, KM; Whelton, A, 2000)
"These cases revealed that low-dose celecoxib may be an effective management for symptoms caused by perihematomal edema in patients with ICH, particularly those involving the thalamus."	4.12	Improvement After Celecoxib Treatment in Patients with Thalamic Hemorrhage - A Case Report. ( Jeng, JS; Lin, YW; Tang, SC; Tsai, LK; Yeh, SJ, 2022)
" The acetylcholinesterase inhibitor (ACHEI); neostigmine, is known clinically for its analgesic effect in the perioperative phases proving high efficacy; besides possessing anti-inflammatory properties controlling immune cells and cytokine level."	4.02	The effective interplay of (non-) selective NSAIDs with neostigmine in animal models of analgesia and inflammation. ( Abdel-Bary, A; El-Tahan, RA; Gowayed, MA, 2021)
" Compounds that showed promising COX-2 selectivity were further subjected to in vivo anti-inflammatory screening applying formalin induced paw edema (acute model) and cotton-pellet induced granuloma (chronic model) assays using celecoxib and diclofenac sodium as reference drugs."	3.88	Design, synthesis and evaluation of some pyrazolo[3,4-d]pyrimidine derivatives bearing thiazolidinone moiety as anti-inflammatory agents. ( Ashour, HM; Fahmy, SM; Khalil, MA; Labouta, IM; Nassra, RA; Tageldin, GN, 2018)
" In the present study, we report the nanoconjugates of mercaptopropionic acid- (MPA-) capped CdTe quantum dots (QDs) and Celecoxib for bio-imaging in carrageenan-induced mouse paw edema model of inflammation."	3.88	Synthesis, Characterization, and Biodistribution of Quantum Dot-Celecoxib Conjugate in Mouse Paw Edema Model. ( Jain, S; Kalangi, SK; Narayana Rao, D; Reddanna, P; Sathyavathi, R; Swarnakar, NK, 2018)
" All synthesized new compounds along with compound III as a parent compound and Celecoxib as a reference, were assessed for their antiinflammatory activity both in-vivo and in-vitro using the formalin-induced hind paw edema method and inhibition of albumin denaturation and Red Blood Cells (RBCs) membrane stabilization, respectively."	3.88	Synthesis, In-vivo and In-vitro Anti-inflammatory Evaluation of some Novel Coumarin Derivatives. ( Al-Wabli, R; El-Haggar, R; Fouad, M, 2018)
" Amongst all the synthesized derivatives, compound 56 showed the significant anti-inflammatory activity in both rat paw edema models with very less ulcerogenic liability in comparison to standard diclofenac, celecoxib, and zileuton."	3.85	Design, synthesis, and biological evaluation of some novel indolizine derivatives as dual cyclooxygenase and lipoxygenase inhibitor for anti-inflammatory activity. ( Bandresh, R; Shrivastava, SK; Srivastava, P; Tripathi, A; Tripathi, PN, 2017)
" The compounds 3a, 3b, 3c, 3e, and 3f presented anti-hyperalgesic action, while the compounds 3a, 3c, 3d, 3f, and 3g exhibited anti-edematogenic effects, without causing locomotive disorders in animals, thus making them comparable to Celecoxib in an arthritic pain model."	3.81	Regioselectively controlled synthesis of 3(5)-(trifluoromethyl)pyrazolylbenzenesulfonamides and their effects on a pathological pain model in mice. ( Bonacorso, HG; Brusco, I; Canova, B; da Silva, TV; de Souza, ON; Dos Santos, JM; Lobo, MM; Machado, P; Martins, MA; Oliveira, SM; Timmers, LF; Zanatta, N, 2015)
" While all the compounds (20mg/kg) showed significant anti-inflammatory activity after 3h of inflammation induction (69-89%) as compared to celecoxib (80%), 1-(4-methanesulfonylphenyl)-5-(4-methylaminomethylphenyl)-3-trifluoromethyl-1H-pyrazole (12 a) was found to be the most effective one (89%)."	3.80	Synthesis of new 1-(4-methane(amino)sulfonylphenyl)-5-(4-substituted-aminomethylphenyl)-3-trifluoromethyl-1H-pyrazoles: a search for novel nitric oxide donor anti-inflammatory agents. ( Abdellatif, KR; Knaus, EE; Moawad, A, 2014)
" In particular, the glycine derivative proved to be extremely active in suppressing hyperalgesia and edema."	3.80	Enhancing the pharmacodynamic profile of a class of selective COX-2 inhibiting nitric oxide donors. ( Alfonso, S; Anzini, M; Battilocchio, C; Biava, M; Calderone, V; Colovic, M; Consalvi, S; Di Capua, A; Di Cesare Mannelli, L; Dovizio, M; Ghelardini, C; Giordani, A; Martelli, A; Patrignani, P; Persiani, S; Poce, G; Rossi, A; Sautebin, L; Testai, L, 2014)
"86% inhibition of edema at 5h) in comparison to celecoxib (51."	3.80	Synthesis, biological evaluation and docking analysis of 3-methyl-1-phenylchromeno[4,3-c]pyrazol-4(1H)-ones as potential cyclooxygenase-2 (COX-2) inhibitors. ( Grover, J; Jachak, SM; Kumar, V; Sobhia, ME, 2014)
"We previously reported that 2-fluoroloxoprofen has lower gastric ulcerogenic activity than loxoprofen, a nonsteroidal anti-inflammatory drug (NSAID) without selectivity for COX-2."	3.78	Synthesis and biological evaluation of derivatives of 2-{2-fluoro-4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid: nonsteroidal anti-inflammatory drugs with low gastric ulcerogenic activity. ( Asano, T; Ishihara, T; Miyata, K; Mizushima, T; Okamoto, Y; Otsuka, M; Suemasu, S; Tanaka, K; Yamakawa, N, 2012)
" Two compounds 2c and 2e showed good anti-inflammatory activity which is comparable to the reference drug celecoxib in carrageenan-induced rat paw edema bioassay and found safe from the point of view of ulcer induction."	3.77	Synthesis and biological evaluation of some new 2-pyrazolines bearing benzene sulfonamide moiety as potential anti-inflammatory and anti-cancer agents. ( Ahmad, S; Alam, MS; Bano, S; Javed, K; Rathish, IG; Singh, S, 2011)
"When compared to celecoxib, WIN-34B exhibited similar or better anti-nociceptive and anti-inflammatory activities in osteoarthritic animal models, which may become a potential novel treatment for osteoarthritis."	3.76	The analgesic and anti-inflammatory effect of WIN-34B, a new herbal formula for osteoarthritis composed of Lonicera japonica Thunb and Anemarrhena asphodeloides BUNGE in vivo. ( Cho, YB; Hur, J; Jung, I; Jung, KC; Kang, JY; Kang, M; Kim, KS; Kim, SH; Lee, JD; Lee, JH; Park, DS; Yoo, MC, 2010)
"Lornoxicam exhibits strong analgesic but weak antipyretic effects in rats with paw inflammation."	3.75	The importance of brain PGE2 inhibition versus paw PGE2 inhibition as a mechanism for the separation of analgesic and antipyretic effects of lornoxicam in rats with paw inflammation. ( Arai, I; Futaki, N; Harada, M; Hashimoto, Y; Honma, Y; Hoshi, K; Nakaike, S; Sugimoto, M, 2009)
" Additionally, LASSBio-1135 (3a) presented activity similar to celecoxib (1) regarding the reduction of the carrageenan-induced rat paw edema (33% of inhibition at 100 micromol/kg, po)."	3.75	Discovery of novel analgesic and anti-inflammatory 3-arylamine-imidazo[1,2-a]pyridine symbiotic prototypes. ( Barreiro, EJ; da Silva, LL; de Lima, CK; Fraga, CA; Lacerda, RB; Miranda, AL; Romeiro, NC, 2009)
"32%), which is comparable to that of celecoxib in the carrageenan-induced rat paw edema method."	3.74	Synthesis and biological evaluation of 2-trifluoromethyl/sulfonamido-5,6-diaryl substituted imidazo[2,1-b]-1,3,4-thiadiazoles: a novel class of cyclooxygenase-2 inhibitors. ( Anand, K; Boreddy, TS; Gadad, AK; Noolvi, MN; Palkar, MB; Wagwade, J, 2008)
" All the target compounds showed anti-inflammatory activity and three of them 3b, 3c and 4c surpassed that of indomethacin both locally and systemically in the cotton pellet granuloma and rat paw edema bioassay."	3.74	Synthesis and biological evaluation of some thiazolyl and thiadiazolyl derivatives of 1H-pyrazole as anti-inflammatory antimicrobial agents. ( Abdel Ghany, YS; Ashour, HM; Baraka, A; Bekhit, AA; Bekhit, Ael-D, 2008)
"Substituted thiazoles with different structural features were synthesized and screened for their anti-inflammatory activity in acute carrageenin induced rat paw edema model and chronic formalin induced rat paw edema model."	3.74	2-Amino-5-thiazolyl motif: a novel scaffold for designing anti-inflammatory agents of diverse structures. ( Franklin, PX; Nivsarkar, M; Padh, H; Pillai, AD; Rathod, PD; Sudarsanam, V; Vasu, KK; Yerande, S, 2008)
"NAF and plasma samples were collected before, 2 weeks after taking celecoxib 400 mg bid, and two weeks after washout from 26 women who were at increased breast cancer risk."	3.73	Celecoxib decreases prostaglandin E2 concentrations in nipple aspirate fluid from high risk postmenopausal women and women with breast cancer. ( Flynn, JT; Hewett, JE; Qin, W; Sauter, ER; Schlatter, L, 2006)
"0032 muM) and COX-2 selectivity (SI > 120 000), 14s exhibited moderate antiinflammatory activity compared to celecoxib in a carrageenan-induced rat paw edema assay."	3.72	Design, synthesis, and biological evaluation of 6-substituted-3-(4-methanesulfonylphenyl)-4-phenylpyran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors. ( Amini, M; Habeeb, AG; Knaus, EE; Li, H; Praveen Rao, PN, 2003)
"For a 100,000-member Medicare Choice population, an estimated 25,630 persons would have OA and hypertension (stages I-III), and an estimated 5126 of these patients would use celecoxib or rofecoxib."	3.72	A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population. ( Becker, RV; Burke, TA; McCoy, MA; Trotter, JP, 2003)
"The effect of valeryl salicylate (VS), an inhibitor of cyclooxygenase-1 (COX-1), was evaluated in arachidonic acid or croton oil-induced ear oedema and carrageenan-induced paw oedema in mice."	3.72	Effects of valeryl salicylate, a COX-1 inhibitor, on models of acute inflammation in mice. ( Brum-Fernandes, AJ; Peters, RR; Ribeiro-do-Valle, RM; Siqueira-Junior, JM, 2003)
"The anti-inflammatory activity of fluoxetine, a selective serotonin reuptake inhibitor (SSRI), was studied on the carrageenan-induced paw inflammation in the rat."	3.72	Studies on the anti-inflammatory effect of fluoxetine in the rat. ( Abdel-Salam, OM; Arbid, MS; Baiuomy, AR, 2004)
"In conscious rats celecoxib, indomethacin and acetylsalicylic acid significantly reduced the paw oedema induced by carrageenan."	3.72	Gastric effects of the selective cyclooxygenase-2 inhibitor, celecoxib, in the rat. ( Coppelli, G; Coruzzi, G; Guaita, E; Spaggiari, S, 2004)
"Rofecoxib, but not celecoxib and NS NSAID, is associated with an increased risk of edema and blood pressure increase compared to nonusers of NSAID."	3.72	Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. ( Pettitt, D; Wolfe, F; Zhao, S, 2004)
"The aim of this study was to describe physician-reported management of clinically significant edema and/or destabilized blood pressure in patients with osteoarthritis (OA) and hypertension when initiating therapy with rofecoxib or celecoxib."	3.71	Physician-reported management of edema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension. ( Bristol, S; Burke, TA; May, C; Osterhaus, JT; Wentworth, C; Whelton, A, 2002)
"This study evaluates the action of celecoxib and rofecoxib, two selective cyclooxygenase-2 (COX-2) inhibitors in two acute models of inflammation, carrageenan (Cg)-induced rat pleurisy, and paw oedema formation."	3.71	Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation. ( Calixto, JB; Pinheiro, RM, 2002)
" Adverse event frequency was higher with tanezumab than with NSAIDs and highest with combination therapy."	2.80	Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain. ( Brown, MT; Ekman, EF; Greenberg, HS; Schnitzer, TJ; Smith, MD; Spierings, EL; Verburg, KM; West, CR, 2015)
"Mechanical hyperalgesia, joint edema, leukocyte recruitment to the joint and damage to cartilage in experimental arthritis and cytotoxicity, spread of disease, phagocytic activity and nitric oxide (NO) and hydrogen peroxide production by macrophages were evaluated."	1.91	1,4-Diaryl-1,2,3-triazole neolignan-celecoxib hybrids inhibit experimental arthritis induced by zymosan. ( B Carvalho, D; Baroni, ACM; Bonfá, IS; Candeloro, L; das Neves, AR; Felipe, JL; Ferreira, GIS; Lencina, JS; Lossavaro, PKMB; Silva-Filho, SE; Souza, MIL; Toffoli-Kadri, MC, 2023)
" However, their long-term administration is associated with various side effects including gastrointestinal ulceration."	1.72	Nonacidic thiophene-based derivatives as potential analgesic and design, synthesis, biological evaluation, and metabolic stability study. ( El-Nassan, HB; Fahim, SH; Mahmoud, ST; Mikhail, DS, 2022)
"Celecoxib (CXB) is a widely used anti-inflammatory drug that also acts as a chemopreventive agent against several types of cancer, including skin cancer."	1.48	Liquid Crystalline Systems Based on Glyceryl Monooleate and Penetration Enhancers for Skin Delivery of Celecoxib: Characterization, In Vitro Drug Release, and In Vivo Studies. ( Borgheti-Cardoso, LN; Dante, MCL; Fantini, MCA; Lara, MG; Medina, WSG; Pierre, MBR; Praça, FSG, 2018)
"Celecoxib (CXB) has been explored as an anti-inflammatory or chemopreventive drug for topical treatment of skin diseases and cancer."	1.46	In Vitro and In Vivo Evaluation of DMSO and Azone as Penetration Enhancers for Cutaneous Application of Celecoxib. ( de Padula, M; Kibwila, DM; Lara, MG; Leitao, AC; Mata Dos Santos, HA; Padua, TA; Riemma Pierre, MB; Rosas, EC; Santos Pyrrho, AD; Senna, TD, 2017)
"Outcome measures were postsurgical pain at rest and during walking, consumption of opioids for pain rescue, knee swelling and knee range of motion, and complications."	1.46	Methylprednisolone reduces pain and decreases knee swelling in the first 24 h after fast-track unicompartmental knee arthroplasty. ( Hansen, TB; Munk, S; Rytter, S; Stilling, M, 2017)
" The lead compound demonstrated very good oral bioavailability in mice, slow metabolic degradation, modest distribution into the brain and a remarkable anti-inflammatory efficacy in carrageenan-induced mouse paw edema model."	1.40	Potent, orally available, selective COX-2 inhibitors based on 2-imidazoline core. ( Gavalas, A; Geronikaki, A; Hammock, B; Hwang, SH; Iurchenko, V; Ivanenkov, Y; Krasavin, M; Morisseau, C; Mujumdar, P; Sarnpitak, P; Zozulya, S, 2014)
" Finally, these compounds have shown efficacy when dosed orally in multiple acute and chronic prostaglandin and leukotriene dependent in vivo models."	1.35	Indole cytosolic phospholipase A2 alpha inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic acid, efipladib. ( Abraham, WM; Albert, L; Behnke, ML; Chen, L; Clark, JD; Donahue, F; Foley, MA; Goodwin, DG; Hegen, M; Hu, B; Hu, Y; Ipek, M; Keith, J; Kirincich, SJ; Ku, MS; Lee, KL; McKew, JC; Michalak, R; Murphy, EA; Nickerson-Nutter, CL; Ramarao, MK; Shen, MW; Sum, FW; Tam, S; Thakker, P; Thomason, J; Williams, C; Wooder, L; Wu, K; Xu, X, 2008)
" Recently, cardiotoxic effects associated with conventional modes of delivery of celecoxib have made it pertinent to develop alternate dosage forms capable of selectively delivering the drug topically to affected joints."	1.34	Niosomal gel for site-specific sustained delivery of anti-arthritic drug: in vitro-in vivo evaluation. ( Jain, S; Kaur, K; Sapra, B; Tiwary, AK, 2007)
"Paw edema and hyperalgesia were monitored from day zero to day 21 after induction as signs of arthritis development."	1.32	Role of endogenous glucocorticoids in hyperalgesia and edema in old arthritic rats. ( Alves, DL; Francischi, JN; Pereira, LS; Tatsuo, MA; Yokoro, CM, 2003)
"Acute inflammation was induced by subplantar injection of carrageenan (1%) in the rat hind paw."	1.32	The anti-inflammatory effects of the phosphodiesterase inhibitor pentoxifylline in the rat. ( Abdel-Salam, OM; Arbid, MS; Baiuomy, AR; El-Shenawy, SM, 2003)
"2."	1.31	Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation. ( Bakhle, YS; Chaves, CT; Ferreira-Alves, DL; Francischi, JN; Lima, AS; Moura, AC; Rocha, OA, 2002)
" Both exhibit good oral bioavailability and are potent in standard models of pain, fever, and inflammation yet have a much reduced effect on the GI integrity of rats compared to standard nonsteroidal antiflammatory drugs."	1.30	2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors. ( Black, WC; Brideau, C; Chan, CC; Charleson, S; Chauret, N; Claveau, D; Ethier, D; Gordon, R; Greig, G; Guay, J; Hughes, G; Jolicoeur, P; Leblanc, Y; Nicoll-Griffith, D; Ouimet, N; Prasit, P; Riendeau, D; Visco, D; Wang, Z; Xu, L, 1999)

Research

Studies (178)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (1.12)	18.2507
2000's	64 (35.96)	29.6817
2010's	87 (48.88)	24.3611
2020's	25 (14.04)	2.80

Authors

Authors	Studies
Black, WC	2
Brideau, C	2
Chan, CC	2
Charleson, S	2
Chauret, N	1
Claveau, D	1
Ethier, D	1
Gordon, R	2
Greig, G	1
Guay, J	1
Hughes, G	2
Jolicoeur, P	1
Leblanc, Y	1
Nicoll-Griffith, D	1
Ouimet, N	1
Riendeau, D	2
Visco, D	1
Wang, Z	2
Xu, L	1
Prasit, P	2
Talley, JJ	2
Brown, DL	1
Carter, JS	1
Graneto, MJ	1
Koboldt, CM	2
Masferrer, JL	2
Perkins, WE	1
Rogers, RS	1
Shaffer, AF	1
Zhang, YY	1
Zweifel, BS	2
Seibert, K	2
Inagaki, M	1
Tsuri, T	1
Jyoyama, H	1
Ono, T	1
Yamada, K	1
Kobayashi, M	1
Hori, Y	1
Arimura, A	1
Yasui, K	1
Ohno, K	1
Kakudo, S	1
Koizumi, K	1
Suzuki, R	1
Kawai, S	1
Kato, M	1
Matsumoto, S	1
Shin, SS	2
Noh, MS	3
Byun, YJ	1
Choi, JK	2
Kim, JY	2
Lim, KM	2
Ha, JY	2
Kim, JK	2
Lee, CH	1
Chung, S	3
Almansa, C	1
de Arriba, AF	1
Cavalcanti, FL	1
Gómez, LA	1
Miralles, A	1
Merlos, M	1
García-Rafanell, J	1
Forn, J	1
Habeeb, AG	2
Praveen Rao, PN	2
Knaus, EE	8
Hyup, YH	1
Kwan, JK	1
Kang, SH	1
Kyu, JK	1
Min, KM	1
Hoon, CH	1
Cromlish, W	1
Grimm, EL	1
Leger, S	1
Li, CS	1
Thérien, M	1
Xu, LJ	1
Pal, M	1
Madan, M	1
Padakanti, S	1
Pattabiraman, VR	1
Kalleda, S	1
Vanguri, A	1
Mullangi, R	1
Mamidi, NV	1
Casturi, SR	1
Malde, A	1
Gopalakrishnan, B	1
Yeleswarapu, KR	1
Amini, M	2
Li, H	1
Byun, Y	1
Lee, KW	1
Moh, JH	1
Jeong, YS	1
Choi, YH	1
Koh, HJ	1
Park, YH	1
Oh, YI	1
Rao, PN	2
Uddin, MJ	1
Chen, QH	1
Kaila, N	1
Janz, K	1
DeBernardo, S	1
Bedard, PW	1
Camphausen, RT	1
Tam, S	2
Tsao, DH	1
Keith, JC	1
Nickerson-Nutter, C	1
Shilling, A	1
Young-Sciame, R	1
Wang, Q	1
Franklin, PX	1
Pillai, AD	1
Rathod, PD	1
Yerande, S	1
Nivsarkar, M	2
Padh, H	1
Vasu, KK	2
Sudarsanam, V	2
Bekhit, AA	3
Ashour, HM	3
Abdel Ghany, YS	1
Bekhit, Ael-D	1
Baraka, A	1
Biava, M	5
Porretta, GC	3
Poce, G	4
Supino, S	2
Forli, S	2
Rovini, M	3
Cappelli, A	2
Manetti, F	3
Botta, M	3
Sautebin, L	6
Rossi, A	6
Pergola, C	4
Ghelardini, C	5
Vivoli, E	1
Makovec, F	3
Anzellotti, P	4
Patrignani, P	5
Anzini, M	5
Gadad, AK	1
Palkar, MB	2
Anand, K	1
Noolvi, MN	1
Boreddy, TS	2
Wagwade, J	1
Szabó, G	1
Fischer, J	1
Kis-Varga, A	1
Gyires, K	1
Abouzid, K	1
Bekhit, SA	1
McKew, JC	1
Lee, KL	1
Shen, MW	1
Thakker, P	1
Foley, MA	1
Behnke, ML	1
Hu, B	1
Sum, FW	1
Hu, Y	1
Chen, L	1
Kirincich, SJ	1
Michalak, R	1
Thomason, J	1
Ipek, M	1
Wu, K	1
Wooder, L	1
Ramarao, MK	1
Murphy, EA	1
Goodwin, DG	1
Albert, L	1
Xu, X	1
Donahue, F	1
Ku, MS	1
Keith, J	1
Nickerson-Nutter, CL	1
Abraham, WM	1
Williams, C	1
Hegen, M	1
Clark, JD	1
Vomero, S	1
Norcini, M	2
Giordani, A	4
Cirilli, R	1
Ferretti, R	1
Gallinella, B	1
La Torre, F	1
Chowdhury, MA	3
Abdellatif, KR	8
Dong, Y	3
Das, D	2
Suresh, MR	2
Rathish, IG	2
Javed, K	4
Ahmad, S	3
Bano, S	4
Alam, MS	6
Pillai, KK	2
Singh, S	3
Bagchi, V	1
Lacerda, RB	1
de Lima, CK	1
da Silva, LL	1
Romeiro, NC	1
Miranda, AL	1
Barreiro, EJ	2
Fraga, CA	1
Feng, Z	1
Chu, F	1
Guo, Z	2
Sun, P	1
Yu, G	1
Velázquez, C	1
Eissa, AA	1
Farag, NA	1
Soliman, GA	1
Koeberle, A	1
Haberl, EM	1
Dehm, F	1
Northoff, H	1
Troschuetz, R	1
Werz, O	1
Youssef, AM	1
White, MS	1
Villanueva, EB	1
El-Ashmawy, IM	1
Klegeris, A	1
da Silva, YK	1
Augusto, CV	1
de Castro Barbosa, ML	1
de Albuquerque Melo, GM	1
de Queiroz, AC	1
de Lima Matos Freire Dias, T	1
Júnior, WB	1
Lima, LM	1
Alexandre-Moreira, MS	1
Fahmy, HT	1
Rostom, SA	1
El-Din A Bekhit, A	1
Liu, W	1
Zhou, J	1
Bensdorf, K	1
Zhang, H	2
Liu, H	1
Wang, Y	1
Qian, H	1
Zhang, Y	2
Wellner, A	1
Rubner, G	1
Huang, W	1
Guo, C	1
Gust, R	1
Akhter, M	1
Akhter, N	1
Alam, MM	2
Zaman, MS	1
Saha, R	1
Kumar, A	2
Abdel-Aziz, AA	5
ElTahir, KE	5
Asiri, YA	3
El-Sayed, MA	1
Abdel-Aziz, NI	3
El-Azab, AS	4
Manivannan, E	2
Chaturvedi, SC	2
Battilocchio, C	2
Alfonso, S	2
Valenti, S	1
Giorgi, G	1
Calderone, V	2
Martelli, A	2
Testai, L	2
Papa, G	1
Di Cesare Mannelli, L	2
Bruno, A	1
Eleftheriou, P	1
Geronikaki, A	2
Hadjipavlou-Litina, D	1
Vicini, P	1
Filz, O	1
Filimonov, D	1
Poroikov, V	1
Chaudhaery, SS	1
Roy, KK	1
Saxena, AK	1
Shafi, S	3
Mulakayala, N	1
Mulakayala, C	1
Vanaja, G	1
Kalle, AM	2
Pallu, R	1
Yamakawa, N	1
Suemasu, S	1
Okamoto, Y	1
Tanaka, K	1
Ishihara, T	1
Asano, T	1
Miyata, K	1
Otsuka, M	1
Mizushima, T	1
Abbas, SE	1
Awadallah, FM	1
Ibrahin, NA	1
Said, EG	1
Kamel, GM	1
Hanna, MM	1
Yewale, SB	1
Ganorkar, SB	1
Baheti, KG	1
Shelke, RU	1
Al-Suwaidan, IA	2
Alanazi, AM	2
Al-Obaid, AM	2
Maarouf, AR	1
Abu El-Enin, MA	1
Haider, S	3
Hamid, H	3
Nargotra, A	1
Mahajan, P	1
Nazreen, S	3
Kharbanda, C	3
Ali, Y	3
Alam, A	1
Panda, AK	1
Irannejad, H	1
Kebriaieezadeh, A	1
Zarghi, A	1
Montazer-Sadegh, F	1
Shafiee, A	1
Assadieskandar, A	1
Consalvi, S	1
Di Capua, A	1
Persiani, S	1
Colovic, M	1
Dovizio, M	1
Lokwani, DK	1
Mokale, SN	2
Shinde, DB	1
Khalil, NA	1
Ahmed, EM	2
Mohamed, KO	2
Nissan, YM	4
Zaitone, SA	1
Abdel-Aziz, M	1
Beshr, EA	1
Abdel-Rahman, IM	1
Ozadali, K	1
Tan, OU	1
Aly, OM	1
Dube, PN	1
Bule, SS	1
Kumbhare, MR	1
Dighe, PR	1
Ushir, YV	1
Pyee, Y	1
Chung, HJ	1
Choi, TJ	1
Park, HJ	1
Hong, JY	1
Kim, JS	1
Kang, SS	1
Lee, SK	1
Mohammed, KO	1
Singhai, AS	1
Ronad, PM	1
Vishwanathswamy, AH	1
Veerapur, VP	1
Shaikh, MS	1
Rane, RA	1
Karpoormath, R	1
Dhulap, A	2
Hussain, F	2
Alam, P	1
Umar, S	2
Pasha, MA	1
Sarnpitak, P	1
Mujumdar, P	1
Morisseau, C	1
Hwang, SH	1
Hammock, B	1
Iurchenko, V	1
Zozulya, S	1
Gavalas, A	1
Ivanenkov, Y	1
Krasavin, M	1
Grover, J	1
Kumar, V	1
Sobhia, ME	1
Jachak, SM	1
Moawad, A	1
Rajanarendar, E	1
Rama Krishna, S	1
Nagaraju, D	1
Govardhan Reddy, K	1
Kishore, B	1
Reddy, YN	1
Lobo, MM	1
Oliveira, SM	1
Brusco, I	1
Machado, P	1
Timmers, LF	1
de Souza, ON	1
Martins, MA	1
Bonacorso, HG	1
Dos Santos, JM	1
Canova, B	1
da Silva, TV	1
Zanatta, N	1
Firke, SD	1
Bari, SB	1
Abdelgawad, MA	2
Labib, MB	1
Zidan, TH	1
Elshemy, HA	1
Alsayed, SS	1
Undare, SS	1
Valekar, NJ	1
Patravale, AA	1
Jamale, DK	1
Vibhute, SS	1
Walekar, LS	1
Kolekar, GB	1
Deshmukh, MB	1
Anbhule, PV	1
Abou-Zeid, LA	1
Ayyad, RR	1
Sun, J	1
Wang, S	1
Sheng, GH	1
Lian, ZM	1
Liu, HY	1
Zhu, HL	1
Banerjee, AG	1
Das, N	1
Shengule, SA	1
Sharma, PA	1
Srivastava, RS	1
Shrivastava, SK	2
Bai, R	1
Shi, Q	1
Liang, Z	1
Yoon, Y	1
Han, Y	1
Feng, A	1
Liu, S	1
Oum, Y	1
Yun, CC	1
Shim, H	1
Rathore, A	1
Sudhakar, R	1
Ahsan, MJ	1
Ali, A	1
Subbarao, N	1
Jadav, SS	1
Yar, MS	1
Li, J	1
Li, D	1
Xu, Y	1
Liu, X	1
Yang, H	1
Wu, L	1
Wang, L	1
Singh, J	1
Saini, V	1
Bansal, R	1
Khatri, CK	1
Indalkar, KS	1
Patil, CR	1
Goyal, SN	1
Chaturbhuj, GU	1
El-Miligy, MMM	1
Hazzaa, AA	1
El-Messmary, H	1
Nassra, RA	3
El-Hawash, SAM	1
Guan, LP	2
Xia, YN	1
Jin, QH	1
Liu, BY	1
Wang, SH	2
Chen, LZ	1
Sun, WW	1
Bo, L	1
Wang, JQ	1
Xiu, C	1
Tang, WJ	1
Shi, JB	1
Zhou, HP	1
Liu, XH	1
Srivastava, P	1
Bandresh, R	1
Tripathi, PN	1
Tripathi, A	1
Abdelall, EKA	2
Abdelhamid, AO	1
Azouz, AA	3
Kaur, A	1
Pathak, DP	1
Sharma, V	1
Wakode, S	1
Navarro, L	1
Rosell, G	1
Sánchez, S	1
Boixareu, N	1
Pors, K	1
Pouplana, R	1
Campanera, JM	1
Pujol, MD	1
Moraes, ADTO	1
Miranda, MDS	1
Jacob, ÍTT	2
Amorim, CADC	1
Moura, RO	1
Silva, SÂSD	1
Soares, MBP	1
Almeida, SMV	1
Souza, TRCL	1
Oliveira, JF	1
Silva, TGD	1
Melo, CML	1
Moreira, DRM	2
Lima, MDCA	1
Kassab, AE	1
El-Malah, AA	1
Hassan, MSA	1
Kumar, R	1
Saha, N	1
Purohit, P	1
Garg, SK	1
Seth, K	1
Meena, VS	1
Dubey, S	1
Dave, K	1
Goyal, R	1
Sharma, SS	1
Banerjee, UC	1
Chakraborti, AK	1
Jan, MS	1
Ahmad, A	1
Mahmood, F	1
Rashid, U	1
Abid, OU	1
Ullah, F	1
Ayaz, M	1
Sadiq, A	1
Maghraby, MT	1
Abou-Ghadir, OMF	1
Abdel-Moty, SG	1
Ali, AY	1
Salem, OIA	1
He, LY	1
Zhang, SS	1
Peng, DX	1
Al-Ostoot, FH	1
Grisha, S	1
Mohammed, YHE	1
Vivek, HK	1
Ara Khanum, S	1
Sagar, SR	1
Singh, DP	1
Das, RD	1
Panchal, NB	1
Kumari, P	1
Singh, P	1
Kaur, J	1
Bhatti, R	1
Said, MF	1
Georgey, HH	1
Mohammed, ER	1
Felipe, JL	2
Cassamale, TB	1
Lourenço, LD	1
Carvalho, DB	1
das Neves, AR	2
Duarte, RCF	1
Carvalho, MG	1
Toffoli-Kadri, MC	2
Baroni, ACM	2
Abdellatif, KRA	1
Elshemy, HAH	1
Philoppes, JN	1
Hassanein, EHM	1
Kahk, NM	1
Darwish, SA	1
El-Kerdawy, MM	1
Elsheakh, AR	1
Abdelrahman, RS	1
Shaldam, MA	1
Abdel-Aziz, HA	1
Hassan, GS	1
Ghaly, MA	1
Lin, YW	1
Yeh, SJ	1
Tang, SC	1
Tsai, LK	1
Jeng, JS	1
Mikhail, DS	1
El-Nassan, HB	1
Mahmoud, ST	1
Fahim, SH	1
Shaker, AMM	1
Shahin, MI	1
AboulMagd, AM	1
Abdel Aleem, SA	1
Abdel-Rahman, HM	1
Abou El Ella, DA	1
Syrova, GO	1
Savelieva, OV	1
Tishakova, TS	1
Lukіаnova, LV	1
Al-Sanea, MM	1
Hamdi, A	1
Brogi, S	1
S Tawfik, S	1
Othman, DIA	1
Elshal, M	1
Ur Rahman, H	1
Parambi, DGT	1
M Elbargisy, R	1
Selim, S	1
Mostafa, EM	1
Mohamed, AAB	1
Bonfá, IS	1
Lossavaro, PKMB	1
Lencina, JS	1
B Carvalho, D	1
Candeloro, L	1
Ferreira, GIS	1
Souza, MIL	1
Silva-Filho, SE	1
El-Saadi, MT	1
Elzayat, SG	1
Amin, NH	1
Oliveira, DH	1
Sousa, FSS	1
Birmann, PT	1
Alves, D	1
Jacob, RG	1
Savegnago, L	1
Shabaan, MA	1
Kamal, AM	1
Faggal, SI	1
Elsahar, AE	1
Khan, A	1
Diwan, A	1
Thabet, HK	1
Imran, M	1
El-Hazek, RMM	1
El-Sabbagh, WA	1
El-Hazek, RM	1
El-Gazzar, MG	1
Ragab, FAE	2
Mohammed, EI	1
Abdel Jaleel, GA	1
Selim, AAMAE	1
Mohamed, MFA	1
Marzouk, AA	1
Nafady, A	1
El-Gamal, DA	1
Allam, RM	1
Abuo-Rahma, GEA	1
El Subbagh, HI	1
Moustafa, AH	1
Gomes, FOS	1
de Miranda, MDS	1
de Almeida, SMV	1
da Cruz-Filho, IJ	1
Peixoto, CA	1
da Silva, TG	1
de Melo, CML	1
de Oliveira, JF	1
de Lima, MCA	1
Salem, MA	1
Ali, MM	1
Selim, AAMA	1
Gowayed, MA	1
Abdel-Bary, A	1
El-Tahan, RA	1
Nossier, ES	1
Fahmy, HH	1
Khalifa, NM	1
El-Eraky, WI	1
Baset, MA	1
Dante, MCL	1
Borgheti-Cardoso, LN	1
Fantini, MCA	1
Praça, FSG	1
Medina, WSG	1
Pierre, MBR	2
Lara, MG	3
Quiñones, OG	2
Hossy, BH	1
Padua, TA	2
Miguel, NCO	1
Rosas, EC	3
Ramos, MFS	1
Tageldin, GN	2
Fahmy, SM	2
Khalil, MA	2
Labouta, IM	2
Kalangi, SK	1
Swarnakar, NK	1
Sathyavathi, R	1
Narayana Rao, D	1
Jain, S	2
Reddanna, P	1
Al-Wabli, R	1
Fouad, M	1
El-Haggar, R	1
Salem, HF	1
Kharshoum, RM	1
Sayed, OM	1
Abdel Hakim, LF	1
Zlatanova, H	1
Vladimirova, S	1
Kostadinov, I	1
Delev, D	1
Deneva, T	1
Kostadinova, I	1
Bakr, RB	2
Ghoneim, AA	1
Ibrahim, TM	1
Yonezawa, Y	1
Kihara, T	1
Ibi, K	1
Senshu, M	1
Nejishima, H	1
Takeda, Y	1
Imai, K	1
Ogawa, H	1
Küçükgüzel, ŞG	1
Coşkun, İ	1
Aydın, S	1
Aktay, G	1
Gürsoy, Ş	1
Çevik, Ö	1
Özakpınar, ÖB	1
Özsavcı, D	1
Şener, A	1
Kaushik-Basu, N	1
Basu, A	1
Talele, TT	1
Mata dos Santos, HA	2
Kibwila, DM	2
Leitão, A	1
dos Santos Pyrrho, A	1
Pádula, Md	1
Pierre, MB	1
Maciel, IS	1
Silva, RB	1
Morrone, FB	1
Calixto, JB	2
Campos, MM	1
Schnitzer, TJ	1
Ekman, EF	1
Spierings, EL	1
Greenberg, HS	1
Smith, MD	1
Brown, MT	1
West, CR	2
Verburg, KM	3
Fetih, G	1
Fathalla, D	1
El-Badry, M	1
Choi, IA	1
Baek, HJ	1
Cho, CS	1
Lee, YA	1
Chung, WT	1
Park, YE	1
Lee, YJ	1
Park, YB	1
Lee, J	1
Lee, SS	1
Yoo, WH	1
Song, JS	1
Kang, SW	1
Kim, HA	1
Song, YW	1
Rytter, S	1
Stilling, M	1
Munk, S	1
Hansen, TB	1
Hochberg, MC	1
Martel-Pelletier, J	1
Monfort, J	1
Möller, I	1
Castillo, JR	1
Arden, N	1
Berenbaum, F	1
Blanco, FJ	1
Conaghan, PG	1
Doménech, G	1
Henrotin, Y	1
Pap, T	1
Richette, P	1
Sawitzke, A	1
du Souich, P	1
Pelletier, JP	1
Onuora, S	1
Xie, Z	1
Zhang, Z	1
Yu, S	1
Cheng, D	1
Han, C	1
Lv, H	1
Ye, F	1
Senna, TD	1
Leitao, AC	1
Santos Pyrrho, AD	1
de Padula, M	1
Riemma Pierre, MB	1
Inoue, N	1
Ito, S	1
Tajima, K	1
Nogawa, M	1
Takahashi, Y	1
Sasagawa, T	1
Nakamura, A	1
Kyoi, T	1
Futaki, N	1
Harada, M	1
Sugimoto, M	1
Hashimoto, Y	1
Honma, Y	1
Arai, I	1
Nakaike, S	1
Hoshi, K	1
Kang, M	1
Jung, I	1
Hur, J	1
Kim, SH	1
Lee, JH	1
Kang, JY	1
Jung, KC	1
Kim, KS	1
Yoo, MC	1
Park, DS	1
Lee, JD	1
Cho, YB	1
Mohy El-Din, MM	1
Senbel, AM	1
Bistawroos, AA	1
El-Mallah, A	1
Nour El-Din, NA	1
Abd El Razik, HA	1
Kellner, H	1
Ovais, S	1
Yaseen, S	1
Bashir, R	1
Rathore, P	1
Samim, M	1
Nair, V	1
Shamsher, AA	1
Charoo, NA	1
Rahman, Z	1
Kohli, K	1
Osterhaus, JT	1
Burke, TA	2
May, C	1
Wentworth, C	1
Whelton, A	4
Bristol, S	1
White, WB	1
Bello, AE	1
Puma, JA	1
Fort, JG	1
Francischi, JN	2
Chaves, CT	1
Moura, AC	1
Lima, AS	1
Rocha, OA	1
Ferreira-Alves, DL	1
Bakhle, YS	1
Yokoro, CM	1
Tatsuo, MA	1
Pereira, LS	1
Alves, DL	1
Pinheiro, RM	1
Abdel-Salam, OM	2
Baiuomy, AR	2
El-Shenawy, SM	1
Arbid, MS	2
Weaver, A	1
Alderman, M	1
Sperling, R	1
Becker, RV	1
McCoy, MA	1
Trotter, JP	1
Siqueira-Junior, JM	1
Peters, RR	1
Brum-Fernandes, AJ	1
Ribeiro-do-Valle, RM	1
Menozzi, G	1
Merello, L	1
Fossa, P	1
Mosti, L	1
Piana, A	1
Mattioli, F	1
Coppelli, G	1
Guaita, E	1
Spaggiari, S	1
Coruzzi, G	1
Wolfe, F	1
Zhao, S	1
Pettitt, D	1
Vajja, BN	1
Juluri, S	1
Kumari, M	1
Kole, L	1
Chakrabarti, R	1
Joshi, VD	1
Wormser, U	1
Langenbach, R	1
Peddada, S	1
Sintov, A	1
Brodsky, B	1
Nyska, A	1
Li, MH	2
Yin, LL	2
Cai, MJ	1
Zhang, WY	2
Huang, Y	1
Wang, X	1
Zhu, XZ	2
Shen, JK	2
Alhan, E	1
Kalyoncu, NI	1
Ercin, C	1
Kural, BV	1
Okumura, T	1
Murata, Y	1
Hizue, M	1
Matsuura, T	1
Naganeo, R	1
Kanai, Y	1
Murase, A	1
Sakakibara, A	1
Fujita, I	1
Nakao, K	1
Lefkowith, JL	1
Sauter, ER	1
Qin, W	1
Schlatter, L	1
Hewett, JE	1
Flynn, JT	1
Valat, JP	1
Deray, G	1
Héloire, F	1
Bijev, A	1
Yaneva, D	1
Bocheva, A	1
Stoev, G	1
Tessier, J	1
Green, C	1
Padgett, D	1
Zhao, W	1
Schwartz, L	1
Hughes, M	1
Hewlett, E	1
Joshi, M	1
Patravale, V	1
Jain, SK	1
Gupta, Y	1
Jain, A	1
Bhola, M	1
Baboota, S	1
Shakeel, F	1
Ahuja, A	1
Ali, J	1
Shafiq, S	1
Queiroz, AF	1
Moura, RM	1
Ribeiro, JK	1
Lyra, IL	1
Cunha, DC	1
Santos, EA	1
de-Sales, MP	1
Kaur, K	1
Sapra, B	1
Tiwary, AK	1
Smith, CJ	1
Muhammad, J	1
Shaffer, A	1
Isakson, PC	1
Wilgus, TA	1
Ross, MS	1
Parrett, ML	1
Oberyszyn, TM	1
Maurath, CJ	1
Geis, GS	1
Salam, OM	1

Clinical Trials (6)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY OF THE LONG-TERM ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB ALONE OR IN COMBINATION WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) VERSUS NSAIDS ALONE IN PATIENTS WITH OSTEOARTHRITIS[NCT00809354]	Phase 3	2,720 participants (Actual)	Interventional	2009-02-12	Terminated (stopped due to See termination reason in detailed description.)
A Randomized, Double-blind, Multicenter, Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. for Comparative Evaluation of Safety & Efficacy in Rheumatoid Arthritis Patients[NCT01781702]	Phase 3	120 participants (Actual)	Interventional	2010-10-31	Completed
The Effect of Preoperative Steroids Injection on Pain and Oedema After Total Knee Arthroplasty . A Double -Blinded Randomized Controlled Study.[NCT04084912]	Phase 3	86 participants (Anticipated)	Interventional	2020-01-01	Not yet recruiting
Efficacy of Steroids on Functional Outcomes After Musculoskeletal Injuries of the Hand[NCT05003596]	Phase 2/Phase 3	60 participants (Anticipated)	Interventional	2021-09-01	Not yet recruiting
Non-Inferiority Clinical Trial On The Efficacy And Safety Of Chondroitin Sulfate And Glucosamine Hydrochloride In Combination Versus Celecoxib In Patients With Knee Osteoarthritis[NCT01425853]	Phase 4	606 participants (Actual)	Interventional	2011-09-30	Completed
Cytokine Responses to Acute Inflammation in the Oral Surgery Model[NCT00006175]		160 participants	Observational	2000-08-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Percent Impairment While Working Due to Osteoarthritis at Week 24 Assessed Using Work Productivity and Activity Impairment Questionnaire- Specific Health Problem (WPAI-SHP): Baseline Observation Carried Forward (BOCF)

The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which a specified health problem affected work productivity and regular activities over the past 7 days. The questions are: Q1 = currently employed. Q2 = hours missed due to health problems. Q3 = hours missed other reasons. Q4 = hours actually worked. Q5 = degree health affected productivity while working (0-10 scale). Q6 = degree health affected regular activities (0-10 scale). Subscale scores are calculated: Percent impairment while working due to health problem: Q5/10. The computed percentage range for each sub-scale is 0-100, where higher numbers indicate greater impairment and less productivity. (NCT00809354)
Timeframe: Baseline, Week 24

Intervention	change in percent impairment (Mean)
Tanezumab 5 mg (Naproxen Exposure)	-11.90
Tanezumab 10 mg (Naproxen Exposure)	-11.68
Tanezumab 5 mg + Naproxen 500 mg	-5.51
Tanezumab 10 mg + Naproxen 500 mg	-13.00
Naproxen 500 mg	-7.35
Tanezumab 5 mg (Celecoxib Exposure)	-17.81
Tanezumab 10 mg (Celecoxib Exposure)	-13.01
Tanezumab 5 mg + Celecoxib 100 mg	-9.33
Tanezumab 10 mg + Celecoxib 100 mg	-9.63
Celecoxib 100 mg	-5.81

Change From Baseline in Percent Work Time Missed Due to Osteoarthritis at Week 24 Assessed Using Work Productivity and Activity Impairment Questionnaire- Specific Health Problem (WPAI-SHP): Baseline Observation Carried Forward (BOCF)

The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which a specified health problem affected work productivity and regular activities over the past 7 days. The questions (Q) are: Q1 = currently employed. Q2 = hours missed due to health problems. Q3 = hours missed other reasons. Q4 = hours actually worked. Q5 = degree health affected productivity while working (0-10 scale). Q6 = degree health affected regular activities (0-10 scale). Subscale scores are calculated: Percent work time missed due to health problem: Q2/(Q2+Q4). The computed percentage range for each sub-scale is 0-100, where higher numbers indicate greater impairment and less productivity. (NCT00809354)
Timeframe: Baseline, Week 24

Intervention	change in percent work time missed (Mean)
Tanezumab 5 mg (Naproxen Exposure)	-0.88
Tanezumab 10 mg (Naproxen Exposure)	0.04
Tanezumab 5 mg + Naproxen 500 mg	0.63
Tanezumab 10 mg + Naproxen 500 mg	-0.77
Naproxen 500 mg	1.11
Tanezumab 5 mg (Celecoxib Exposure)	-2.85
Tanezumab 10 mg (Celecoxib Exposure)	-0.42
Tanezumab 5 mg + Celecoxib 100 mg	1.51
Tanezumab 10 mg + Celecoxib 100 mg	-1.64
Celecoxib 100 mg	-0.61

Change From Baseline in the Percent Activity Impairment Due to Osteoarthritis at Week 24 Assessed Using Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP): Baseline Observation Carried Forward (BOCF)

The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which a specified health problem affected work productivity and regular activities over the past 7 days. The questions are: Q1 = currently employed. Q2 = hours missed due to health problems. Q3 = hours missed other reasons. Q4 = hours actually worked. Q5 = degree health affected productivity while working (0-10 scale). Q6 = degree health affected regular activities (0-10 scale). Subscale scores are calculated: Percent activity impairment due to health problem: Q6/10. The computed percentage range for each sub-scale is 0-100, where higher numbers indicate greater impairment and less productivity. (NCT00809354)
Timeframe: Baseline, Week 24

Intervention	change in percent activity impairment (Mean)
Tanezumab 5 mg (Naproxen Exposure)	-12.30
Tanezumab 10 mg (Naproxen Exposure)	-15.51
Tanezumab 5 mg + Naproxen 500 mg	-13.55
Tanezumab 10 mg + Naproxen 500 mg	-14.96
Naproxen 500 mg	-10.00
Tanezumab 5 mg (Celecoxib Exposure)	-17.24
Tanezumab 10 mg (Celecoxib Exposure)	-17.84
Tanezumab 5 mg + Celecoxib 100 mg	-18.04
Tanezumab 10 mg + Celecoxib 100 mg	-17.31
Celecoxib 100 mg	-11.90

Change From Baseline in the Percent Overall Work Impairment Due to Osteoarthritis at Week 24 Assessed Using Work Productivity and Activity Impairment Questionnaire- Specific Health Problem (WPAI-SHP): BOCF

The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which a specified health problem affected work productivity and regular activities over the past 7 days. The questions are: Q1 = currently employed. Q2 = hours missed due to health problems. Q3 = hours missed other reasons. Q4 = hours actually worked. Q5 = degree health affected productivity while working (0-10 scale). Q6 = degree health affected regular activities (0-10 scale). Subscale scores are calculated: Percent overall work impairment due to health problem: Q2/(Q2+Q4)+[(1-Q2/(Q2+Q4))*(Q5/10)]. The computed percentage range for each sub-scale is 0-100, where higher numbers indicate greater impairment and less productivity. (NCT00809354)
Timeframe: Baseline, Week 24

Intervention	change in percent work impairment (Mean)
Tanezumab 5 mg (Naproxen Exposure)	-5.40
Tanezumab 10 mg (Naproxen Exposure)	-1.46
Tanezumab 5 mg + Naproxen 500 mg	-0.75
Tanezumab 10 mg + Naproxen 500 mg	-1.35
Naproxen 500 mg	2.09
Tanezumab 5 mg (Celecoxib Exposure)	-10.17
Tanezumab 10 mg (Celecoxib Exposure)	-0.22
Tanezumab 5 mg + Celecoxib 100 mg	1.25
Tanezumab 10 mg + Celecoxib 100 mg	-4.30
Celecoxib 100 mg	-2.29

Number of Participants Who Had Discontinued Study Due to Lack of Efficacy

(NCT00809354)
Timeframe: Baseline up to Week 56

Intervention	Participants (Count of Participants)
Tanezumab 5 mg (Naproxen Exposure)	23
Tanezumab 10 mg (Naproxen Exposure)	23
Tanezumab 5 mg + Naproxen 500 mg	22
Tanezumab 10 mg + Naproxen 500 mg	15
Naproxen 500 mg	40
Tanezumab 5 mg (Celecoxib Exposure)	19
Tanezumab 10 mg (Celecoxib Exposure)	21
Tanezumab 5 mg + Celecoxib 100 mg	15
Tanezumab 10 mg + Celecoxib 100 mg	18
Celecoxib 100 mg	38

Number of Participants With Positive Urine or Serum Pregnancy Test

Female participants, who reported positive in urine or serum pregnancy test were reported. (NCT00809354)
Timeframe: Baseline up to Week 56

Intervention	Participants (Count of Participants)
Tanezumab 5 mg (Naproxen Exposure)	0
Tanezumab 10 mg (Naproxen Exposure)	1
Tanezumab 5 mg + Naproxen 500 mg	0
Tanezumab 10 mg + Naproxen 500 mg	0
Naproxen 500 mg	0
Tanezumab 5 mg (Celecoxib Exposure)	0
Tanezumab 10 mg (Celecoxib Exposure)	0
Tanezumab 5 mg + Celecoxib 100 mg	0
Tanezumab 10 mg + Celecoxib 100 mg	0
Celecoxib 100 mg	0

Time to Discontinuation Due to Lack of Efficacy

Time to discontinuation due to lack of efficacy was defined as the time interval from the date of study drug administration up to the date of discontinuation of participant from study due to lack of efficacy. (NCT00809354)
Timeframe: Baseline up to Week 56

Intervention	days (Mean)
Tanezumab 5 mg (Naproxen Exposure)	319.87
Tanezumab 10 mg (Naproxen Exposure)	331.69
Tanezumab 5 mg + Naproxen 500 mg	394.80
Tanezumab 10 mg + Naproxen 500 mg	271.89
Naproxen 500 mg	306.11
Tanezumab 5 mg (Celecoxib Exposure)	329.79
Tanezumab 10 mg (Celecoxib Exposure)	314.16
Tanezumab 5 mg + Celecoxib 100 mg	334.84
Tanezumab 10 mg + Celecoxib 100 mg	324.25
Celecoxib 100 mg	303.08

Amount of Rescue Medication Used

In case of inadequate pain relief for osteoarthritis, acetaminophen up to 4000 mg per day up to 3 days in a week could be taken as rescue medication. The total dosage of acetaminophen in mg used during the specified time intervals were summarized. (NCT00809354)
Timeframe: Weeks 1-2, 3-4, 5-8, 9-12, 13-16, 17-24, 25-32, 33-40, 41-48, and 49-56

,,,,,,,,,

Intervention	milligram (mg) (Mean)
	Weeks 1-2	Weeks 3-4	Weeks 5-8	Weeks 9-12	Weeks 13-16	Weeks 17-24	Weeks 25-32	Weeks 33-40	Weeks 41-48	Weeks 49-56
Celecoxib 100 mg	3455.85	3281.23	3182.45	3067.56	3269.78	2816.00	3126.26	3032.17	3101.63	3035.33
Naproxen 500 mg	3543.99	3415.52	2991.01	2919.20	2920.39	2759.90	2792.04	2755.66	2746.29	3106.46
Tanezumab 10 mg (Celecoxib Exposure)	3834.79	3769.17	2969.34	3008.85	2938.95	2725.86	2927.44	2976.37	3033.87	2770.28
Tanezumab 10 mg (Naproxen Exposure)	3365.46	3582.77	2875.55	2955.84	2912.14	2778.55	2824.83	2900.69	2906.70	2910.73
Tanezumab 10 mg + Celecoxib 100 mg	3250.69	3011.67	2223.15	2266.13	2486.23	2370.30	2723.26	2682.35	2618.83	2842.74
Tanezumab 10 mg + Naproxen 500 mg	3524.27	3066.65	2396.99	2415.93	2551.21	2261.93	2289.28	2361.40	2373.66	2545.36
Tanezumab 5 mg (Celecoxib Exposure)	3132.30	3255.16	2571.99	2380.78	2450.55	2261.84	2383.27	2449.87	2521.27	2840.21
Tanezumab 5 mg (Naproxen Exposure)	3144.66	3411.93	2846.58	2863.10	2993.63	2733.43	2823.39	2810.18	2927.31	2979.89
Tanezumab 5 mg + Celecoxib 100 mg	2910.68	2672.18	2140.44	2166.23	2244.74	2235.23	2432.81	2428.51	2408.58	2511.61
Tanezumab 5 mg + Naproxen 500 mg	2739.96	2660.11	2131.45	2291.41	2562.94	2525.71	2548.20	2608.91	2673.48	2938.47

Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24: Baseline Observation Carried Forward (BOCF)

The SF-36 health survey is a self-administered questionnaire that measures each of the following 8 health domains: domain 1= general health, domain 2= physical function, domain 3= role physical, domain 4= bodily pain, domain 5= vitality, domain 6= social function, domain 7= role emotional, domain 8= mental health. Total score for each domain are scaled 0 (minimum) to 100 (maximum), where higher scores represent better health status. (NCT00809354)
Timeframe: Baseline, Weeks 12 and 24

,,,,,,,,,

Intervention	units on a scale (Mean)
	General health at baseline	Physical function at baseline	Role physical at baseline	Bodily pain at baseline	Vitality at baseline	Social function at baseline	Role emotional at baseline	Mental health at baseline	Change at Week 12: General health	Change at Week 12: Physical function	Change at Week 12: Role physical	Change at Week 12: Bodily pain	Change at Week 12: Vitality	Change at Week 12: Social function	Change at Week 12: Role emotional	Change at Week 12: Mental health	Change at Week 24: General health	Change at Week 24: Physical function	Change at Week 24: Role physical	Change at Week 24: Bodily pain	Change at Week 24: Vitality	Change at Week 24: Social function	Change at Week 24: Role emotional	Change at Week 24: Mental health
Celecoxib 100 mg	55.69	32.81	43.55	36.96	51.52	64.31	63.39	69.08	4.68	7.48	7.58	8.01	2.43	3.33	4.13	0.67	3.90	8.00	7.70	8.72	2.87	4.07	2.23	0.00
Naproxen 500 mg	57.61	35.46	46.09	35.72	50.78	62.23	68.45	70.34	3.88	5.76	6.70	7.83	3.97	7.41	0.92	1.57	2.90	5.75	7.28	8.87	1.90	6.16	2.92	1.52
Tanezumab 10 mg (Celecoxib Exposure)	56.93	34.79	42.86	35.57	51.52	63.68	64.07	71.08	3.37	9.05	10.04	12.50	4.35	5.36	3.64	0.36	4.25	9.33	10.46	10.22	4.00	6.25	4.95	0.42
Tanezumab 10 mg (Naproxen Exposure)	57.41	32.74	43.88	35.90	51.28	65.97	66.35	70.23	4.66	12.88	12.59	13.08	5.14	5.25	5.50	3.28	2.95	9.50	7.42	9.63	3.93	3.21	0.58	1.48
Tanezumab 10 mg + Celecoxib 100 mg	58.27	35.11	45.60	36.47	53.63	66.90	65.05	71.07	5.66	12.99	13.71	16.83	6.47	8.94	6.82	3.17	4.28	12.00	10.50	13.47	4.15	5.78	3.39	0.87
Tanezumab 10 mg + Naproxen 500 mg	57.92	33.88	44.69	37.67	52.57	64.47	67.92	70.40	5.14	14.38	15.39	16.53	6.12	7.76	4.47	3.04	4.54	12.30	11.54	13.04	4.52	6.14	2.16	2.26
Tanezumab 5 mg (Celecoxib Exposure)	56.20	33.43	42.59	34.14	50.52	63.19	63.02	70.95	5.46	12.70	13.36	16.74	7.41	10.19	8.23	3.00	4.07	10.40	10.24	10.69	5.71	7.63	5.81	1.33
Tanezumab 5 mg (Naproxen Exposure)	56.76	32.82	43.29	36.91	51.58	65.63	66.08	70.42	3.29	11.68	9.73	11.44	5.68	5.90	5.08	2.85	3.08	10.52	9.40	10.73	5.94	4.01	3.35	2.31
Tanezumab 5 mg + Celecoxib 100 mg	56.34	33.41	42.65	34.11	51.45	64.51	62.68	68.25	5.18	13.84	15.51	17.15	6.32	8.14	8.63	3.78	3.46	11.83	10.93	14.02	2.84	7.06	6.47	0.94
Tanezumab 5 mg + Naproxen 500 mg	60.66	34.79	44.58	37.80	53.73	68.13	67.74	72.20	3.66	14.23	13.13	14.41	6.47	5.36	4.91	0.96	3.77	9.83	9.58	10.41	3.77	3.21	2.38	0.95

Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Weeks 12, 24, 40 and 56: Last Observation Carried Forward (LOCF)

,,,,,,,,,

Intervention	units on a scale (Mean)
	Change at Week 12: General health	Change at Week 12: Physical function	Change at Week 12: Role physical	Change at Week 12: Bodily pain	Change at Week 12: Vitality	Change at Week 12: Social function	Change at Week 12: Role emotional	Change at Week 12: Mental health	Change at Week 24: General health	Change at Week 24: Physical function	Change at Week 24: Role physical	Change at Week 24: Bodily pain	Change at Week 24: Vitality	Change at Week 24: Social function	Change at Week 24: Role emotional	Change at Week 24: Mental health	Change at Week 40: General health	Change at Week 40: Physical function	Change at Week 40: Role physical	Change at Week 40: Bodily pain	Change at Week 40: Vitality	Social function at Week 40	Change at Week 40: Role emotional	Change at Week 40: Mental health	Change at Week 56: General health	Change at Week 56: Physical function	Change at Week 56: Role physical	Change at Week 56: Bodily pain	Change at Week 56: Vitality	Change at Week 56: Social function	Change at Week 56: Role emotional	Change at Week 56: Mental health
Celecoxib 100 mg	4.68	7.48	7.58	8.01	2.43	3.33	4.13	0.67	4.45	8.41	8.27	9.09	2.40	3.97	2.76	0.20	4.09	7.24	7.58	8.17	2.67	2.65	3.41	0.82	3.99	6.91	7.28	8.69	2.08	2.84	3.51	0.96
Naproxen 500 mg	3.88	35.46	46.09	7.83	3.97	7.41	0.92	1.57	3.77	6.43	7.97	9.19	2.57	7.32	2.59	1.38	3.47	6.23	7.01	7.11	2.32	7.23	1.61	0.49	3.33	5.95	7.19	7.47	2.68	7.23	1.67	0.41
Tanezumab 10 mg (Celecoxib Exposure)	3.37	9.05	10.04	12.50	4.35	5.36	3.64	0.36	4.59	10.00	11.84	12.00	4.87	7.09	5.09	0.30	3.31	8.74	10.53	10.87	4.40	6.20	2.99	0.26	3.41	8.25	10.46	10.32	4.47	6.10	3.25	0.18
Tanezumab 10 mg (Naproxen Exposure)	4.66	32.74	43.88	13.08	5.14	5.25	5.50	3.28	3.18	11.35	9.53	11.63	4.34	3.56	1.56	1.51	2.45	10.23	8.79	10.73	3.30	3.21	1.91	1.41	2.31	9.19	8.01	10.21	3.10	2.95	1.53	1.42
Tanezumab 10 mg + Celecoxib 100 mg	5.66	12.99	13.71	16.83	6.47	8.94	6.82	3.17	4.62	12.91	12.45	14.83	4.50	6.57	4.58	1.06	3.45	11.78	12.13	13.28	4.17	6.23	5.47	1.11	3.75	11.48	12.06	13.36	4.15	6.67	5.07	1.25
Tanezumab 10 mg + Naproxen 500 mg	5.14	33.88	44.69	16.53	6.12	7.76	4.47	3.04	4.66	13.73	13.03	14.73	5.48	7.11	3.10	2.65	3.87	11.96	10.00	12.42	4.45	4.56	0.76	1.76	3.69	11.15	9.01	11.92	3.82	3.99	0.47	1.53
Tanezumab 5 mg (Celecoxib Exposure)	5.46	12.70	13.36	16.74	7.41	10.19	8.23	3.00	4.42	11.23	11.74	12.24	5.95	8.51	6.73	1.37	3.74	9.91	11.32	11.45	5.29	7.43	6.69	1.22	3.75	10.12	11.20	11.52	4.82	7.73	6.10	1.10
Tanezumab 5 mg (Naproxen Exposure)	3.29	32.82	43.29	11.44	5.68	5.90	5.08	2.85	3.95	11.70	11.14	12.95	7.17	5.19	5.22	2.90	3.40	10.00	9.64	11.27	5.92	4.05	4.08	2.16	3.12	9.95	9.13	11.58	5.70	4.53	4.23	2.28
Tanezumab 5 mg + Celecoxib 100 mg	5.18	13.84	15.51	17.15	6.32	8.14	8.63	3.78	3.72	12.92	11.84	15.22	3.09	7.35	6.83	1.39	3.20	12.32	12.38	13.96	3.24	6.03	5.98	1.22	3.10	12.07	11.96	13.53	3.41	6.23	6.11	1.47
Tanezumab 5 mg + Naproxen 500 mg	3.66	34.79	44.58	14.41	6.47	5.36	4.91	0.96	3.93	10.85	10.71	11.75	4.42	2.81	3.63	0.45	2.83	10.49	10.98	10.79	4.42	2.19	2.80	0.25	2.59	10.19	10.49	10.38	4.17	1.65	1.99	-0.11

Change From Baseline in Medial Minimum Joint Space Width of the Index Knee at Week 56

(NCT00809354)
Timeframe: Baseline, Week 56

,,,,

Intervention	millimeter (mm) (Mean)
	Baseline	Change at Week 56
NSAID	3.022	-0.041
Tanezumab 10 mg (Naproxen or Celecoxib Exposure)	2.850	-0.213
Tanezumab 10 mg + NSAID	2.982	-0.172
Tanezumab 5 mg (Naproxen or Celecoxib Exposure)	2.769	-0.189
Tanezumab 5 mg + NSAID	3.005	-0.162

Change From Baseline in Minimum Joint Space Width of the Index Hip at Week 56

(NCT00809354)
Timeframe: Baseline, Week 56

,,,,

Intervention	millimeter (Mean)
	Baseline	Change at Week 56
NSAID	2.724	-0.028
Tanezumab 10 mg (Naproxen or Celecoxib Exposure)	2.372	-0.137
Tanezumab 10 mg + NSAID	2.195	-0.136
Tanezumab 5 mg (Naproxen or Celecoxib Exposure)	2.447	-0.075
Tanezumab 5 mg + NSAID	2.346	-0.240

Change From Baseline in Neuropathy Impairment Score (NIS) at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)

The Neuropathy Impairment Score is the sum of scores over all 37 items from both the left and right side. The neurological impairment score assessed strength of groups of muscles of the head and neck, upper limbs and lower limbs, deep tendon reflexes and sensation (tactile, vibration, joint position sense, and pin prick) of index fingers and great toes through neurological examination. NIS calculated scoring muscle weakness (0=normal, 1=25% weak, 2=50% weak, 3=75% week, 3.25= move against gravity, 3.5=movement gravity eliminated, 3.75= muscle flicker no movement, 4=paralysis), scoring reflexes (0=normal, 1=reduced. 2=absent), scoring sensation (0=normal, 1=decreased, 2=absent). For NIS possible overall score (combined of both left and right sides of each domain), ranged from 0 (no impairment) to 244 (maximum impairment), higher scores indicated increased/more neuropathic deficits. (NCT00809354)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56

,,,,,,,,,

Intervention	units on a scale (Mean)
	Baseline	Change at Week 2	Change at Week 4	Change at Week 8	Change at Week 12	Change at Week 16	Change at Week 24	Change at Week 32	Change at Week 40	Change at Week 48	Change at Week 56
Celecoxib 100 mg	2.18	-0.34	-0.13	-0.22	-0.28	-0.34	-0.36	-0.34	-0.39	-0.36	-0.41
Naproxen 500 mg	2.31	-0.11	-0.08	-0.12	-0.26	-0.18	-0.31	-0.32	-0.40	-0.43	-0.46
Tanezumab 10 mg (Celecoxib Exposure)	2.09	-0.29	-0.30	-0.35	-0.50	-0.56	-0.38	-0.56	-0.50	-0.52	-0.44
Tanezumab 10 mg (Naproxen Exposure)	2.56	-0.25	-0.46	-0.46	-0.43	-0.48	-0.57	-0.57	-0.55	-0.58	-0.53
Tanezumab 10 mg + Celecoxib 100 mg	2.08	-0.33	-0.40	-0.33	-0.26	-0.30	-0.22	-0.26	-0.33	-0.34	-0.43
Tanezumab 10 mg + Naproxen 500 mg	2.54	-0.16	-0.33	-0.38	-0.65	-0.58	-0.60	-0.53	-0.49	-0.65	-0.58
Tanezumab 5 mg (Celecoxib Exposure)	2.04	-0.11	-0.21	-0.32	-0.53	-0.43	-0.35	-0.44	-0.41	-0.44	-0.41
Tanezumab 5 mg (Naproxen Exposure)	2.64	-0.20	-0.37	-0.49	-0.52	-0.77	-0.73	-0.56	-0.50	-0.43	-0.48
Tanezumab 5 mg + Celecoxib 100 mg	2.24	-0.14	-0.40	-0.53	-0.69	-0.79	-0.90	-0.93	-0.50	-0.87	-0.89
Tanezumab 5 mg + Naproxen 500 mg	1.93	-0.30	-0.20	-0.25	-0.38	-0.35	-0.44	-0.52	-0.32	-0.38	-0.45

Change From Baseline in Neuropathy Impairment Score (NIS) at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Observed Data

,,,,,,,,,

Intervention	units on a scale (Mean)
	Baseline	Change at Week 2	Change at Week 4	Change at Week 8	Change at Week 12	Change at Week 16	Change at Week 24	Change at Week 32	Change at Week 40	Change at Week 48	Change at Week 56
Celecoxib 100 mg	2.18	-0.34	-0.11	-0.35	-0.44	-0.50	-0.50	-0.63	-0.73	-0.69	-0.54
Naproxen 500 mg	2.31	-0.11	-0.11	-0.12	-0.29	-0.26	-0.43	-0.39	-0.42	-0.48	-0.36
Tanezumab 10 mg (Celecoxib Exposure)	2.09	-0.29	-0.30	-0.36	-0.56	-0.64	-0.46	-0.71	-0.58	-0.65	-0.42
Tanezumab 10 mg (Naproxen Exposure)	2.56	-0.25	-0.42	-0.42	-0.38	-0.41	-0.50	-0.53	-0.47	-0.81	-0.70
Tanezumab 10 mg + Celecoxib 100 mg	2.08	-0.33	-0.39	-0.22	-0.38	-0.48	-0.47	-0.49	-0.71	-0.50	-0.38
Tanezumab 10 mg + Naproxen 500 mg	2.54	-0.16	-0.29	-0.30	-0.62	-0.58	-0.57	-0.47	-0.38	-0.80	-0.10
Tanezumab 5 mg (Celecoxib Exposure)	2.04	-0.11	-0.20	-0.32	-0.52	-0.41	-0.37	-0.50	-0.42	-0.56	-0.53
Tanezumab 5 mg (Naproxen Exposure)	2.64	-0.20	-0.40	-0.47	-0.53	-0.81	-0.78	-0.56	-0.61	-0.55	-0.30
Tanezumab 5 mg + Celecoxib 100 mg	2.24	-0.14	-0.41	-0.55	-0.72	-0.83	-0.99	-1.05	-1.06	-1.07	-1.01
Tanezumab 5 mg + Naproxen 500 mg	1.93	-0.30	-0.18	-0.22	-0.34	-0.38	-0.57	-0.78	-0.63	-0.67	-0.83

Change From Baseline in Percent Impairment While Working Due to Osteoarthritis at Week 24 and 56 Assessed Using Work Productivity and Activity Impairment Questionnaire- Specific Health Problem (WPAI-SHP): Last Observation Carried Forward (LOCF)

,,,,,,,,,

Intervention	change in percent impairment (Mean)
	Change at Week 24	Change at Week 56
Celecoxib 100 mg	-5.81	-5.93
Naproxen 500 mg	-7.35	-5.31
Tanezumab 10 mg (Celecoxib Exposure)	-13.01	-12.88
Tanezumab 10 mg (Naproxen Exposure)	-11.68	-11.88
Tanezumab 10 mg + Celecoxib 100 mg	-9.63	-4.25
Tanezumab 10 mg + Naproxen 500 mg	-13.00	-11.33
Tanezumab 5 mg (Celecoxib Exposure)	-17.81	-16.99
Tanezumab 5 mg (Naproxen Exposure)	-11.90	-10.30
Tanezumab 5 mg + Celecoxib 100 mg	-9.33	-8.09
Tanezumab 5 mg + Naproxen 500 mg	-5.51	-4.08

Change From Baseline in Percent Work Time Missed Due to Osteoarthritis at Week 24 and 56 Assessed Using Work Productivity and Activity Impairment Questionnaire- Specific Health Problem (WPAI-SHP): Last Observation Carried Forward (LOCF)

The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which a specified health problem affected work productivity and regular activities over the past 7 days. The questions are: Q1 = currently employed. Q2 = hours missed due to health problems. Q3 = hours missed other reasons. Q4 = hours actually worked. Q5 = degree health affected productivity while working (0-10 scale). Q6 = degree health affected regular activities (0-10 scale). Subscale scores are calculated: Percent work time missed due to health problem: Q2/(Q2+Q4). The computed percentage range for each sub-scale is 0-100, where higher numbers indicate greater impairment and less productivity. (NCT00809354)
Timeframe: Baseline, Week 24 and 56

,,,,,,,,,

Intervention	change in percent work time missed (Mean)
	Change at Week 24	Change at Week 56
Celecoxib 100 mg	-0.61	-0.82
Naproxen 500 mg	1.11	2.26
Tanezumab 10 mg (Celecoxib Exposure)	-0.42	-0.46
Tanezumab 10 mg (Naproxen Exposure)	0.04	-0.39
Tanezumab 10 mg + Celecoxib 100 mg	-1.64	-1.64
Tanezumab 10 mg + Naproxen 500 mg	0.77	-0.41
Tanezumab 5 mg (Celecoxib Exposure)	-2.85	-3.06
Tanezumab 5 mg (Naproxen Exposure)	-0.88	-1.10
Tanezumab 5 mg + Celecoxib 100 mg	1.51	1.51
Tanezumab 5 mg + Naproxen 500 mg	0.63	1.08

Change From Baseline in the Patient Global Assessment (PGA) of Osteoarthritis at Week 16

"Patient global assessment of osteoarthritis was assessed by asking a question from participants: Considering all the ways your osteoarthritis in your knee or hip affects you, how are you doing today? Participants responded by using a 5-point likert scale ranging from 1=very good (asymptomatic and no limitation of normal activities, 2= good (mild symptoms and no limitation of normal activities), 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5= very poor (very severe symptoms which are intolerable and inability to carry out all normal activities). Higher scores indicating worse condition." (NCT00809354)
Timeframe: Baseline, Week 16

,,,,,,,,,

Intervention	units on a scale (Mean)
	Baseline	Change at Week 16
Celecoxib 100 mg	3.37	-0.51
Naproxen 500 mg	3.38	-0.53
Tanezumab 10 mg (Celecoxib Exposure)	3.48	-0.64
Tanezumab 10 mg (Naproxen Exposure)	3.41	-0.63
Tanezumab 10 mg + Celecoxib 100 mg	3.41	-0.75
Tanezumab 10 mg + Naproxen 500 mg	3.39	-0.72
Tanezumab 5 mg (Celecoxib Exposure)	3.44	-0.69
Tanezumab 5 mg (Naproxen Exposure)	3.39	-0.54
Tanezumab 5 mg + Celecoxib 100 mg	3.45	-0.76
Tanezumab 5 mg + Naproxen 500 mg	3.39	-0.61

Change From Baseline in the Patient Global Assessment (PGA) of Osteoarthritis at Weeks 2, 4, 8, 12 and 24: Baseline Observation Carried Forward (BOCF)

"Patient global assessment of osteoarthritis was assessed by asking a question from participants: Considering all the ways your osteoarthritis in your knee or hip affects you, how are you doing today? Participants responded by using a 5-point likert scale ranging from 1=very good (asymptomatic and no limitation of normal activities, 2= mild symptoms and no limitation of normal activities, 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (Very severe symptoms which are intolerable and inability to carry out all normal activities). Higher scores indicating worse condition." (NCT00809354)
Timeframe: Baseline, Weeks 2, 4, 8, 12, and 24

,,,,,,,,,

Intervention	units on a scale (Mean)
	Change at Week 2	Change at Week 4	Change at Week 8	Change at Week 12	Change at Week 24
Celecoxib 100 mg	-0.37	-0.49	-0.51	-0.54	-0.55
Naproxen 500 mg	-0.39	-0.43	-0.45	-0.46	-0.49
Tanezumab 10 mg (Celecoxib Exposure)	-0.33	-0.75	-0.69	-0.75	-0.59
Tanezumab 10 mg (Naproxen Exposure)	-0.42	-0.69	-0.70	-0.68	-0.54
Tanezumab 10 mg + Celecoxib 100 mg	-0.26	-0.75	-0.79	-0.83	-0.74
Tanezumab 10 mg + Naproxen 500 mg	-0.40	-0.68	-0.82	-0.84	-0.60
Tanezumab 5 mg (Celecoxib Exposure)	-0.46	-0.68	-0.63	-0.71	-0.57
Tanezumab 5 mg (Naproxen Exposure)	-0.45	-0.60	-0.58	-0.60	-0.58
Tanezumab 5 mg + Celecoxib 100 mg	-0.45	-0.80	-0.81	-0.77	-0.67
Tanezumab 5 mg + Naproxen 500 mg	-0.50	-0.74	-0.69	-0.69	-0.50

Change From Baseline in the Patient Global Assessment (PGA) of Osteoarthritis at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)

"Patient global assessment of osteoarthritis was assessed by asking a question from participants: Considering all the ways your osteoarthritis in your knee or hip affects you, how are you doing today? Participants responded by using a 5-point likert scale ranging from 1=very good (asymptomatic and no limitation of normal activities, 2= mild symptoms and no limitation of normal activities, 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (Very severe symptoms which are intolerable and inability to carry out all normal activities). Higher scores indicating worse condition." (NCT00809354)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56

,,,,,,,,,

Intervention	units on a scale (Mean)
	Change at Week 2	Change at Week 4	Change at Week 8	Change at Week 12	Change at Week 16	Change at Week 24	Change at Week 32	Change at Week 40	Change at Week 48	Change at Week 56
Celecoxib 100 mg	-0.37	-0.51	-0.54	-0.57	-0.54	-0.59	-0.57	-0.57	-0.54	-0.54
Naproxen 500 mg	-0.39	-0.44	-0.48	-0.49	-0.57	-0.57	-0.57	-0.50	-0.49	-0.47
Tanezumab 10 mg (Celecoxib Exposure)	-0.33	-0.76	-0.74	-0.84	-0.73	-0.69	-0.66	-0.67	-0.62	-0.56
Tanezumab 10 mg (Naproxen Exposure)	-0.42	-0.72	-0.77	-0.79	-0.74	-0.68	-0.66	-0.60	-0.60	-0.55
Tanezumab 10 mg + Celecoxib 100 mg	-0.26	-0.74	-0.81	-0.86	-0.77	-0.77	-0.66	-0.66	-0.59	-0.58
Tanezumab 10 mg + Naproxen 500 mg	-0.40	-0.72	-0.86	-0.91	-0.79	-0.69	-0.68	-0.56	-0.48	-0.46
Tanezumab 5 mg (Celecoxib Exposure)	-0.46	-0.70	-0.68	-0.77	-0.76	-0.66	-0.63	-0.61	-0.53	-0.51
Tanezumab 5 mg (Naproxen Exposure)	-0.45	-0.60	-0.63	-0.67	-0.63	-0.69	-0.60	-0.58	-0.53	-0.53
Tanezumab 5 mg + Celecoxib 100 mg	-0.45	-0.78	-0.81	-0.81	-0.80	-0.73	-0.73	-0.59	-0.63	-0.61
Tanezumab 5 mg + Naproxen 500 mg	-0.50	-0.76	-0.75	-0.78	-0.72	-0.64	-0.60	-0.53	-0.51	-0.49

Change From Baseline in the Percent Activity Impairment Due to Osteoarthritis at Week 24 and 56 Assessed Using Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP): Last Observation Carried Forward (LOCF)

The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which a specified health problem affected work productivity and regular activities over the past 7 days. The questions are: Q1 = currently employed. Q2 = hours missed due to health problems. Q3 = hours missed other reasons. Q4 = hours actually worked. Q5 = degree health affected productivity while working (0-10 scale). Q6 = degree health affected regular activities (0-10 scale). Subscale scores are calculated: Percent activity impairment due to health problem: Q6/10. The computed percentage range for each sub-scale is 0-100, where higher numbers indicate greater impairment and less productivity. (NCT00809354)
Timeframe: Baseline, Weeks 24, and 56

,,,,,,,,,

Intervention	change in percent activity impairment (Mean)
	Change at Week 24	Change at Week 56
Celecoxib 100 mg	-11.90	-11.19
Naproxen 500 mg	-10.00	-9.32
Tanezumab 10 mg (Celecoxib Exposure)	-17.84	-15.76
Tanezumab 10 mg (Naproxen Exposure)	-15.51	-14.77
Tanezumab 10 mg + Celecoxib 100 mg	-17.31	-15.86
Tanezumab 10 mg + Naproxen 500 mg	-14.96	-13.20
Tanezumab 5 mg (Celecoxib Exposure)	-17.24	-15.39
Tanezumab 5 mg (Naproxen Exposure)	-12.30	-12.12
Tanezumab 5 mg + Celecoxib 100 mg	-18.04	-18.04
Tanezumab 5 mg + Naproxen 500 mg	-13.55	-12.19

Change From Baseline in the Percent Overall Work Impairment Due to Osteoarthritis at Week 24 and 56 Assessed Using Work Productivity and Activity Impairment Questionnaire- Specific Health Problem (WPAI-SHP): LOCF

The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which a specified health problem affected work productivity and regular activities over the past 7 days. The questions are: Q1 = currently employed. Q2 = hours missed due to health problems. Q3 = hours missed other reasons. Q4 = hours actually worked. Q5 = degree health affected productivity while working (0-10 scale). Q6 = degree health affected regular activities (0-10 scale). Subscale scores are calculated: Percent overall work impairment due to health problem: Q2/(Q2+Q4)+[(1-Q2/(Q2+Q4))*(Q5/10)]. The computed percentage range for each sub-scale is 0-100, where higher numbers indicate greater impairment and less productivity. (NCT00809354)
Timeframe: Baseline, Weeks 24 and 56

,,,,,,,,,

Intervention	change in percent work impairment (Mean)
	Change at Week 24	Change at Week 56
Celecoxib 100 mg	-2.29	-3.02
Naproxen 500 mg	2.09	4.11
Tanezumab 10 mg (Celecoxib Exposure)	-0.22	-1.01
Tanezumab 10 mg (Naproxen Exposure)	-1.46	-1.88
Tanezumab 10 mg + Celecoxib 100 mg	-4.30	-4.30
Tanezumab 10 mg + Naproxen 500 mg	-1.35	-0.85
Tanezumab 5 mg (Celecoxib Exposure)	-10.17	-10.32
Tanezumab 5 mg (Naproxen Exposure)	-5.40	-6.08
Tanezumab 5 mg + Celecoxib 100 mg	1.25	1.25
Tanezumab 5 mg + Naproxen 500 mg	-0.75	0.77

Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 16

WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). The WOMAC pain subscale was a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 5 individual questions scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Total score range for WOMAC pain subscale score was 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. (NCT00809354)
Timeframe: Baseline, Week 16

,,,,,,,,,

Intervention	units on a scale (Mean)
	Baseline	Change at Week 16
Celecoxib 100 mg	6.29	-1.48
Naproxen 500 mg	6.32	-1.34
Tanezumab 10 mg (Celecoxib Exposure)	6.44	-2.12
Tanezumab 10 mg (Naproxen Exposure)	6.50	-1.97
Tanezumab 10 mg + Celecoxib 100 mg	6.27	-2.41
Tanezumab 10 mg + Naproxen 500 mg	6.33	-2.26
Tanezumab 5 mg (Celecoxib Exposure)	6.49	-2.11
Tanezumab 5 mg (Naproxen Exposure)	6.39	-1.80
Tanezumab 5 mg + Celecoxib 100 mg	6.41	-2.28
Tanezumab 5 mg + Naproxen 500 mg	6.52	-2.09

Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Weeks 2, 4, 8, 12 and 24: Baseline Observation Carried Forward (BOCF)

WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). The WOMAC pain subscale was a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 5 individual questions scored on a NRS of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Total score range for WOMAC pain subscale score was 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. (NCT00809354)
Timeframe: Baseline, Weeks 2, 4, 8, 12, and 24

,,,,,,,,,

Intervention	units on a scale (Mean)
	Change at Week 2	Change at Week 4	Change at Week 8	Change at Week 12	Change at Week 24
Celecoxib 100 mg	-0.93	-1.09	-1.15	-1.40	-1.63
Naproxen 500 mg	-0.90	-1.14	-1.13	-1.23	-1.32
Tanezumab 10 mg (Celecoxib Exposure)	-0.74	-1.78	-2.01	-2.20	-2.04
Tanezumab 10 mg (Naproxen Exposure)	-1.00	-1.87	-2.08	-1.95	-1.82
Tanezumab 10 mg + Celecoxib 100 mg	-0.86	-2.03	-2.36	-2.47	-2.29
Tanezumab 10 mg + Naproxen 500 mg	-0.89	-1.98	-2.18	-2.34	-1.95
Tanezumab 5 mg (Celecoxib Exposure)	-1.01	-1.69	-1.83	-2.15	-1.81
Tanezumab 5 mg (Naproxen Exposure)	-0.96	-1.68	-1.68	-1.86	-1.65
Tanezumab 5 mg + Celecoxib 100 mg	-1.08	-2.07	-2.23	-2.28	-2.10
Tanezumab 5 mg + Naproxen 500 mg	-1.27	-2.09	-2.10	-2.26	-1.83

Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)

WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). The WOMAC pain subscale was a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 5 individual questions scored on a NRS of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Total score range for WOMAC pain subscale score was 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. (NCT00809354)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56

,,,,,,,,,

Intervention	units on a scale (Mean)
	Change at Week 2	Change at Week 4	Change at Week 8	Change at Week 12	Change at Week 16	Change at Week 24	Change at Week 32	Change at Week 40	Change at Week 48	Change at Week 56
Celecoxib 100 mg	-0.93	-1.10	-1.17	-1.40	-1.50	-1.69	-1.62	-1.54	-1.45	-1.48
Naproxen 500 mg	-0.90	-1.15	-1.17	-1.32	-1.44	-1.54	-1.62	-1.44	-1.40	-1.36
Tanezumab 10 mg (Celecoxib Exposure)	-0.74	-1.73	-2.07	-2.32	-2.23	-2.25	-2.14	-1.99	-1.93	-1.72
Tanezumab 10 mg (Naproxen Exposure)	-1.00	-1.92	-2.20	-2.14	-2.19	-2.12	-2.08	-1.94	-1.93	-1.86
Tanezumab 10 mg + Celecoxib 100 mg	-0.86	-2.00	-2.34	-2.51	-2.46	-2.39	-2.14	-2.18	-2.03	-2.02
Tanezumab 10 mg + Naproxen 500 mg	-0.89	-2.05	-2.36	-2.56	-2.56	-2.33	-2.33	-2.12	-2.08	-2.03
Tanezumab 5 mg (Celecoxib Exposure)	-1.01	-1.76	-1.92	-2.29	-2.27	-2.05	-2.02	-1.98	-1.86	-1.83
Tanezumab 5 mg (Naproxen Exposure)	-0.96	-1.66	-1.76	-2.04	-2.00	-2.04	-1.94	-1.90	-1.86	-1.84
Tanezumab 5 mg + Celecoxib 100 mg	-1.08	-2.04	-2.22	-2.32	-2.34	-2.21	-2.20	-1.98	-2.05	-1.92
Tanezumab 5 mg + Naproxen 500 mg	-1.27	-2.12	-2.26	-2.45	-2.36	-2.20	-2.10	-1.88	-1.86	-1.84

Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score at Week 16

WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip).The WOMAC physical function subscale was comprised of 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 17 individual questions scored on a NRS of 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicated worse physical function. Total score range for WOMAC physical function subscale score was 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicated worse physical function. Physical function refers to participant's ability to move around and perform usual activities of daily living. (NCT00809354)
Timeframe: Baseline, Week 16

,,,,,,,,,

Intervention	units on a scale (Mean)
	Baseline	Change at Week 16
Celecoxib 100 mg	6.47	-1.42
Naproxen 500 mg	6.32	-1.28
Tanezumab 10 mg (Celecoxib Exposure)	6.58	-2.09
Tanezumab 10 mg (Naproxen Exposure)	6.47	-1.84
Tanezumab 10 mg + Celecoxib 100 mg	6.39	-2.41
Tanezumab 10 mg + Naproxen 500 mg	6.39	-2.18
Tanezumab 5 mg (Celecoxib Exposure)	6.67	-2.13
Tanezumab 5 mg (Naproxen Exposure)	6.46	-1.80
Tanezumab 5 mg + Celecoxib 100 mg	6.57	-2.27
Tanezumab 5 mg + Naproxen 500 mg	6.57	-2.12

Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score at Weeks 2, 4, 8, 12 and 24: Baseline Observation Carried Forward (BOCF)

WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip).The WOMAC physical function subscale was comprised of 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 17 individual questions scored on a NRS of 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicated worse physical function. Total score range for WOMAC physical function subscale score was 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicated worse physical function. Physical function refers to participant's ability to move around and perform usual activities of daily living. (NCT00809354)
Timeframe: Baseline, Weeks 2, 4, 8, 12, and 24

,,,,,,,,,

Intervention	units on a scale (Mean)
	Change at Week 2	Change at Week 4	Change at Week 8	Change at Week 12	Change at Week 24
Celecoxib 100 mg	-0.90	-1.07	-1.13	-1.36	-1.57
Naproxen 500 mg	-0.90	-1.01	-1.07	-1.23	-1.30
Tanezumab 10 mg (Celecoxib Exposure)	-0.95	-1.78	-2.00	-2.13	-2.00
Tanezumab 10 mg (Naproxen Exposure)	-1.13	-1.79	-2.01	-1.87	-1.76
Tanezumab 10 mg + Celecoxib 100 mg	-1.02	-2.00	-2.30	-2.46	-2.33
Tanezumab 10 mg + Naproxen 500 mg	-1.06	-2.00	-2.15	-2.29	-1.96
Tanezumab 5 mg (Celecoxib Exposure)	-1.18	-1.73	-1.89	-2.23	-1.92
Tanezumab 5 mg (Naproxen Exposure)	-1.10	-1.71	-1.62	-1.85	-1.66
Tanezumab 5 mg + Celecoxib 100 mg	-1.21	-1.97	-2.15	-2.34	-2.08
Tanezumab 5 mg + Naproxen 500 mg	-1.44	-2.04	-2.05	-2.18	-1.76

Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score at Weeks 2, 4, 8, 12, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)

WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip).The WOMAC physical function subscale was comprised of 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 17 individual questions scored on a NRS of 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicated worse physical function. Total score range for WOMAC physical function subscale score was 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicated worse physical function. Physical function refers to participant's ability to move around and perform usual activities of daily living. (NCT00809354)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 24, 32, 40, 48, and 56

,,,,,,,,,

Intervention	units on a scale (Mean)
	Baseline	Change at Week 2	Change at Week 4	Change at Week 8	Change at Week 12	Change at Week 24	Change at Week 32	Change at Week 40	Change at Week 48	Change at Week 56
Celecoxib 100 mg	6.47	-0.90	-1.09	-1.14	-1.36	-1.62	-1.57	-1.52	-1.44	-1.45
Naproxen 500 mg	6.32	-0.90	-1.04	-1.11	-1.31	-1.49	-1.53	-1.44	-1.39	-1.34
Tanezumab 10 mg (Celecoxib Exposure)	6.58	-0.95	-1.75	-2.08	-2.31	-2.24	-2.16	-2.04	-1.97	-1.78
Tanezumab 10 mg (Naproxen Exposure)	6.47	-1.13	-1.84	-2.13	-2.08	-2.08	-2.01	-1.90	-1.93	-1.84
Tanezumab 10 mg + Celecoxib 100 mg	6.39	-1.02	-1.91	-2.29	-2.50	-2.44	-2.20	-2.18	-2.05	-2.05
Tanezumab 10 mg + Naproxen 500 mg	6.39	-1.06	-2.06	-2.33	-2.50	-2.29	-2.25	-2.04	-1.96	-1.87
Tanezumab 5 mg (Celecoxib Exposure)	6.67	-1.18	-1.81	-2.02	-2.35	-2.14	-2.08	-2.06	-1.94	-1.90
Tanezumab 5 mg (Naproxen Exposure)	6.46	-1.10	-1.70	-1.69	-2.02	-2.04	-1.87	-1.87	-1.82	-1.82
Tanezumab 5 mg + Celecoxib 100 mg	6.57	-1.21	-1.95	-2.13	-2.37	-2.20	-2.22	-2.00	-2.03	-1.92
Tanezumab 5 mg + Naproxen 500 mg	6.57	-1.44	-2.08	-2.23	-2.40	-2.22	-2.15	-1.95	-1.90	-1.88

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Average Score at Weeks 2, 4, 8, 12, 16 and 24: Baseline Observation Carried Forward (BOCF)

,,,,,,,,,

Intervention	units on a scale (Mean)
	Baseline	Change at Week 2	Change at Week 4	Change at Week 8	Change at Week 12	Change at Week 16	Change at Week 24
Celecoxib 100 mg	6.38	-0.89	-1.06	-1.14	-1.33	-1.42	-1.53
Naproxen 500 mg	6.41	-0.93	-1.13	-1.15	-1.27	-1.34	-1.34
Tanezumab 10 mg (Celecoxib Exposure)	6.54	-0.98	-1.87	-2.08	-2.24	-2.17	-2.05
Tanezumab 10 mg (Naproxen Exposure)	6.54	-1.15	-1.92	-2.11	-1.98	-1.98	-1.84
Tanezumab 10 mg + Celecoxib 100 mg	6.33	-0.99	-2.10	-2.42	-2.55	-2.48	-2.33
Tanezumab 10 mg + Naproxen 500 mg	6.38	-1.04	-2.06	-2.22	-2.35	-2.28	-1.99
Tanezumab 5 mg (Celecoxib Exposure)	6.60	-1.17	-1.79	-1.93	-2.26	-2.13	-1.90
Tanezumab 5 mg (Naproxen Exposure)	6.45	-1.13	-1.74	-1.68	-1.90	-1.84	-1.70
Tanezumab 5 mg + Celecoxib 100 mg	6.48	-1.23	-2.08	-2.23	-2.35	-2.30	-2.09
Tanezumab 5 mg + Naproxen 500 mg	6.60	-1.46	-2.15	-2.14	-2.31	-2.17	-1.87

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Average Score at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)

,,,,,,,,,

Intervention	units on a scale (Mean)
	Change at Week 2	Change at Week 4	Change at Week 8	Change at Week 12	Change at Week 16	Change at Week 24	Change at Week 32	Change at Week 40	Change at Week 48	Change at Week 56
Celecoxib 100 mg	-0.89	-1.07	-1.16	-1.33	-1.45	-1.58	-1.53	-1.49	-1.40	-1.42
Naproxen 500 mg	-0.93	-1.15	-1.20	-1.37	-1.45	-1.58	-1.64	-1.51	-1.48	-1.43
Tanezumab 10 mg (Celecoxib Exposure)	-0.98	-1.84	-2.15	-2.37	-2.29	-2.28	-2.20	-2.07	-2.00	-1.81
Tanezumab 10 mg (Naproxen Exposure)	-1.15	-1.98	-2.25	-2.20	-2.24	-2.18	-2.10	-1.99	-2.02	-1.93
Tanezumab 10 mg + Celecoxib 100 mg	-0.99	-2.07	-2.41	-2.59	-2.53	-2.46	-2.22	-2.20	-2.08	-2.07
Tanezumab 10 mg + Naproxen 500 mg	-1.04	-2.13	-2.41	-2.58	-2.57	-2.36	-2.35	-2.14	-2.08	-1.99
Tanezumab 5 mg (Celecoxib Exposure)	-1.17	-1.87	-2.03	-2.40	-2.31	-2.16	-2.10	-2.05	-1.94	-1.90
Tanezumab 5 mg (Naproxen Exposure)	-1.13	-1.74	-1.78	-2.08	-2.05	-2.10	-1.96	-1.94	-1.91	-1.89
Tanezumab 5 mg + Celecoxib 100 mg	-1.23	-2.06	-2.22	-2.40	-2.36	-2.22	-2.30	-2.05	-2.10	-1.98
Tanezumab 5 mg + Naproxen 500 mg	-1.46	-2.18	-2.31	-2.52	-2.48	-2.30	-2.20	-1.99	-1.96	-1.93

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Going Up or Down Stairs at Weeks 2, 4, 8, 12, 16 and 24: Baseline Observation Carried Forward (BOCF)

"WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). Participants responded about the amount of pain they experienced when going up or down stairs by answering the question: How much pain have you had when going up or down the stairs? Participants responded by using a NRS of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain." (NCT00809354)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, and 24

,,,,,,,,,

Intervention	units on a scale (Mean)
	Baseline	Change at Week 2	Change at Week 4	Change at Week 8	Change at Week 12	Change at Week 16	Change at Week 24
Celecoxib 100 mg	7.52	-1.05	-1.29	-1.33	-1.50	-1.66	-1.73
Naproxen 500 mg	7.40	-0.94	-1.22	-1.34	-1.37	-1.53	-1.51
Tanezumab 10 mg (Celecoxib Exposure)	7.59	-1.23	-2.07	-2.26	-2.52	-2.35	-2.28
Tanezumab 10 mg (Naproxen Exposure)	7.68	-1.34	-2.13	-2.32	-2.16	-2.20	-2.01
Tanezumab 10 mg + Celecoxib 100 mg	7.54	-1.37	-2.36	-2.65	-2.79	-2.76	-2.63
Tanezumab 10 mg + Naproxen 500 mg	7.50	-1.36	-2.32	-2.53	-2.67	-2.53	-2.22
Tanezumab 5 mg (Celecoxib Exposure)	7.80	-1.41	-2.05	-2.17	-2.45	-2.39	-2.02
Tanezumab 5 mg (Naproxen Exposure)	7.55	-1.29	-1.78	-1.79	-2.09	-1.99	-1.82
Tanezumab 5 mg + Celecoxib 100 mg	7.55	-1.45	-2.43	-2.48	-2.48	-2.52	-2.47
Tanezumab 5 mg + Naproxen 500 mg	7.72	-1.67	-2.46	-2.41	-2.49	-2.35	-2.02

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Going Up or Down Stairs at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)

,,,,,,,,,

Intervention	units on a scale (Mean)
	Change at Week 2	Change at Week 4	Change at Week 8	Change at Week 12	Change at Week 16	Change at Week 24	Change at Week 32	Change at Week 40	Change at Week 48	Change at Week 56
Celecoxib 100 mg	-1.05	-1.30	-1.35	-1.55	-1.75	-1.84	-1.78	-1.76	-1.64	-1.71
Naproxen 500 mg	-0.94	-1.26	-1.35	-1.47	-1.63	-1.74	-1.70	-1.51	-1.48	-1.43
Tanezumab 10 mg (Celecoxib Exposure)	-1.23	-2.05	-2.37	-2.69	-2.53	-2.57	-2.50	-2.28	-2.24	-1.98
Tanezumab 10 mg (Naproxen Exposure)	-1.34	-2.20	-2.48	-2.40	-2.47	-2.38	-2.28	-2.21	-2.17	-2.08
Tanezumab 10 mg + Celecoxib 100 mg	-1.37	-2.37	-2.71	-2.90	-2.89	-2.83	-2.55	-2.47	-2.31	-2.34
Tanezumab 10 mg + Naproxen 500 mg	-1.36	-2.41	-2.75	-2.94	-2.88	-2.66	-2.62	-2.41	-2.29	-2.24
Tanezumab 5 mg (Celecoxib Exposure)	-1.41	-2.14	-2.27	-2.64	-2.62	-2.35	-2.27	-2.31	-2.20	-2.16
Tanezumab 5 mg (Naproxen Exposure)	-1.29	-1.80	-1.90	-2.29	-2.23	-2.26	-2.12	-2.06	-1.99	-2.00
Tanezumab 5 mg + Celecoxib 100 mg	-1.45	-2.43	-2.50	-2.57	-2.59	-2.60	-2.52	-2.26	-2.30	-2.16
Tanezumab 5 mg + Naproxen 500 mg	-1.67	-2.51	-2.62	-2.76	-2.70	-2.48	-2.43	-2.09	-2.10	-2.10

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Walking on a Flat Surface at Weeks 2, 4, 8, 12, 16 and 24: Baseline Observation Carried Forward (BOCF)

"WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis in index joint (knee or hip). Participants responded about the amount of pain they experienced when walking on a flat surface by answering the question: How much pain have you had when walking on a flat surface?. Participants responded by using a NRS of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain." (NCT00809354)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, and 24

,,,,,,,,,

Intervention	units on a scale (Mean)
	Baseline	Change at Week 2	Change at Week 4	Change at Week 8	Change at Week 12	Change at Week 16	Change at Week 24
Celecoxib 100 mg	6.10	-0.86	-0.95	-1.11	-1.35	-1.38	-1.55
Naproxen 500 mg	6.12	-0.80	-1.04	-1.05	-1.10	-1.23	-1.20
Tanezumab 10 mg (Celecoxib Exposure)	6.30	-0.68	-1.64	-1.84	-2.02	-1.91	-1.88
Tanezumab 10 mg (Naproxen Exposure)	6.37	-1.02	-1.88	-1.95	-1.78	-1.77	-1.65
Tanezumab 10 mg + Celecoxib 100 mg	6.14	-0.86	-1.93	-2.26	-2.25	-2.22	-2.06
Tanezumab 10 mg + Naproxen 500 mg	6.13	-0.87	-1.92	-2.09	-2.22	-2.19	-1.83
Tanezumab 5 mg (Celecoxib Exposure)	6.28	-1.04	-1.49	-1.67	-2.04	-1.94	-1.63
Tanezumab 5 mg (Naproxen Exposure)	6.22	-1.05	-1.67	-1.57	-1.74	-1.71	-1.56
Tanezumab 5 mg + Celecoxib 100 mg	6.21	-1.01	-1.88	-2.11	-2.20	-2.08	-1.96
Tanezumab 5 mg + Naproxen 500 mg	6.34	-1.31	-1.98	-1.93	-2.15	-1.95	-1.64

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Walking on a Flat Surface at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)

"WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis in index joint (knee or hip). Participants responded about the amount of pain they experienced when walking on a flat surface by answering the question: How much pain have you had when walking on a flat surface?. Participants responded by using a NRS of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain." (NCT00809354)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56

,,,,,,,,,

Intervention	units on a scale (Mean)
	Change at Week 2	Change at Week 4	Change at Week 8	Change at Week 12	Change at Week 16	Change at Week 24	Change at Week 32	Change at Week 40	Change at Week 48	Change at Week 56
Celecoxib 100 mg	-0.86	-0.96	-1.13	-1.36	-1.42	-1.64	-1.56	-1.40	-1.33	-1.36
Naproxen 500 mg	-0.80	-1.04	-1.07	-1.20	-1.33	-1.36	-1.45	-1.23	-1.22	-1.15
Tanezumab 10 mg (Celecoxib Exposure)	-0.68	-1.59	-1.85	-2.08	-1.98	-1.97	-1.80	-1.75	-1.64	-1.42
Tanezumab 10 mg (Naproxen Exposure)	-1.02	-1.92	-2.09	-1.98	-2.00	-1.94	-1.80	-1.78	-1.72	-1.64
Tanezumab 10 mg + Celecoxib 100 mg	-0.86	-1.91	-2.22	-2.27	-2.25	-2.15	-1.89	-1.89	-1.74	-1.72
Tanezumab 10 mg + Naproxen 500 mg	-0.87	-1.99	-2.26	-2.41	-2.44	-2.15	-2.12	-1.77	-1.78	-1.73
Tanezumab 5 mg (Celecoxib Exposure)	-1.04	-1.54	-1.73	-2.11	-2.03	-1.79	-1.78	-1.72	-1.62	-1.61
Tanezumab 5 mg (Naproxen Exposure)	-1.05	-1.65	-1.65	-1.93	-1.93	-1.95	-1.78	-1.69	-1.63	-1.65
Tanezumab 5 mg + Celecoxib 100 mg	-1.01	-1.84	-2.06	-2.20	-2.11	-2.04	-1.96	-1.73	-1.79	-1.67
Tanezumab 5 mg + Naproxen 500 mg	-1.31	-2.01	-2.08	-2.32	-2.20	-1.98	-1.91	-1.69	-1.68	-1.68

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale Score at Weeks 2, 4, 8, 12, 16 and 24: Baseline Observation Carried Forward (BOCF)

WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). The WOMAC stiffness subscale was a 2-item questionnaire used to assess the amount of stiffness experienced due to osteoarthritis of the index joint (knee or hip) during the past 48 hours. Stiffness was defined as a sensation of decreased ease of movement in the index joint (knee or hip). It was calculated as mean of the scores from 2 individual questions scored on NRS of 0 (no stiffness) to 10 (worst stiffness), with higher scores indicate more stiffness. Total score range for WOMAC stiffness subscale score was 0 (no stiffness) to 10 (worst stiffness), where higher scores indicated more stiffness. (NCT00809354)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, and 24

,,,,,,,,,

Intervention	units on a scale (Mean)
	Baseline	Change at Week 2	Change at Week 4	Change at Week 8	Change at Week 12	Change at Week 16	Change at Week 24
Celecoxib 100 mg	6.39	-0.82	-1.00	-1.13	-1.23	-1.34	-1.38
Naproxen 500 mg	6.60	-1.02	-1.23	-1.29	-1.40	-1.42	-1.46
Tanezumab 10 mg (Celecoxib Exposure)	6.58	-1.21	-2.05	-2.22	-2.36	-2.28	-2.10
Tanezumab 10 mg (Naproxen Exposure)	6.66	-1.32	-2.10	-2.26	-2.14	-2.15	-1.96
Tanezumab 10 mg + Celecoxib 100 mg	6.33	-1.11	-2.25	-2.60	-2.72	-2.62	-2.39
Tanezumab 10 mg + Naproxen 500 mg	6.42	-1.19	-2.19	-2.31	-2.42	-2.40	-2.04
Tanezumab 5 mg (Celecoxib Exposure)	6.62	-1.35	-1.94	-2.02	-2.38	-2.14	-1.97
Tanezumab 5 mg (Naproxen Exposure)	6.50	-1.35	-1.85	-1.76	-1.98	-1.93	-1.80
Tanezumab 5 mg + Celecoxib 100 mg	6.47	-1.41	-2.15	-2.28	-2.42	-2.35	-2.08
Tanezumab 5 mg + Naproxen 500 mg	6.70	-1.65	-2.31	-2.26	-2.49	-2.31	-1.98

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale Score at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)

WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). The WOMAC stiffness subscale was a 2-item questionnaire used to assess the amount of stiffness experienced due to osteoarthritis in the index joint (knee or hip) during the past 48 hours. Stiffness was defined as a sensation of decreased ease of movement in the index joint (knee or hip). It was calculated as mean of the scores from 2 individual questions scored on NRS of 0 (no stiffness) to 10 (worst stiffness), with higher scores indicate more stiffness. Total score range for WOMAC stiffness subscale score was 0 (no stiffness) to 10 (worst stiffness), where higher scores indicated more stiffness. (NCT00809354)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56

,,,,,,,,,

Intervention	units on a scale (Mean)
	Change at Week 2	Change at Week 4	Change at Week 8	Change at Week 12	Change at Week 16	Change at Week 24	Change at Week 32	Change at Week 40	Change at Week 48	Change at Week 56
Celecoxib 100 mg	-0.82	-1.01	-1.15	-1.24	-1.38	-1.43	-1.41	-1.43	-1.34	-1.34
Naproxen 500 mg	-1.02	-1.26	-1.35	-1.52	-1.58	-1.75	-1.80	-1.69	-1.69	-1.63
Tanezumab 10 mg (Celecoxib Exposure)	-1.21	-2.03	-2.30	-2.49	-2.41	-2.37	-2.31	-2.20	-2.10	-1.94
Tanezumab 10 mg (Naproxen Exposure)	-1.32	-2.17	-2.43	-2.39	-2.44	-2.36	-2.23	-2.15	-2.23	-2.10
Tanezumab 10 mg + Celecoxib 100 mg	-1.11	-2.22	-2.58	-2.76	-2.68	-2.55	-2.31	-2.26	-2.17	-2.14
Tanezumab 10 mg + Naproxen 500 mg	-1.19	-2.27	-2.52	-2.68	-2.70	-2.46	-2.48	-2.24	-2.20	-2.08
Tanezumab 5 mg (Celecoxib Exposure)	-1.35	-2.04	-2.15	-2.55	-2.35	-2.28	-2.18	-2.10	-2.01	-1.97
Tanezumab 5 mg (Naproxen Exposure)	-1.35	-1.88	-1.88	-2.18	-2.16	-2.22	-2.07	-2.05	-2.03	-1.99
Tanezumab 5 mg + Celecoxib 100 mg	-1.41	-2.13	-2.30	-2.49	-2.43	-2.23	-2.46	-2.16	-2.22	-2.10
Tanezumab 5 mg + Naproxen 500 mg	-1.65	-2.34	-2.44	-2.71	-2.64	-2.48	-2.36	-2.13	-2.11	-2.07

Number of Participants With Anti-Drug Antibody (ADA) Response

Human serum ADA samples were analyzed for the presence or absence of anti--tanezumab antibodies by using a semi quantitative enzyme -linked immunosorbent assay (ELISA). Participants tested positive for ADA response on at least one post-baseline visit were reported. Participants with ADA titer level >=4.32 for tanezumab were considered ADA positive. (NCT00809354)
Timeframe: Baseline, Weeks 16, 40, 24, and 56

,,,

Intervention	Participants (Count of Participants)
	Baseline	Week 16	Week 24	Week 40	Week 56
Tanezumab 10 mg (Naproxen or Celecoxib Exposure)	2	3	2	2	2
Tanezumab 10 mg + NSAID	2	0	1	2	2
Tanezumab 5 mg (Naproxen or Celecoxib Exposure)	3	5	4	2	3
Tanezumab 5 mg + NSAID	4	4	1	5	1

Number of Participants With Cumulative Reduction From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score: Baseline Observation Carried Forward (BOCF)

WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). The WOMAC pain subscale was a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 5 individual questions scored on a NRS of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Total score range for WOMAC pain subscale score was 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Number of participants who experienced reduction (as percent) of >0% to >=100% from Baseline in WOMAC pain subscale scores at Week 16 were reported. (NCT00809354)
Timeframe: Baseline, Week 16

,,,,,,,,,

Intervention	Participants (Count of Participants)
	>0%	>=10%	>=20%	>=30%	>=40%	>=50%	>=60%	>=70%	>=80%	>=90%	100%
Celecoxib 100 mg	170	150	124	100	81	62	44	25	13	7	5
Naproxen 500 mg	172	153	130	102	81	56	39	22	14	7	3
Tanezumab 10 mg (Celecoxib Exposure)	182	167	150	124	114	89	68	46	34	15	8
Tanezumab 10 mg (Naproxen Exposure)	201	184	162	135	117	94	75	50	29	18	11
Tanezumab 10 mg + Celecoxib 100 mg	194	184	162	138	123	108	79	63	50	32	11
Tanezumab 10 mg + Naproxen 500 mg	203	194	174	154	132	104	82	71	45	24	10
Tanezumab 5 mg (Celecoxib Exposure)	177	162	142	122	108	89	70	51	31	19	5
Tanezumab 5 mg (Naproxen Exposure)	198	179	148	127	103	78	53	43	29	17	4
Tanezumab 5 mg + Celecoxib 100 mg	193	176	151	135	115	96	72	56	36	20	7
Tanezumab 5 mg + Naproxen 500 mg	199	183	158	139	118	96	61	42	31	19	12

Number of Participants With Cumulative Reduction From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score: Last Observation Carried Forward (LOCF)

WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). The WOMAC pain subscale was a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 5 individual questions scored on a NRS of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Total score range for WOMAC pain subscale score was 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Number of participants who experienced reduction (as percent) of >0% to >=100% from Baseline in WOMAC pain subscale scores at Week 16 were reported. (NCT00809354)
Timeframe: Baseline, Week 16

,,,,,,,,,

Intervention	Participants (Count of Participants)
	>0%	>=10%	>=20%	>=30%	>=40%	>=50%	>=60%	>=70%	>=80%	>=90%	100%
Celecoxib 100 mg	188	162	134	106	84	65	45	25	13	7	5
Naproxen 500 mg	201	175	144	112	88	61	43	24	16	7	3
Tanezumab 10 mg (Celecoxib Exposure)	202	184	167	137	120	93	72	50	38	17	8
Tanezumab 10 mg (Naproxen Exposure)	234	210	183	150	129	103	79	52	30	19	12
Tanezumab 10 mg + Celecoxib 100 mg	208	197	173	145	127	111	80	63	50	32	11
Tanezumab 10 mg + Naproxen 500 mg	245	229	201	176	150	119	92	78	48	26	12
Tanezumab 5 mg (Celecoxib Exposure)	197	179	157	133	117	97	77	53	32	20	5
Tanezumab 5 mg (Naproxen Exposure)	228	203	167	140	114	86	58	46	31	17	4
Tanezumab 5 mg + Celecoxib 100 mg	208	188	163	145	120	100	75	58	37	20	7
Tanezumab 5 mg + Naproxen 500 mg	233	215	181	159	132	105	68	47	36	21	14

Number of Participants With Intravenous (IV) Doses of Study Medication

Number of participants are reported based on the maximum number of IV doses of either tanezumab or placebo received. (NCT00809354)
Timeframe: Baseline up to Week 48

,,,,,,,,,

Intervention	Participants (Count of Participants)
	Number of IV Doses: 1	Number of IV Doses: 2	Number of IV Doses: 3	Number of IV Doses: 4	Number of IV Doses: 5	Number of IV Doses: 6	Number of IV Doses: 7
Celecoxib 100 mg	22	24	12	37	73	44	44
Naproxen 500 mg	35	30	21	44	74	33	46
Tanezumab 10 mg (Celecoxib Exposure)	30	19	16	35	78	34	42
Tanezumab 10 mg (Naproxen Exposure)	36	18	28	51	70	44	41
Tanezumab 10 mg + Celecoxib 100 mg	21	12	22	48	72	38	41
Tanezumab 10 mg + Naproxen 500 mg	44	16	21	55	74	31	47
Tanezumab 5 mg (Celecoxib Exposure)	25	15	13	39	82	41	41
Tanezumab 5 mg (Naproxen Exposure)	32	19	27	41	71	45	50
Tanezumab 5 mg + Celecoxib 100 mg	22	12	18	44	84	43	33
Tanezumab 5 mg + Naproxen 500 mg	36	19	17	51	66	45	46

Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Week 64 that were absent before treatment or that worsened relative to pre-treatment state. AEs included both serious and non-serious adverse events. (NCT00809354)
Timeframe: Baseline up to Week 64

,,,,,,,,,

Intervention	Participants (Count of Participants)
	AEs	SAEs
Celecoxib 100 mg	172	21
Naproxen 500 mg	192	22
Tanezumab 10 mg (Celecoxib Exposure)	188	23
Tanezumab 10 mg (Naproxen Exposure)	211	23
Tanezumab 10 mg + Celecoxib 100 mg	193	34
Tanezumab 10 mg + Naproxen 500 mg	207	30
Tanezumab 5 mg (Celecoxib Exposure)	202	22
Tanezumab 5 mg (Naproxen Exposure)	203	22
Tanezumab 5 mg + Celecoxib 100 mg	185	26
Tanezumab 5 mg + Naproxen 500 mg	205	28

Percentage of Participants Who Used Rescue Medication: Last Observation Carried Forward (LOCF)

In case of inadequate pain relief for osteoarthritis, acetaminophen up to 4000 mg per day for maximum of 3 days within a week could be taken as rescue medication. Percentage of participants with any use of rescue medication during each study interval were summarized. (NCT00809354)
Timeframe: Weeks 1-2, 3-4, 5-8, 9-12, 13-16, 17-24, 25-32, 33-40, 41-48 and 49-56

,,,,,,,,,

Intervention	percentage of participants (Number)
	Weeks 1-2	Weeks 3-4	Weeks 5-8	Weeks 9-12	Weeks 13-16	Weeks 17-24	Weeks 25-32	Weeks 33-40	Weeks 41-48	Weeks 49-56
Celecoxib 100 mg	63.1	66.0	67.6	68.4	70.7	69.1	74.2	71.5	72.3	71.5
Naproxen 500 mg	63.0	63.0	69.8	66.2	69.4	75.8	70.8	71.9	71.5	72.6
Tanezumab 10 mg (Celecoxib Exposure)	64.4	64.4	61.0	63.9	62.3	64.3	67.5	67.5	67.9	70.0
Tanezumab 10 mg (Naproxen Exposure)	59.4	61.7	63.8	64.2	62.5	64.6	64.9	66.3	66.0	69.1
Tanezumab 10 mg + Celecoxib 100 mg	62.7	61.1	64.3	59.3	59.7	65.6	66.4	65.2	65.0	68.1
Tanezumab 10 mg + Naproxen 500 mg	63.0	60.7	58.9	60.3	57.8	64.5	63.1	64.1	64.8	67.6
Tanezumab 5 mg (Celecoxib Exposure)	70.0	69.4	69.8	65.1	67.5	69.8	71.8	71.4	71.4	71.5
Tanezumab 5 mg (Naproxen Exposure)	60.4	63.0	66.5	65.8	65.3	68.1	66.7	68.1	69.5	71.2
Tanezumab 5 mg + Celecoxib 100 mg	60.5	59.2	62.4	60.5	62.5	60.9	63.7	62.9	63.7	66.8
Tanezumab 5 mg + Naproxen 500 mg	56.9	54.7	55.0	55.4	60.0	63.2	60.0	61.8	63.9	65.4

Percentage of Participants Who Used Rescue Medication: Observed Data

,,,,,,,,,

Intervention	percentage of participants (Number)
	Weeks 1-2	Weeks 3-4	Weeks 5-8	Weeks 9-12	Weeks 13-16	Weeks 17-24	Weeks 25-32	Weeks 33-40	Weeks 41-48	Weeks 49-56
Celecoxib 100 mg	63.2	66.0	66.7	65.9	68.8	66.3	71.2	61.6	65.1	77.5
Naproxen 500 mg	61.9	62.3	68.8	64.8	68.1	76.6	69.5	73.7	66.0	78.2
Tanezumab 10 mg (Celecoxib Exposure)	64.2	64.9	61.2	64.5	61.3	65.1	70.2	71.2	70.7	74.1
Tanezumab 10 mg (Naproxen Exposure)	59.3	61.8	64.7	65.3	63.7	67.0	67.3	69.5	62.5	71.1
Tanezumab 10 mg + Celecoxib 100 mg	62.5	60.3	63.9	57.1	57.8	66.2	66.2	61.8	52.5	79.3
Tanezumab 10 mg + Naproxen 500 mg	62.9	60.6	57.9	61.4	57.8	66.0	59.6	61.8	60.9	74.2
Tanezumab 5 mg (Celecoxib Exposure)	69.7	68.4	68.0	62.9	64.2	67.0	66.5	63.8	64.1	75.9
Tanezumab 5 mg (Naproxen Exposure)	60.5	63.3	67.7	67.8	66.7	68.9	66.0	64.4	66.7	69.2
Tanezumab 5 mg + Celecoxib 100 mg	60.2	59.3	62.5	60.3	62.3	59.4	63.5	64.8	63.3	72.4
Tanezumab 5 mg + Naproxen 500 mg	57.6	55.1	55.1	56.3	62.1	64.7	59.1	58.2	59.2	62.9

Percentage of Participants With at Least 30 Percent (%), 50%, 70% and 90% Reduction in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score From Baseline at Weeks 2, 4, 8, 12, 16, and 24: BOCF

WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis in index joint (knee or hip). The WOMAC pain subscale was a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 5 individual questions scored on a NRS of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Total score range for WOMAC pain subscale score was 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Percentage of participants who experienced an improvement (reduction) of >=30%, >=50%, >=70%, or >=90% in the WOMAC pain subscale scores from Baseline were reported. (NCT00809354)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, and 24

,,,,,,,,,

Intervention	percentage of participants (Number)
	Week 2: >=30% Reduction	Week 2: >=50% Reduction	Week 2: >=70% Reduction	Week 2: >=90% Reduction	Week 4: >=30% Reduction	Week 4: >=50% Reduction	Week 4: >=70% Reduction	Week 4: >=90% Reduction	Week 8: >=30% Reduction	Week 8: >=50% Reduction	Week 8: >=70% Reduction	Week 8: >=90% Reduction	Week 12: >=30% Reduction	Week 12: >=50% Reduction	Week 12: >=70% Reduction	Week 12: >=90% Reduction	Week 16: >=30% Reduction	Week 16: >=50% Reduction	Week 16: >=70% Reduction	Week 16: >=90% Reduction	Week 24: >=30% Reduction	Week 24: >=50% Reduction	Week 24: >=70% Reduction	Week 24: >=90% Reduction
Celecoxib 100 mg	24.7	11.0	5.5	1.6	31.0	18.4	7.1	1.0	30.2	18.8	9.0	2.7	36.5	21.6	9.0	2.4	39.2	24.3	9.8	2.7	41.6	25.9	11.4	3.9
Naproxen 500 mg	22.7	12.8	5.3	1.1	29.8	19.5	6.7	2.5	29.8	16.7	8.2	2.1	34.0	19.5	7.8	2.8	36.2	19.9	7.8	2.5	36.5	21.3	11.7	3.5
Tanezumab 10 mg (Celecoxib Exposure)	22.8	13.8	6.3	1.2	41.7	26.0	11.4	3.9	45.7	29.9	16.5	6.7	52.0	35.8	19.3	7.9	48.8	35.0	18.1	5.9	46.5	33.5	18.5	7.1
Tanezumab 10 mg (Naproxen Exposure)	26.8	17.1	8.7	1.4	45.6	30.0	12.5	3.1	49.8	33.8	16.4	3.8	46.3	32.8	16.0	6.3	47.0	32.8	17.4	6.3	44.9	31.7	17.4	7.3
Tanezumab 10 mg + Celecoxib 100 mg	26.0	18.5	8.3	3.1	50.4	32.7	19.3	5.5	55.9	36.2	23.2	7.1	58.3	41.7	23.6	10.6	54.3	42.5	24.8	12.6	53.5	41.3	23.6	11.8
Tanezumab 10 mg + Naproxen 500 mg	24.9	16.1	7.4	1.8	47.7	32.3	17.5	4.2	49.8	35.1	21.1	7.7	54.4	39.3	23.9	9.8	54.0	36.5	24.9	8.4	46.0	34.4	21.4	6.0
Tanezumab 5 mg (Celecoxib Exposure)	28.0	12.6	7.1	2.4	39.8	22.4	13.8	4.3	44.1	27.2	13.8	5.1	48.0	33.5	19.3	4.7	48.0	35.0	20.1	7.5	42.5	30.3	15.4	7.5
Tanezumab 5 mg (Naproxen Exposure)	28.4	17.5	5.6	1.1	40.7	24.6	11.9	2.1	43.9	27.7	13.7	4.2	45.6	30.2	14.4	6.3	44.6	27.4	15.1	6.0	40.4	27.7	14.0	6.7
Tanezumab 5 mg + Celecoxib 100 mg	30.6	17.3	7.8	1.2	49.0	30.2	16.5	6.3	51.0	33.7	18.8	6.3	53.7	37.6	20.8	7.1	52.9	37.6	22.0	7.8	47.1	35.3	21.6	7.5
Tanezumab 5 mg + Naproxen 500 mg	35.0	20.4	6.4	2.9	52.1	27.5	15.0	6.8	49.3	29.6	18.2	6.4	53.2	32.1	18.6	6.8	49.6	34.3	15.0	6.8	44.3	28.2	16.4	6.4

Percentage of Participants With at Least 30%, 50%, 70% and 90% Reduction in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score: Last Observation Carried Forward (LOCF)

WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). The WOMAC pain subscale was a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 5 individual questions scored on a NRS of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Total score range for WOMAC pain subscale score was 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Percentage of participants who experienced an improvement (reduction) of >=30 percent, >=50%, >=70%, or >=90% in the WOMAC pain subscale scores from Baseline were reported. (NCT00809354)
Timeframe: Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56

,,,,,,,,,

Intervention	percentage of participants (Number)
	Week 2: >=30% Reduction	Week 2: >=50% Reduction	Week 2: >=70% Reduction	Week 2: >=90% Reduction	Week 4: >=30% Reduction	Week 4: >=50% Reduction	Week 4: >=70% Reduction	Week 4: >=90% Reduction	Week 8: >=30% Reduction	Week 8: >=50% Reduction	Week 8: >=70% Reduction	Week 8: >=90% Reduction	Week 12: >=30% Reduction	Week 12: >=50% Reduction	Week 12: >=70% Reduction	Week 12: >=90% Reduction	Week 16: >=30% Reduction	Week 16: >=50% Reduction	Week 16: >=70% Reduction	Week 16: >=90% Reduction	Week 24: >=30% Reduction	Week 24: >=50% Reduction	Week 24: >=70% Reduction	Week 24: >=90% Reduction	Week 32: >=30% Reduction	Week 32: >=50% Reduction	Week 32: >=70% Reduction	Week 32: >=90% Reduction	Week 40: >=30% Reduction	Week 40: >=50% Reduction	Week 40: >=70% Reduction	Week 40: >=90% Reduction	Week 48: >=30% Reduction	Week 48: >=50% Reduction	Week 48: >=70% Reduction	Week 48: >=90% Reduction	Week 56: >=30% Reduction	Week 56: >=50% Reduction	Week 56: >=70% Reduction	Week 56: >=90% Reduction
Celecoxib 100 mg	24.7	11.0	5.5	1.6	31.0	18.4	7.1	1.0	31.0	18.8	9.0	2.7	37.6	22.0	9.0	2.4	41.6	25.5	9.8	2.7	45.5	27.8	11.4	3.9	43.1	28.2	12.5	2.4	41.6	29.0	11.4	2.4	42.0	27.1	11.8	2.7	41.6	27.5	12.5	2.4
Naproxen 500 mg	22.7	12.8	5.3	1.1	30.5	20.2	6.7	2.5	31.2	17.7	8.5	2.1	36.9	21.3	8.5	2.8	39.7	21.6	8.5	2.5	42.9	25.2	13.1	4.3	44.3	27.3	12.1	5.0	42.2	25.5	9.2	3.2	40.4	23.4	11.0	3.9	40.4	22.7	9.9	3.2
Tanezumab 10 mg (Celecoxib Exposure)	22.8	13.8	6.3	1.2	41.7	26.0	11.4	3.9	48.8	30.7	17.3	7.1	57.1	37.8	20.9	8.7	53.9	36.6	19.7	6.7	53.9	35.4	20.5	7.9	51.6	36.2	21.7	9.1	50.8	31.1	20.5	5.9	49.2	31.9	18.9	5.5	46.5	28.7	16.5	4.7
Tanezumab 10 mg (Naproxen Exposure)	26.8	17.1	8.7	1.4	46.3	30.7	12.5	3.1	51.9	35.2	16.7	4.2	50.9	35.5	16.4	6.6	52.3	35.9	18.1	6.6	53.0	36.2	18.5	7.7	52.3	33.8	17.8	7.0	50.9	31.7	17.4	5.6	51.6	30.7	16.0	5.9	50.2	28.9	15.3	5.2
Tanezumab 10 mg + Celecoxib 100 mg	26.0	18.5	8.3	3.1	50.4	32.7	19.3	5.5	56.7	37.0	23.6	7.5	60.2	42.9	24.0	11.0	57.1	43.7	24.8	12.6	57.9	43.3	24.0	11.8	53.5	39.4	22.0	12.6	53.9	39.0	21.7	9.4	51.2	37.0	20.5	9.4	52.0	37.8	20.5	8.7
Tanezumab 10 mg + Naproxen 500 mg	24.9	16.1	7.4	1.8	49.8	33.7	17.9	4.6	55.1	38.9	22.8	8.4	60.7	43.5	26.0	10.5	61.8	41.8	27.4	9.1	55.8	40.7	24.6	7.4	56.5	42.5	22.1	8.4	52.6	38.2	19.3	5.6	51.9	36.5	18.9	6.7	52.6	36.1	17.9	6.3
Tanezumab 5 mg (Celecoxib Exposure)	28.0	12.6	7.1	2.4	41.3	23.6	14.2	4.7	46.5	28.7	14.6	5.9	52.8	36.6	20.5	5.1	52.4	38.2	20.9	7.9	49.2	34.3	16.5	7.9	49.6	35.4	19.3	7.9	49.2	34.3	17.7	7.5	48.4	30.7	16.1	5.9	46.9	29.9	14.2	5.1
Tanezumab 5 mg (Naproxen Exposure)	28.4	17.5	5.6	1.1	41.1	24.6	11.9	2.1	46.3	29.1	14.4	4.2	49.8	32.6	15.4	6.3	49.1	30.2	16.1	6.0	49.5	34.0	16.8	7.4	49.5	30.2	18.2	5.6	49.5	31.9	16.1	5.3	48.8	30.9	17.2	5.6	47.7	30.2	16.5	6.0
Tanezumab 5 mg + Celecoxib 100 mg	30.6	17.3	7.8	1.2	49.8	30.6	16.9	6.3	52.9	34.5	19.2	6.3	57.3	39.2	21.6	7.1	56.9	39.2	22.7	7.8	52.5	37.6	22.7	7.8	52.5	39.2	21.6	10.6	49.8	33.3	19.6	8.6	50.2	33.7	20.4	7.5	47.8	31.8	18.4	7.5
Tanezumab 5 mg + Naproxen 500 mg	35.0	20.4	6.4	2.9	53.2	27.9	15.0	6.8	53.9	31.4	19.3	6.4	59.3	34.3	19.6	7.1	56.8	37.5	16.8	7.5	54.3	33.2	19.6	7.5	53.6	33.9	16.1	5.4	51.8	30.4	15.7	4.6	51.4	30.4	15.4	4.6	51.4	28.6	16.1	4.6

Percentage of Participants With Improvement of At Least 2 Points in Patient's Global Assessment (PGA) of Osteoarthritis at Weeks 2, 4, 8, 12, 16, and 24: Baseline Observation Carried Forward (BOCF)

"Patient global assessment of osteoarthritis was assessed by asking a question from participants: Considering all the ways your osteoarthritis in your knee or hip affects you, how are you doing today? Participants responded by using a 5-point likert scale ranging from 1=very good (asymptomatic and no limitation of normal activities, 2= mild symptoms and no limitation of normal activities, 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (Very severe symptoms which are intolerable and inability to carry out all normal activities). Higher scores indicating worse condition. Improvement signifies a decrease of at least 2 points on the 5-point scale relative to baseline value. Percentage of participants who showed an improvement of >=2 points on scale were reported." (NCT00809354)
Timeframe: Weeks 2, 4, 8, 12, 16, and 24

,,,,,,,,,

Intervention	percentage of participants (Number)
	Week 2	Week 4	Week 8	Week 12	Week 16	Week 24
Celecoxib 100 mg	6.3	10.6	11.8	12.2	13.4	13.0
Naproxen 500 mg	6.4	10.6	9.2	12.7	10.6	14.1
Tanezumab 10 mg (Celecoxib Exposure)	9.4	18.5	16.5	17.7	15.4	12.6
Tanezumab 10 mg (Naproxen Exposure)	10.1	13.5	18.4	17.4	19.1	18.1
Tanezumab 10 mg + Celecoxib 100 mg	5.9	14.6	17.4	22.1	18.2	20.9
Tanezumab 10 mg + Naproxen 500 mg	10.9	15.1	19.3	25.3	22.5	18.6
Tanezumab 5 mg (Celecoxib Exposure)	11.3	19.1	15.6	17.2	18.4	13.3
Tanezumab 5 mg (Naproxen Exposure)	9.9	10.2	14.1	15.5	14.8	17.6
Tanezumab 5 mg + Celecoxib 100 mg	12.5	18.8	19.6	20.8	20.0	18.8
Tanezumab 5 mg + Naproxen 500 mg	8.2	17.5	18.2	18.2	16.4	12.1

Percentage of Participants With Improvement of Atleast 2 Points in Patient's Global Assessment (PGA) of Osteoarthritis at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56: Last Observation Carried Forward (LOCF)

"Patient global assessment of osteoarthritis was assessed by asking a question from participants: Considering all the ways your osteoarthritis in your knee or hip affects you, how are you doing today? Participants responded by using a 5-point likert scale ranging from 1=very good (asymptomatic and no limitation of normal activities, 2= mild symptoms and no limitation of normal activities, 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (Very severe symptoms which are intolerable and inability to carry out all normal activities). Higher scores indicating worse condition. Improvement signifies a decrease of at least 2 points on the 5-point scale relative to baseline value. Percentage of participants who showed an improvement of >=2 points on scale were reported." (NCT00809354)
Timeframe: Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56

,,,,,,,,,

Intervention	percentage of participants (Number)
	Week 2	Week 4	Week 8	Week 12	Week 16	Week 24	Week 32	Week 40	Week 48	Week 56
Celecoxib 100 mg	6.3	11.0	13.0	13.4	14.6	15.0	15.0	15.4	14.6	15.0
Naproxen 500 mg	6.4	10.6	9.9	13.8	12.0	16.3	15.5	14.1	14.5	13.4
Tanezumab 10 mg (Celecoxib Exposure)	9.4	18.9	18.5	20.9	18.1	15.4	16.5	15.0	14.6	11.8
Tanezumab 10 mg (Naproxen Exposure)	10.1	14.2	20.5	20.8	22.6	22.2	18.8	17.4	16.7	15.3
Tanezumab 10 mg + Celecoxib 100 mg	5.9	14.6	18.2	23.3	19.4	22.5	20.2	20.6	17.4	17.8
Tanezumab 10 mg + Naproxen 500 mg	10.9	16.1	20.7	27.0	24.2	21.4	23.2	18.9	16.1	15.8
Tanezumab 5 mg (Celecoxib Exposure)	11.3	20.3	17.2	19.1	21.1	16.8	19.1	18.4	17.2	14.8
Tanezumab 5 mg (Naproxen Exposure)	9.9	10.6	15.1	16.9	16.5	20.1	14.4	14.8	14.4	14.4
Tanezumab 5 mg + Celecoxib 100 mg	12.5	18.8	19.6	21.6	20.8	20.4	19.2	18.4	18.8	18.4
Tanezumab 5 mg + Naproxen 500 mg	8.2	17.9	19.3	20.4	18.9	15.4	16.4	13.9	12.9	13.6

Percentage of Participants With Outcome Measures in Rheumatology - Osteoarthritis Research Society International (OMERACT-OARSI) Response: Baseline Observation Carried Forward (BOCF)

Participants were considered as OMERACT-OARSI responder: if the improvement from baseline to week of interest was greater than or equal to (>=) 50 percent and >=2 units in WOMAC pain subscale or WOMAC physical function subscale score, or at least 2 of the following 3 being true: improvement from baseline to week of interest was >=20 percent and >=1 unit in 1) WOMAC pain subscale score, 2) WOMAC physical function subscale score, 3) PGA of osteoarthritis. WOMAC pain subscale assess amount of pain experienced (score: 0 [no pain] to 10 [worst possible pain], higher score = more pain), WOMAC physical function subscale assess degree of difficulty experienced (score: 0 [minimum difficulty] to 10 [maximum difficulty], higher score = worse physical function) and PGA of osteoarthritis (score: 1 [very good] to 5 [very poor], higher score = worse condition). (NCT00809354)
Timeframe: Weeks 2, 4, 8, 12, 16, and 24

,,,,,,,,,

Intervention	percentage of participants (Number)
	Week 2	Week 4	Week 8	Week 12	Week 16	Week 24
Celecoxib 100 mg	32.4	41.0	42.6	45.3	47.3	49.2
Naproxen 500 mg	31.8	39.7	39.0	42.9	45.2	41.1
Tanezumab 10 mg (Celecoxib Exposure)	33.9	55.5	57.5	59.1	55.9	53.5
Tanezumab 10 mg (Naproxen Exposure)	35.5	57.6	58.9	56.1	53.0	50.9
Tanezumab 10 mg + Celecoxib 100 mg	33.1	57.5	65.0	65.7	63.4	59.4
Tanezumab 10 mg + Naproxen 500 mg	36.1	54.5	58.3	61.1	60.1	51.0
Tanezumab 5 mg (Celecoxib Exposure)	39.6	51.6	53.9	56.6	55.1	49.8
Tanezumab 5 mg (Naproxen Exposure)	40.4	53.0	49.5	54.0	52.3	48.1
Tanezumab 5 mg + Celecoxib 100 mg	39.5	57.4	59.4	62.1	59.8	54.7
Tanezumab 5 mg + Naproxen 500 mg	43.2	60.7	60.4	61.4	56.8	51.4

Percentage of Participants With Outcome Measures in Rheumatology - Osteoarthritis Research Society International (OMERACT-OARSI) Response: Last Observation Carried Forward (LOCF)

Participants were considered as OMERACT-OARSI responder: if the improvement from baseline to week of interest was >=50 percent and >=2 units in WOMAC pain subscale or WOMAC physical function subscale score, or at least 2 of the following 3 being true: improvement from baseline to week of interest was >=20 percent and >=1 unit in 1) WOMAC pain subscale score, 2) WOMAC physical function subscale score, 3) PGA of osteoarthritis. WOMAC pain subscale assess amount of pain experienced (score: 0 [no pain] to 10 [worst possible pain], higher score = more pain), WOMAC physical function subscale assess degree of difficulty experienced (score: 0 [minimum difficulty] to 10 [maximum difficulty], higher score = worse physical function) and PGA of osteoarthritis (score: 1 [very good] to 5 [very poor], higher score = worse condition). (NCT00809354)
Timeframe: Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56

,,,,,,,,,

Intervention	percentage of participants (Number)
	Week 2	Week 4	Week 8	Week 12	Week 16	Week 24	Week 32	Week 40	Week 48	Week 56
Celecoxib 100 mg	32.4	41.8	43.8	47.7	51.2	55.1	53.1	49.2	49.2	49.2
Naproxen 500 mg	31.8	41.0	41.0	46.6	49.5	48.4	52.3	50.9	49.5	50.5
Tanezumab 10 mg (Celecoxib Exposure)	33.9	55.9	61.4	65.0	62.2	63.4	56.3	56.3	55.9	53.5
Tanezumab 10 mg (Naproxen Exposure)	35.5	59.0	62.2	61.8	59.7	60.1	57.6	56.3	57.6	54.9
Tanezumab 10 mg + Celecoxib 100 mg	33.1	57.9	66.5	68.1	66.5	64.2	60.6	62.2	58.3	59.4
Tanezumab 10 mg + Naproxen 500 mg	36.1	57.6	64.2	68.4	69.1	62.2	63.2	59.0	58.0	58.0
Tanezumab 5 mg (Celecoxib Exposure)	39.6	53.1	56.3	60.9	60.5	58.6	57.4	58.2	57.4	56.6
Tanezumab 5 mg (Naproxen Exposure)	40.4	53.7	53.3	60.4	59.3	60.4	60.7	57.9	58.2	57.2
Tanezumab 5 mg + Celecoxib 100 mg	39.5	57.8	61.3	65.6	64.1	60.5	62.5	57.4	58.2	57.0
Tanezumab 5 mg + Naproxen 500 mg	43.2	62.5	65.7	68.2	65.7	63.2	61.4	58.9	57.9	57.5

Plasma Trough (Pre-dose) Concentration of Tanezumab

(NCT00809354)
Timeframe: Predose on Day 1, Weeks 16, 24, 40, and 56

,,,

Intervention	nanogram/milliliter (Mean)
	Day 1	Week 16	Week 24	Week 40	Week 56
Tanezumab 10 mg (Naproxen or Celecoxib Exposure)	164.068	556.854	545.672	523.214	385.733
Tanezumab 10 mg + NSAID	96.4720	723.316	538.756	527.108	377.231
Tanezumab 5 mg (Naproxen or Celecoxib Exposure)	48.4570	222.779	250.813	231.840	168.673
Tanezumab 5 mg + NSAID	102.398	255.246	271.632	263.049	138.159

Consumption of Rescue Medication

"Use of rescue medication as number of paracetamol tablets 500 mg since the last visit. The tablet count was reconciled with the patient diary.~Total Number of pills per month" (NCT01425853)
Timeframe: 6 months

Intervention	daily tablets consumed/month (Mean)
Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican)	31.0
Celecoxib	29.0

Number of Participants With at Least One Adverse Events

The safety evaluation was done in the set of randomized patients who took at least one dose of the medication (NCT01425853)
Timeframe: 6 months

Intervention	number of participants (Number)
Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican)	155
Celecoxib	151

Percentage of Participants With Response as Defined by Outcome Variables for Osteoarthritis Clinical Trials - Osteoarthritis Research Society International (OMERACT-OARSI)

"The OARSI Standing Committee for Clinical Trials Response Criteria Initiative and the OMERACT committee, in concert with the international rheumatology community, has led to the development of a uniform core set of outcome measures for OA. One of the objectives was to propose a set of criteria for measurement based on multiple domains to present the results of changes after treatment in symptomatic parameters as a single variable for clinical trials.~To be considered as responder patients should met one the following criteria:~High improvement in pain or in function ≥ 50% and absolute change ≥ 20 or~Improvement in at least 2 of the 3 following:~Pain ≥ 20% and absolute change ≥ 10~Function ≥ 20% and absolute change ≥ 10~Patient's global assessment ≥ 20% and absolute change ≥ 10" (NCT01425853)
Timeframe: 6 months

Intervention	percentage of participants (Number)
Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican)	79.7
Celecoxib	79.2

Percentage of Presence of Joint Effusion

Study knees were evaluated at each visit for the presence or absence of swelling and/or effusion. (NCT01425853)
Timeframe: 6 months

Intervention	percentage of participants (Number)
Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican)	4.1
Celecoxib	3.8

Percentage of Presence of Joint Swelling

Study knees were evaluated at each visit for the presence or absence of swelling and/or effusion. (NCT01425853)
Timeframe: 6 months

Intervention	percentage of participants (Number)
Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican)	5.9
Celecoxib	4.5

WOMAC Pain Subscale

Western Ontario & McMaster Universities Osteoarthritis Index (WOMAC) Pain subscale Score Range: 0 (no pain) - 500 (maximum pain) The study was designed such that the outcome of primary interest is knee pain related to OA. The measure selected to best evaluate this is an improvement in the WOMAC pain subscales. This subscale consists of 5 items which assesses the pain during walking, using stairs, in bed, sitting or lying, and standing. (NCT01425853)
Timeframe: 6 months

Intervention	units on a scale (Mean)
Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican)	185.79
Celecoxib	184.67

Health Status According to EuroQoL

"EuroQoL-5D was a standardized instrument for use as a measure of health outcome that provides a simple descriptive profile and a single index value for health status. It was assessed at all of the study visits.~The EQ-5D-3L essentially consists of 2 pages - the EQ-5D descriptive system (page 2) and the EQ visual analogue scale (EQ VAS) (page 3). The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems. Total scale range for each dimension reported is 1 to 3.~The EQ VAS records the respondent's self-rated health on a vertical, visual analogue scale where the endpoints are labelled 'Best imaginable health state' and 'Worst imaginable health state'. This information can be used as a quantitative measure of health outcome as judged by the individual respondents.~Total scale range for VAS dimension reported is 0 to 100." (NCT01425853)
Timeframe: 6 months

Intervention	points (Mean)
	Mobility Baseline	Mobility 180 Days	Self-care Baseline	Self-care 180 days	Usual activities Baseline	Usual activities 180 days	Pain Discomfort Baseline	Pain Discomfort 180 days	Anxiety depression baseline	Anxiety depression 180 days	VAS Baseline	VAS 180 days
Celecoxib	1.84	1.46	1.44	1.21	1.79	1.42	2.27	1.86	1.60	1.34	52.488	70.219
Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican)	1.84	1.52	1.39	1.19	1.78	1.42	2.25	1.84	1.70	1.43	54.545	69.080

Huskisson's VAS

"Visual Analogue Scale: 0 No Pain 100 Maximum Pain Huskisson's VAS measures global pain intensity. Patients were asked to quantify their disease status on a 100 mm VAS as follows: Please indicate the severity of knee pain experienced during the last 48 hours by marking a (I) through the line. Left hand marker represents No pain and right hand marker represents The worst pain imaginable." (NCT01425853)
Timeframe: 6 months

Intervention	units on a scale (Mean)
	Baseline	180 days
Celecoxib	73.47	37.64
Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican)	72.79	37.86

Number of Adverse Events Defined by Relationship With Treatment

The safety evaluation was done in the set of randomized patients who took at least one dose of the medication (NCT01425853)
Timeframe: 6 months

Intervention	number of events (Number)
	Treatment-related AEs: Definitive	Treatment-related AEs: Possibly	Treatment-related AEs: Probably	Treatment-related AEs: Non-appraisable	Treatment-related AEs: unlikely or unrelated
Celecoxib	10	38	12	1	90
Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican)	3	43	25	0	84

Patient's and Investigator's Global Assessment of Response to Therapy

"The investigator were asked to evaluated the patient's response to therapy of the index knee by marking a (I) a VAS scale with range 0 mm (best) and 100 mm (worst) as follows: Left hand marker Excellent-Best possible anticipated response, considering the severity and stage of the disease, right hand marker None-no response, absence of drug effect." (NCT01425853)
Timeframe: 6 months

Intervention	units on a scale (Mean)
	PGA Therapy Baseline	PGA Therapy 180 days	IGA Therapy Baseline	IGA Therapy 180 days
Celecoxib	45.9	36.04	42.25	33.83
Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican)	54.59	36.85	51.4	34.72

Patient's Global Assessment (PGA) and Investigator's Global Assessment (IGA) of Disease Activity

"Patients were asked to quantify their disease status on a VAS scale with range 0 mm (best) and 100 mm (worst) as follows: Considering all the ways your arthritis of the knee affects you, mark (I) on the scale how well you are doing. Left hand marker Very Well, Right hand marked Very Poor." (NCT01425853)
Timeframe: 6 months

Intervention	units on a scale (Mean)
	PGA Activity Baseline	PGA Activity 180 days	IGA Activity Baseline	IGA Activity 180 daus
Celecoxib	69.41	36.88	63.28	33.40
Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican)	69.11	38.35	63.2	35.33

WOMAC Function Subscale

Western Ontario & McMaster Universities Osteoarthritis Index, from 0 No Function to 1700 Maximum Function WOMAC functional limitation subscale was used to measure the functionality of the knee with pain. Seventeen items are used to assess functionality of the knee: tair use, rising from sitting, standing, bending, walking, getting in / out of a car, shopping, putting on / taking off socks, rising from bed, lying in bed, getting in / out of bath, sitting, getting on / off toilet, heavy household duties, light household duties. (NCT01425853)
Timeframe: 6 months

Intervention	units on a scale (Mean)
	Baseline	180 days
Celecoxib	1111.60	595.78
Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican)	1131.40	616.96

WOMAC Stiffness Subscale

Western Ontario & McMaster Universities Osteoarthritis Index, from 0 No Stiffness to 200 Maximum Stiffness WOMAC stiffness subscale was used to measure the stiffness of the knee with pain. Two items are used to assess stiffness grade: after first waking and later in the day. (NCT01425853)
Timeframe: 6 months

Intervention	units on a scale (Mean)
	Baseline	180 days
Celecoxib	129.48	65.78
Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican)	130.15	69.06

Reviews

2 reviews available for celecoxib and Edema

Article	Year
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?]. Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:9 Spec No Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseas	2006
Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. American journal of therapeutics, 2000, Volume: 7, Issue:3 Topics: Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal	2000

Trials

5 trials available for celecoxib and Edema

Article	Year
Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain. Annals of the rheumatic diseases, 2015, Volume: 74, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Hum	2015
Comparison of the efficacy and safety profiles of a pelubiprofen versus celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, phase III, non-inferiority clinical trial. BMC musculoskeletal disorders, 2014, Nov-18, Volume: 15 Topics: Adult; Aged; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Ede	2014
Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Annals of the rheumatic diseases, 2016, Volume: 75, Issue:1 Topics: Aged; Celecoxib; Chondroitin Sulfates; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Drug Combin	2016
Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. The American journal of cardiology, 2002, Nov-01, Volume: 90, Issue:9 Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure;	2002
Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen. Kidney international, 2006, Volume: 70, Issue:8 Topics: Acid-Base Equilibrium; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis,	2006

Other Studies

171 other studies available for celecoxib and Edema

Article	Year
2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors. Journal of medicinal chemistry, 1999, Apr-08, Volume: 42, Issue:7 Topics: Analgesics, Non-Narcotic; Animals; Arthritis, Experimental; Biological Availability; Carrageenan; Ce	1999
4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. Journal of medicinal chemistry, 2000, Mar-09, Volume: 43, Issue:5 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Cyclooxygenase 2; Edema;	2000
Novel antiarthritic agents with 1,2-isothiazolidine-1,1-dioxide (gamma-sultam) skeleton: cytokine suppressive dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase. Journal of medicinal chemistry, 2000, May-18, Volume: 43, Issue:10 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Experimental; Blood Platelet	2000
2,2-Dimethyl-4,5-diaryl-3(2H)furanone derivatives as selective cyclo-oxygenase-2 inhibitors. Bioorganic & medicinal chemistry letters, 2001, Jan-22, Volume: 11, Issue:2 Topics: Animals; Arthritis, Experimental; Combinatorial Chemistry Techniques; Cyclooxygenase 1; Cyclooxygena	2001
Synthesis and SAR of a new series of COX-2-selective inhibitors: pyrazolo[1,5-a]pyrimidines. Journal of medicinal chemistry, 2001, Feb-01, Volume: 44, Issue:3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cell Line; Cyclooxygenase 1; Cyclooxy	2001
Design and synthesis of 4,5-diphenyl-4-isoxazolines: novel inhibitors of cyclooxygenase-2 with analgesic and antiinflammatory activity. Journal of medicinal chemistry, 2001, Aug-30, Volume: 44, Issue:18 Topics: Abdominal Muscles; Androstenols; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cycl	2001
2,3-Diarylbenzopyran derivatives as a novel class of selective cyclooxygenase-2 inhibitors. Bioorganic & medicinal chemistry letters, 2003, Feb-10, Volume: 13, Issue:3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzopyrans; Carrageenan; Chemical Phenomena; Chem	2003
3,4-Diaryl-5-hydroxyfuranones: highly selective inhibitors of cyclooxygenase-2 with aqueous solubility. Bioorganic & medicinal chemistry letters, 2003, Mar-24, Volume: 13, Issue:6 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Chemical Phenomena; Chemi	2003
Synthesis and cyclooxygenase-2 inhibiting property of 1,5-diarylpyrazoles with substituted benzenesulfonamide moiety as pharmacophore: Preparation of sodium salt for injectable formulation. Journal of medicinal chemistry, 2003, Sep-11, Volume: 46, Issue:19 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzenesulfonamides; Binding Sites; Cyclooxygenase	2003
Design, synthesis, and biological evaluation of 6-substituted-3-(4-methanesulfonylphenyl)-4-phenylpyran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors. Journal of medicinal chemistry, 2003, Nov-06, Volume: 46, Issue:23 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Binding Sites; Cyclooxygenase 1; Cyclooxygenase 2;	2003
In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives. Journal of medicinal chemistry, 2004, Feb-12, Volume: 47, Issue:4 Topics: Adult; Animals; Arthritis, Experimental; Carrageenan; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxyge	2004
Design, synthesis, and structure-activity relationship studies of 3,4,6-triphenylpyran-2-ones as selective cyclooxygenase-2 inhibitors. Journal of medicinal chemistry, 2004, Jul-29, Volume: 47, Issue:16 Topics: Analgesics; Animals; Carrageenan; Cyclooxygenase 1; Cyclooxygenase 2; Edema; Isoenzymes; Membrane Pr	2004
Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases. Journal of medicinal chemistry, 2006, Mar-09, Volume: 49, Issue:5 Topics: Administration, Oral; Alkynes; Analgesics; Animals; Arachidonate 15-Lipoxygenase; Carrageenan; Cyclo	2006
Synthesis and biological evaluation of quinoline salicylic acids as P-selectin antagonists. Journal of medicinal chemistry, 2007, Jan-11, Volume: 50, Issue:1 Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Art	2007
2-Amino-5-thiazolyl motif: a novel scaffold for designing anti-inflammatory agents of diverse structures. European journal of medicinal chemistry, 2008, Volume: 43, Issue:1 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Chronic Disease; Cyclooxygenase Inhib	2008
Synthesis and biological evaluation of some thiazolyl and thiadiazolyl derivatives of 1H-pyrazole as anti-inflammatory antimicrobial agents. European journal of medicinal chemistry, 2008, Volume: 43, Issue:3 Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Bacteria; Carrageenan; Cyclooxygenase 1; C	2008
Cyclooxygenase-2 inhibitors. 1,5-diarylpyrrol-3-acetic esters with enhanced inhibitory activity toward cyclooxygenase-2 and improved cyclooxygenase-2/cyclooxygenase-1 selectivity. Journal of medicinal chemistry, 2007, Nov-01, Volume: 50, Issue:22 Topics: Acetates; Adult; Animals; Carrageenan; Cell Line; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase	2007
Synthesis and biological evaluation of 2-trifluoromethyl/sulfonamido-5,6-diaryl substituted imidazo[2,1-b]-1,3,4-thiadiazoles: a novel class of cyclooxygenase-2 inhibitors. Bioorganic & medicinal chemistry, 2008, Jan-01, Volume: 16, Issue:1 Topics: Animals; Anti-Inflammatory Agents; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Edema; In	2008
New celecoxib derivatives as anti-inflammatory agents. Journal of medicinal chemistry, 2008, Jan-10, Volume: 51, Issue:1 Topics: Acetic Acid; Animals; Carrageenan; Celecoxib; Chronic Disease; Crystallization; Cyclooxygenase 1; Cy	2008
Novel anti-inflammatory agents based on pyridazinone scaffold; design, synthesis and in vivo activity. Bioorganic & medicinal chemistry, 2008, May-15, Volume: 16, Issue:10 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Binding Sites; Carrageenan; Cyclooxygenase 2; Cycl	2008
Indole cytosolic phospholipase A2 alpha inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic acid, efipladib. Journal of medicinal chemistry, 2008, Jun-26, Volume: 51, Issue:12 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Benzoates; Biological Ava	2008
Synthesis, biological evaluation, and enzyme docking simulations of 1,5-diarylpyrrole-3-alkoxyethyl ethers as selective cyclooxygenase-2 inhibitors endowed with anti-inflammatory and antinociceptive activity. Journal of medicinal chemistry, 2008, Aug-14, Volume: 51, Issue:15 Topics: Analgesics; Animals; Anti-Inflammatory Agents; Computer Simulation; Cyclooxygenase 2 Inhibitors; Ede	2008
Synthesis, in vitro, and in vivo biological evaluation and molecular docking simulations of chiral alcohol and ether derivatives of the 1,5-diarylpyrrole scaffold as novel anti-inflammatory and analgesic agents. Bioorganic & medicinal chemistry, 2008, Sep-01, Volume: 16, Issue:17 Topics: Acetic Acid; Alcohols; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Binding Sites;	2008
Synthesis of new 4-[2-(4-methyl(amino)sulfonylphenyl)-5-trifluoromethyl-2H-pyrazol-3-yl]-1,2,3,6-tetrahydropyridines: a search for novel nitric oxide donor anti-inflammatory agents. Bioorganic & medicinal chemistry, 2008, Oct-01, Volume: 16, Issue:19 Topics: Animals; Anti-Inflammatory Agents; Aspirin; Carrageenan; Celecoxib; Edema; Inflammation; Nitric Oxid	2008
Synthesis of celecoxib analogs that possess a N-hydroxypyrid-2(1H)one 5-lipoxygenase pharmacophore: biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity. Bioorganic & medicinal chemistry letters, 2008, Dec-01, Volume: 18, Issue:23 Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Caffeic Acids; Celecoxib; Cy	2008
Synthesis and antiinflammatory activity of some new 1,3,5-trisubstituted pyrazolines bearing benzene sulfonamide. Bioorganic & medicinal chemistry letters, 2009, Jan-01, Volume: 19, Issue:1 Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Benzenesulfonamides; Celecoxib; Chalcones;	2009
Discovery of novel analgesic and anti-inflammatory 3-arylamine-imidazo[1,2-a]pyridine symbiotic prototypes. Bioorganic & medicinal chemistry, 2009, Jan-01, Volume: 17, Issue:1 Topics: Analgesics; Animals; Anti-Inflammatory Agents; Cell Line; Cyclooxygenase 2 Inhibitors; Disease Model	2009
Synthesis and anti-inflammatory activity of the major metabolites of imrecoxib. Bioorganic & medicinal chemistry letters, 2009, Apr-15, Volume: 19, Issue:8 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Dose-Respo	2009
Diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of 5-(4-carboxymethylphenyl)-1-(4-methanesulfonylphenyl)-3-trifluoromethyl-1H-pyrazole and its aminosulfonyl analog: Synthesis, biological evaluation and nitric oxide release studies. Bioorganic & medicinal chemistry, 2009, Jul-15, Volume: 17, Issue:14 Topics: Animals; Anti-Inflammatory Agents; Azo Compounds; Cyclooxygenase Inhibitors; Edema; Foot; Humans; Ni	2009
Synthesis, biological evaluation and docking studies of novel benzopyranone congeners for their expected activity as anti-inflammatory, analgesic and antipyretic agents. Bioorganic & medicinal chemistry, 2009, Jul-15, Volume: 17, Issue:14 Topics: Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzopyrans; Catalytic D	2009
Discovery of benzo[g]indol-3-carboxylates as potent inhibitors of microsomal prostaglandin E(2) synthase-1. Bioorganic & medicinal chemistry, 2009, Dec-01, Volume: 17, Issue:23 Topics: Animals; Anti-Inflammatory Agents; Carboxylic Acids; Cell Line, Tumor; Edema; Enzyme Inhibitors; Hum	2009
Synthesis and biological evaluation of novel pyrazolyl-2,4-thiazolidinediones as anti-inflammatory and neuroprotective agents. Bioorganic & medicinal chemistry, 2010, Mar-01, Volume: 18, Issue:5 Topics: Animals; Anti-Inflammatory Agents; Cell Line, Tumor; Cyclooxygenase 1; Cyclooxygenase 2; Edema; Gran	2010
Synthesis and pharmacological evaluation of pyrazine N-acylhydrazone derivatives designed as novel analgesic and anti-inflammatory drug candidates. Bioorganic & medicinal chemistry, 2010, Jul-15, Volume: 18, Issue:14 Topics: Analgesics; Animals; Anti-Inflammatory Agents; Arthritis; Ear; Edema; Female; Freund's Adjuvant; Hyd	2010
Synthesis and biological evaluation of some thiazolylpyrazole derivatives as dual anti-inflammatory antimicrobial agents. European journal of medicinal chemistry, 2010, Volume: 45, Issue:12 Topics: Animals; Anti-Bacterial Agents; Candida albicans; Carrageenan; Catalytic Domain; Cotton Fiber; Cyclo	2010
Investigations on cytotoxicity and anti-inflammatory potency of licofelone derivatives. European journal of medicinal chemistry, 2011, Volume: 46, Issue:3 Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell S	2011
Synthesis and biological evaluation of 2,5-disubstituted 1,3,4-oxadiazole derivatives with both COX and LOX inhibitory activity. Journal of enzyme inhibition and medicinal chemistry, 2011, Volume: 26, Issue:6 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Edema; Enzyme Inhibitors; Lipid Perox	2011
Synthesis, anti-inflammatory activity and COX-1/COX-2 inhibition of novel substituted cyclic imides. Part 1: Molecular docking study. European journal of medicinal chemistry, 2011, Volume: 46, Issue:5 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Crystallography, X-Ray; Cyclooxygenas	2011
Design, synthesis, and biological evaluation of substituted hydrazone and pyrazole derivatives as selective COX-2 inhibitors: Molecular docking study. Bioorganic & medicinal chemistry, 2011, Jun-01, Volume: 19, Issue:11 Topics: Animals; Anti-Inflammatory Agents; Binding Sites; Computer Simulation; Cyclooxygenase 1; Cyclooxygen	2011
Analogue-based design, synthesis and molecular docking analysis of 2,3-diaryl quinazolinones as non-ulcerogenic anti-inflammatory agents. Bioorganic & medicinal chemistry, 2011, Aug-01, Volume: 19, Issue:15 Topics: Animals; Anti-Inflammatory Agents; Carrageenan; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase I	2011
Novel analgesic/anti-inflammatory agents: diarylpyrrole acetic esters endowed with nitric oxide releasing properties. Journal of medicinal chemistry, 2011, Nov-24, Volume: 54, Issue:22 Topics: Acetates; Animals; Cell Line; Constriction, Pathologic; Cyclooxygenase 2 Inhibitors; Edema; Esters;	2011
Synthesis and biological evaluation of some new 2-pyrazolines bearing benzene sulfonamide moiety as potential anti-inflammatory and anti-cancer agents. European journal of medicinal chemistry, 2011, Volume: 46, Issue:12 Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Benzene; Cell Line, Tumor; Cyclooxygenase	2011
Fragment-based design, docking, synthesis, biological evaluation and structure-activity relationships of 2-benzo/benzisothiazolimino-5-aryliden-4-thiazolidinones as cycloxygenase/lipoxygenase inhibitors. European journal of medicinal chemistry, 2012, Volume: 47, Issue:1 Topics: Animals; Anti-Inflammatory Agents; Catalytic Domain; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygen	2012
Synthesis of novel 2-mercapto benzothiazole and 1,2,3-triazole based bis-heterocycles: their anti-inflammatory and anti-nociceptive activities. European journal of medicinal chemistry, 2012, Volume: 49 Topics: Analgesics; Animals; Anti-Inflammatory Agents; Benzothiazoles; Click Chemistry; Cyclooxygenase Inhib	2012
Synthesis and biological evaluation of derivatives of 2-{2-fluoro-4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid: nonsteroidal anti-inflammatory drugs with low gastric ulcerogenic activity. Journal of medicinal chemistry, 2012, Jun-14, Volume: 55, Issue:11 Topics: Aniline Compounds; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cyclooxygenase 1;	2012
New quinazolinone-pyrimidine hybrids: synthesis, anti-inflammatory, and ulcerogenicity studies. European journal of medicinal chemistry, 2012, Volume: 53 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Chemistry Techniques, Synthetic; Edema; Female; Ma	2012
New pyrimido[5,4-e]pyrrolo[1,2-c]pyrimidines: synthesis, 2D-QSAR, anti-inflammatory, analgesic and ulcerogenicity studies. European journal of medicinal chemistry, 2012, Volume: 55 Topics: Analgesics; Animals; Anti-Inflammatory Agents; Chemistry Techniques, Synthetic; Cyclooxygenase 1; Cy	2012
Novel 3-substituted-1-aryl-5-phenyl-6-anilinopyrazolo[3,4-d]pyrimidin-4-ones: docking, synthesis and pharmacological evaluation as a potential anti-inflammatory agents. Bioorganic & medicinal chemistry letters, 2012, Nov-01, Volume: 22, Issue:21 Topics: Animals; Anti-Inflammatory Agents; Celecoxib; Diclofenac; Dose-Response Relationship, Drug; Edema; M	2012
Analogue-based design, synthesis and docking of non-steroidal anti-inflammatory agents. Part 2: methyl sulfanyl/methyl sulfonyl substituted 2,3-diaryl-2,3-dihydro-1H-quinazolin-4-ones. Bioorganic & medicinal chemistry, 2012, Dec-15, Volume: 20, Issue:24 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Drug	2012
Molecular design, synthesis and biological evaluation of cyclic imides bearing benzenesulfonamide fragment as potential COX-2 inhibitors. Part 2. Bioorganic & medicinal chemistry letters, 2013, May-01, Volume: 23, Issue:9 Topics: Animals; Anti-Inflammatory Agents; Benzenesulfonamides; Binding Sites; Catalytic Domain; Cyclization	2013
Synthesis of novel 1,2,3-triazole based benzoxazolinones: their TNF-α based molecular docking with in-vivo anti-inflammatory, antinociceptive activities and ulcerogenic risk evaluation. European journal of medicinal chemistry, 2013, Volume: 70 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzoxazoles; Carrageenan; Cyclooxygenase 2; Cyclo	2013
Synthesis, docking simulation, biological evaluations and 3D-QSAR study of 5-Aryl-6-(4-methylsulfonyl)-3-(metylthio)-1,2,4-triazine as selective cyclooxygenase-2 inhibitors. Bioorganic & medicinal chemistry, 2014, Jan-15, Volume: 22, Issue:2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cyclooxygenase 2; Cyclooxygenase 2 In	2014
Enhancing the pharmacodynamic profile of a class of selective COX-2 inhibiting nitric oxide donors. Bioorganic & medicinal chemistry, 2014, Jan-15, Volume: 22, Issue:2 Topics: Acetic Acid; Amides; Animals; Carrageenan; Cell Line; Constriction, Pathologic; Cyclooxygenase 2; Cy	2014
3D QSAR studies based in silico screening of 4,5,6-triphenyl-1,2,3,4-tetrahydropyrimidine analogs for anti-inflammatory activity. European journal of medicinal chemistry, 2014, Feb-12, Volume: 73 Topics: Animals; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Drug Design; Edema; Female; Male; Mode	2014
Synthesis and biological evaluation of new pyrazolone-pyridazine conjugates as anti-inflammatory and analgesic agents. Bioorganic & medicinal chemistry, 2014, Apr-01, Volume: 22, Issue:7 Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cyclooxygenase 1; Cycloox	2014
1-(4-Methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-1H-1,2,4-triazole-3-carboxamides: synthesis, molecular modeling, evaluation of their anti-inflammatory activity and ulcerogenicity. European journal of medicinal chemistry, 2014, Apr-22, Volume: 77 Topics: Animals; Anisoles; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cyclooxygenase 1; Cyclooxyg	2014
Synthesis and biologic evaluation of substituted 5-methyl-2-phenyl-1H-pyrazol-3(2H)-one derivatives as selective COX-2 inhibitors: molecular docking study. Chemical biology & drug design, 2014, Volume: 84, Issue:4 Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Binding Sites; Carrageenan; Catalytic Domain; Cyclo	2014
Suppression of inflammatory responses by handelin, a guaianolide dimer from Chrysanthemum boreale, via downregulation of NF-κB signaling and pro-inflammatory cytokine production. Journal of natural products, 2014, Apr-25, Volume: 77, Issue:4 Topics: Animals; Anti-Inflammatory Agents; Chrysanthemum; Cyclooxygenase 2; Cytokines; Dinoprostone; Down-Re	2014
Synthesis, molecular docking, and biological evaluation of some novel hydrazones and pyrazole derivatives as anti-inflammatory agents. Chemical biology & drug design, 2014, Volume: 84, Issue:4 Topics: Animals; Anti-Inflammatory Agents; Binding Sites; Carrageenan; Catalytic Domain; Cyclooxygenase 1; C	2014
Synthesis, pharmacological screening and in silico studies of new class of Diclofenac analogues as a promising anti-inflammatory agents. Bioorganic & medicinal chemistry, 2014, May-15, Volume: 22, Issue:10 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Computer Simulation; Cyclooxygenase 1	2014
Synthesis of novel 2-mercaptobenzoxazole based 1,2,3-triazoles as inhibitors of proinflammatory cytokines and suppressors of COX-2 gene expression. European journal of medicinal chemistry, 2014, Jun-23, Volume: 81 Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzoxazoles; Cyclooxygenase 2; Cycloo	2014
Potent, orally available, selective COX-2 inhibitors based on 2-imidazoline core. European journal of medicinal chemistry, 2014, Sep-12, Volume: 84 Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biological Availability; Car	2014
Synthesis, biological evaluation and docking analysis of 3-methyl-1-phenylchromeno[4,3-c]pyrazol-4(1H)-ones as potential cyclooxygenase-2 (COX-2) inhibitors. Bioorganic & medicinal chemistry letters, 2014, Oct-01, Volume: 24, Issue:19 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Coumarins; Cyclooxygenase 2; Cyclooxy	2014
Synthesis of new 1-(4-methane(amino)sulfonylphenyl)-5-(4-substituted-aminomethylphenyl)-3-trifluoromethyl-1H-pyrazoles: a search for novel nitric oxide donor anti-inflammatory agents. Bioorganic & medicinal chemistry letters, 2014, Nov-01, Volume: 24, Issue:21 Topics: Animals; Anti-Inflammatory Agents; Carrageenan; Celecoxib; Edema; Inflammation; Nitric Oxide; Nitric	2014
Synthesis and evaluation of pyrazolines bearing benzothiazole as anti-inflammatory agents. Bioorganic & medicinal chemistry, 2014, Nov-01, Volume: 22, Issue:21 Topics: Animals; Anti-Inflammatory Agents; Benzothiazoles; Binding Sites; Carrageenan; Catalytic Domain; Cel	2014
Structure-based design of phthalimide derivatives as potential cyclooxygenase-2 (COX-2) inhibitors: anti-inflammatory and analgesic activities. European journal of medicinal chemistry, 2015, Mar-06, Volume: 92 Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cyclooxygenase 2 Inhibito	2015
Environmentally benign synthesis, molecular properties prediction and anti-inflammatory activity of novel isoxazolo[5,4-d]isoxazol-3-yl-aryl-methanones via vinylogous Henry nitroaldol adducts as synthons. Bioorganic & medicinal chemistry letters, 2015, Apr-01, Volume: 25, Issue:7 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cyclooxygenase 1; Cyclooxygenase 2; C	2015
Regioselectively controlled synthesis of 3(5)-(trifluoromethyl)pyrazolylbenzenesulfonamides and their effects on a pathological pain model in mice. European journal of medicinal chemistry, 2015, Sep-18, Volume: 102 Topics: Animals; Celecoxib; Disease Models, Animal; Edema; Hydrocarbons, Fluorinated; Hyperalgesia; Male; Mi	2015
Synthesis, biological evaluation and docking study of maleimide derivatives bearing benzenesulfonamide as selective COX-2 inhibitors and anti-inflammatory agents. Bioorganic & medicinal chemistry, 2015, Sep-01, Volume: 23, Issue:17 Topics: Animals; Anti-Inflammatory Agents; Benzenesulfonamides; Carrageenan; Cyclooxygenase 1; Cyclooxygenas	2015
Synthesis, cyclooxygenase inhibition, anti-inflammatory evaluation and ulcerogenic liability of novel triarylpyrazoline derivatives as selective COX-2 inhibitors. Bioorganic & medicinal chemistry letters, 2015, Dec-15, Volume: 25, Issue:24 Topics: Animals; Anti-Inflammatory Agents; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 I	2015
Design, synthesis and biological screening of new 4-thiazolidinone derivatives with promising COX-2 selectivity, anti-inflammatory activity and gastric safety profile. Bioorganic chemistry, 2016, Volume: 64 Topics: Animals; Anti-Inflammatory Agents; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 I	2016
Synthesis, anti-inflammatory, ulcerogenic and cyclooxygenase activities of indenopyrimidine derivatives. Bioorganic & medicinal chemistry letters, 2016, Feb-01, Volume: 26, Issue:3 Topics: Animals; Anti-Inflammatory Agents; Anti-Ulcer Agents; Binding Sites; Carrageenan; Catalytic Domain;	2016
Synthesis, anti-inflammatory, analgesic and COX-1/2 inhibition activities of anilides based on 5,5-diphenylimidazolidine-2,4-dione scaffold: Molecular docking studies. European journal of medicinal chemistry, 2016, Jun-10, Volume: 115 Topics: Analgesics; Anilides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cyclooxygenase	2016
Synthesis of phenylpiperazine derivatives of 1,4-benzodioxan as selective COX-2 inhibitors and anti-inflammatory agents. Bioorganic & medicinal chemistry, 2016, 11-01, Volume: 24, Issue:21 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Catalytic Domain; Cyclooxygenase 2; C	2016
Design, synthesis, evaluation and molecular modelling studies of some novel 5,6-diphenyl-1,2,4-triazin-3(2H)-ones bearing five-member heterocyclic moieties as potential COX-2 inhibitors: A hybrid pharmacophore approach. Bioorganic chemistry, 2016, Volume: 69 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cyclooxygenase 2; Cyclooxygenase 2 In	2016
Development of CXCR4 modulators by virtual HTS of a novel amide-sulfamide compound library. European journal of medicinal chemistry, 2017, Jan-27, Volume: 126 Topics: Amides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chemokine CXCL12; Drug Design; Drug Evalua	2017
In vivo anti-inflammatory activity and docking study of newly synthesized benzimidazole derivatives bearing oxadiazole and morpholine rings. Bioorganic chemistry, 2017, Volume: 70 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzimidazoles; Cyclooxygenase 2 Inhibitors; Edema	2017
Design, synthesis, biological evaluation, and molecular docking of chalcone derivatives as anti-inflammatory agents. Bioorganic & medicinal chemistry letters, 2017, 02-01, Volume: 27, Issue:3 Topics: Animals; Anti-Inflammatory Agents; Binding Sites; Chalcone; Cyclooxygenase 2; Drug Design; Edema; In	2017
Synthesis, molecular docking and biological evaluation of some newer 2-substituted-4-(benzo[d][1,3]dioxol-5-yl)-6-phenylpyridazin-3(2H)-ones as potential anti-inflammatory and analgesic agents. Bioorganic chemistry, 2017, Volume: 71 Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Platelets; Carrageenan; Cyclooxy	2017
Novel 2-phenyl-4,5,6,7-tetrahydro[b]benzothiophene analogues as selective COX-2 inhibitors: Design, synthesis, anti-inflammatory evaluation, and molecular docking studies. Bioorganic & medicinal chemistry letters, 2017, 04-15, Volume: 27, Issue:8 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cyclooxygenase 2 Inhibitors; Drug Des	2017
New hybrid molecules combining benzothiophene or benzofuran with rhodanine as dual COX-1/2 and 5-LOX inhibitors: Synthesis, biological evaluation and docking study. Bioorganic chemistry, 2017, Volume: 72 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 5-Lipoxygenase; Benzofurans; Catalyti	2017
Synthesis, potential anti-inflammatory and analgesic activities study of (S)-N-substituted-1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxamides. Bioorganic & medicinal chemistry letters, 2017, 08-01, Volume: 27, Issue:15 Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 1; Cyclooxygenase 2; Cy	2017
New arylpyrazoline-coumarins: Synthesis and anti-inflammatory activity. European journal of medicinal chemistry, 2017, Sep-29, Volume: 138 Topics: Animals; Ankle Joint; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cell Survival; Cells, Cu	2017
Design, synthesis, and biological evaluation of some novel indolizine derivatives as dual cyclooxygenase and lipoxygenase inhibitor for anti-inflammatory activity. Bioorganic & medicinal chemistry, 2017, 08-15, Volume: 25, Issue:16 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Carrageenan; Cyclooxygenase Inhi	2017
Synthesis and biological evaluations of new nitric oxide-anti-inflammatory drug hybrids. Bioorganic & medicinal chemistry letters, 2017, 09-15, Volume: 27, Issue:18 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Dose-Response Relationship, Drug; Ede	2017
Synthesis, biological evaluation and docking study of a new series of di-substituted benzoxazole derivatives as selective COX-2 inhibitors and anti-inflammatory agents. Bioorganic & medicinal chemistry, 2018, 02-15, Volume: 26, Issue:4 Topics: Animals; Anti-Inflammatory Agents; Benzoxazoles; Binding Sites; Catalytic Domain; Cattle; Cyclooxyge	2018
Synthesis and biological properties of aryl methyl sulfones. Bioorganic & medicinal chemistry, 2018, 08-07, Volume: 26, Issue:14 Topics: Acetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Carrageenan; Dimet	2018
Synthesis, in vitro and in vivo biological evaluation, COX-1/2 inhibition and molecular docking study of indole-N-acylhydrazone derivatives. Bioorganic & medicinal chemistry, 2018, 11-01, Volume: 26, Issue:20 Topics: Acylation; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cell Line; Cyclooxygenase	2018
Synthesis and biological evaluation of pyridazinone derivatives as selective COX-2 inhibitors and potential anti-inflammatory agents. European journal of medicinal chemistry, 2019, Jun-01, Volume: 171 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cyclooxygenase 2; Cyclooxygenase 2 In	2019
Cyclic enaminone as new chemotype for selective cyclooxygenase-2 inhibitory, anti-inflammatory, and analgesic activities. European journal of medicinal chemistry, 2019, Nov-15, Volume: 182 Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Carrageenan; Cyclooxygen	2019
Design, synthesis, in-vitro, in-vivo and in-silico studies of pyrrolidine-2,5-dione derivatives as multitarget anti-inflammatory agents. European journal of medicinal chemistry, 2020, Jan-15, Volume: 186 Topics: Albumins; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 5-Lipoxygenase; Carrageenan	2020
Novel class of benzimidazole-thiazole hybrids: The privileged scaffolds of potent anti-inflammatory activity with dual inhibition of cyclooxygenase and 15-lipoxygenase enzymes. Bioorganic & medicinal chemistry, 2020, 04-01, Volume: 28, Issue:7 Topics: Animals; Anti-Inflammatory Agents; Arachidonate 15-Lipoxygenase; Benzimidazoles; Carrageenan; Cycloo	2020
Synthesis and evaluations of selective COX-2 inhibitory effects: Benzo[d]thiazol analogs. Bioorganic & medicinal chemistry letters, 2020, 09-01, Volume: 30, Issue:17 Topics: Analgesics; Animals; Anti-Inflammatory Agents; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2	2020
Molecular docking and synthesis of caffeic acid analogous and its anti-inflammatory, analgesic and ulcerogenic studies. Bioorganic & medicinal chemistry letters, 2021, 02-01, Volume: 33 Topics: Acetic Acid; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Caffeic Acids; Carrageena	2021
Investigations on substituted (2-aminothiazol-5-yl)(imidazo[1,2-a]pyridin-3-yl)methanones for the treatment of Alzheimer's disease. Bioorganic & medicinal chemistry, 2021, 04-15, Volume: 36 Topics: Aluminum Chloride; Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dose-Respons	2021
Design, Synthesis, and Activity Evaluation of Stereoconfigured Tartarate Derivatives as Potential Anti-inflammatory Agents Journal of medicinal chemistry, 2021, 07-08, Volume: 64, Issue:13 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cyclooxygenase 2; Cyclooxygenase 2 In	2021
Synthesis and computational studies of novel fused pyrimidinones as a promising scaffold with analgesic, anti-inflammatory and COX inhibitory potential. European journal of medicinal chemistry, 2021, Nov-15, Volume: 224 Topics: Analgesics; Animals; Anti-Inflammatory Agents; Behavior, Animal; Cyclooxygenase 1; Cyclooxygenase 2;	2021
Anti-inflammatory, ulcerogenic and platelet activation evaluation of novel 1,4-diaryl-1,2,3-triazole neolignan-celecoxib hybrids. Bioorganic chemistry, 2022, Volume: 119 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Carrageenan; Celecoxib; Dose-Re	2022
Design, synthesis, and pharmacological evaluation of novel and selective COX-2 inhibitors based on celecoxib scaffold supported with in vivo anti-inflammatory activity, ulcerogenic liability, ADME profiling and docking study. Bioorganic chemistry, 2022, Volume: 120 Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cycl	2022
New tilomisole-based benzimidazothiazole derivatives as anti-inflammatory agents: Synthesis, in vivo, in vitro evaluation, and in silico studies. Bioorganic chemistry, 2022, Volume: 120 Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Benzimidazoles; Celecoxi	2022
Improvement After Celecoxib Treatment in Patients with Thalamic Hemorrhage - A Case Report. Acta neurologica Taiwanica, 2022, Dec-30, Volume: 31(4) Topics: Brain Edema; Celecoxib; Cerebral Hemorrhage; Edema; Hematoma; Humans	2022
Nonacidic thiophene-based derivatives as potential analgesic and design, synthesis, biological evaluation, and metabolic stability study. Drug development research, 2022, Volume: 83, Issue:8 Topics: Analgesics; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; C	2022
Novel 1,3-diaryl pyrazole derivatives bearing methylsulfonyl moiety: Design, synthesis, molecular docking and dynamics, with dual activities as anti-inflammatory and anticancer agents through selectively targeting COX-2. Bioorganic chemistry, 2022, Volume: 129 Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhib	2022
EXPERIMENTAL RESEARCH OF THE EFFECT OF COXIBS ON THE CERULOPLASMIN LEVEL IN RAT SERUM ON THE FORMALIN-INDUCED EDEMA MODEL. Wiadomosci lekarskie (Warsaw, Poland : 1960), 2022, Volume: 75, Issue:9 pt 1 Topics: Animals; Anti-Inflammatory Agents; Benzenesulfonamides; Celecoxib; Ceruloplasmin; Cyclooxygenase 2 I	2022
Design, synthesis, and biological investigation of oxadiazolyl, thiadiazolyl, and pyrimidinyl linked antipyrine derivatives as potential non-acidic anti-inflammatory agents. Journal of enzyme inhibition and medicinal chemistry, 2023, Volume: 38, Issue:1 Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Celecoxib; Cyclooxyge	2023
1,4-Diaryl-1,2,3-triazole neolignan-celecoxib hybrids inhibit experimental arthritis induced by zymosan. Inflammopharmacology, 2023, Volume: 31, Issue:6 Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Celecoxib; Edema;	2023
New substituted pyrazole derivatives targeting COXs as potential safe anti-inflammatory agents. Future medicinal chemistry, 2019, Volume: 11, Issue:15 Topics: Animals; Anti-Inflammatory Agents; Binding Sites; Catalytic Domain; Celecoxib; Cyclooxygenase 1; Cyc	2019
Antinociceptive and anti-inflammatory effects of 4-(arylchalcogenyl)-1H-pyrazoles containing selenium or sulfur. Pharmacological reports : PR, 2020, Volume: 72, Issue:1 Topics: Analgesics; Animals; Anti-Inflammatory Agents; Celecoxib; Disease Models, Animal; Dose-Response Rela	2020
Synthesis and biological evaluation of pyrazolone analogues as potential anti-inflammatory agents targeting cyclooxygenases and 5-lipoxygenase. Archiv der Pharmazie, 2020, Volume: 353, Issue:4 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 5-Lipoxygenase; Carrageenan; Celecoxi	2020
Synthesis of novel N-substitutedphenyl-6-oxo-3-phenylpyridazine derivatives as cyclooxygenase-2 inhibitors. Drug development research, 2020, Volume: 81, Issue:5 Topics: Animals; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Edema; Female;	2020
Anti-inflammatory and analgesic effect of LD-RT and some novel thiadiazole derivatives through COX-2 inhibition. Archiv der Pharmazie, 2020, Volume: 353, Issue:10 Topics: Analgesics; Animals; Anti-Inflammatory Agents; Celecoxib; Combined Modality Therapy; Cyclooxygenase	2020
Synthesis of Hydroxybenzofuranyl-pyrazolyl and Hydroxyphenyl-pyrazolyl Chalcones and Their Corresponding Pyrazoline Derivatives as COX Inhibitors, Anti-inflammatory and Gastroprotective Agents. Chemical & pharmaceutical bulletin, 2020, Volume: 68, Issue:8 Topics: Animals; Anti-Inflammatory Agents; Benzenesulfonamides; Binding Sites; Catalytic Domain; Celecoxib;	2020
Design, synthesis and molecular modeling of novel aryl carboximidamides and 3-aryl-1,2,4-oxadiazoles derived from indomethacin as potent anti-inflammatory iNOS/PGE2 inhibitors. Bioorganic chemistry, 2020, Volume: 105 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Celecoxib; Dinoprostone; Dose-Respons	2020
Anti-inflammatory activity of novel thiosemicarbazone compounds indole-based as COX inhibitors. Pharmacological reports : PR, 2021, Volume: 73, Issue:3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Celecoxib; Cell Proliferation; Cycloo	2021
Non-ulcerogenic pyrazolyl 2-hydroxychalcones and pyrazolylpyrazolines derived from naturally existing furochromone (khellin): semi-synthesis, docking study and anti-inflammatory activity. Natural product research, 2022, Volume: 36, Issue:10 Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenas	2022
The effective interplay of (non-) selective NSAIDs with neostigmine in animal models of analgesia and inflammation. BMC pharmacology & toxicology, 2021, 05-01, Volume: 22, Issue:1 Topics: Acetic Acid; Analgesia; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Dic	2021
Design and Synthesis of Novel Pyrazole-Substituted Different Nitrogenous Heterocyclic Ring Systems as Potential Anti-Inflammatory Agents. Molecules (Basel, Switzerland), 2017, Mar-24, Volume: 22, Issue:4 Topics: Animals; Anti-Inflammatory Agents; Carrageenan; Celecoxib; Cyclooxygenase Inhibitors; Drug Design; E	2017
Liquid Crystalline Systems Based on Glyceryl Monooleate and Penetration Enhancers for Skin Delivery of Celecoxib: Characterization, In Vitro Drug Release, and In Vivo Studies. Journal of pharmaceutical sciences, 2018, Volume: 107, Issue:3 Topics: Administration, Cutaneous; Animals; Anti-Inflammatory Agents; Celecoxib; Chemistry, Pharmaceutical;	2018
Copaiba oil enhances in vitro/in vivo cutaneous permeability and in vivo anti-inflammatory effect of celecoxib. The Journal of pharmacy and pharmacology, 2018, Volume: 70, Issue:7 Topics: Animals; Anti-Inflammatory Agents; Celecoxib; Diclofenac; Diethylamines; Drug Synergism; Edema; Faba	2018
Design, synthesis and evaluation of some pyrazolo[3,4-d]pyrimidine derivatives bearing thiazolidinone moiety as anti-inflammatory agents. Bioorganic chemistry, 2018, Volume: 80 Topics: Animals; Anti-Inflammatory Agents; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 I	2018
Synthesis, Characterization, and Biodistribution of Quantum Dot-Celecoxib Conjugate in Mouse Paw Edema Model. Oxidative medicine and cellular longevity, 2018, Volume: 2018 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Disease Models, Animal; Edema; Magnetic	2018
Synthesis, In-vivo and In-vitro Anti-inflammatory Evaluation of some Novel Coumarin Derivatives. Anti-inflammatory & anti-allergy agents in medicinal chemistry, 2018, Volume: 17, Issue:2 Topics: Albumins; Animals; Anti-Inflammatory Agents; Celecoxib; Coumarins; Disease Models, Animal; Dose-Resp	2018
Formulation development of self-nanoemulsifying drug delivery system of celecoxib for the management of oral cavity inflammation. Journal of liposome research, 2019, Volume: 29, Issue:2 Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Camelus; Carrageenan; Celeco	2019
Biological Screening of Novel Structural Analog of Celecoxib as Potential Anti-Inflammatory and Analgesic Agent. Medicina (Kaunas, Lithuania), 2019, Apr-05, Volume: 55, Issue:4 Topics: Analgesics; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal	2019
Selective cyclooxygenase inhibition and ulcerogenic liability of some newly prepared anti-inflammatory agents having thiazolo[4,5-d]pyrimidine scaffold. Bioorganic chemistry, 2019, Volume: 88 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhi	2019
Synthesis, modeling and biological evaluation of some pyrazolo[3,4-d]pyrimidinones and pyrazolo[4,3-e][1,2,4]triazolo[4,3-a]pyrimidinones as anti-inflammatory agents. Bioorganic chemistry, 2019, Volume: 90 Topics: Animals; Anti-Inflammatory Agents; Binding Sites; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhi	2019
Olive-Derived Hydroxytyrosol Shows Anti-inflammatory Effect without Gastric Damage in Rats. Biological & pharmaceutical bulletin, 2019, Volume: 42, Issue:7 Topics: Animals; Aspirin; Carrageenan; Celecoxib; Cyclooxygenase 2 Inhibitors; Dinoprostone; Edema; Gastric	2019
Synthesis and characterization of celecoxib derivatives as possible anti-inflammatory, analgesic, antioxidant, anticancer and anti-HCV agents. Molecules (Basel, Switzerland), 2013, Mar-21, Volume: 18, Issue:3 Topics: Animals; Antineoplastic Agents; Antioxidants; Antiviral Agents; Catalytic Domain; Celecoxib; Cell Li	2013
In vitro and in vivo influence of penetration enhancers in the topical application of celecoxib. Drug development and industrial pharmacy, 2014, Volume: 40, Issue:9 Topics: Administration, Cutaneous; Animals; Anti-Inflammatory Agents; Celecoxib; Chemistry, Pharmaceutical;	2014
Synergistic effects of celecoxib and bupropion in a model of chronic inflammation-related depression in mice. PloS one, 2013, Volume: 8, Issue:9 Topics: Analgesics; Animals; Anti-Inflammatory Agents; Antidepressive Agents; Behavior, Animal; Brain-Derive	2013
Liposomal gels for site-specific, sustained delivery of celecoxib: in vitro and in vivo evaluation. Drug development research, 2014, Volume: 75, Issue:4 Topics: Administration, Cutaneous; Animals; Anti-Inflammatory Agents; Celecoxib; Cholesterol; Drug Compoundi	2014
Methylprednisolone reduces pain and decreases knee swelling in the first 24 h after fast-track unicompartmental knee arthroplasty. Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA, 2017, Volume: 25, Issue:1 Topics: Acetaminophen; Aged; Aged, 80 and over; Amines; Analgesics; Anti-Inflammatory Agents; Arthroplasty,	2017
Methylprednisolone reduces pain and decreases knee swelling in the first 24 h after fast-track unicompartmental knee arthroplasty. Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA, 2017, Volume: 25, Issue:1 Topics: Acetaminophen; Aged; Aged, 80 and over; Amines; Analgesics; Anti-Inflammatory Agents; Arthroplasty,	2017
Methylprednisolone reduces pain and decreases knee swelling in the first 24 h after fast-track unicompartmental knee arthroplasty. Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA, 2017, Volume: 25, Issue:1 Topics: Acetaminophen; Aged; Aged, 80 and over; Amines; Analgesics; Anti-Inflammatory Agents; Arthroplasty,	2017
Methylprednisolone reduces pain and decreases knee swelling in the first 24 h after fast-track unicompartmental knee arthroplasty. Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA, 2017, Volume: 25, Issue:1 Topics: Acetaminophen; Aged; Aged, 80 and over; Amines; Analgesics; Anti-Inflammatory Agents; Arthroplasty,	2017
Clinical trials: Glucosamine-chondroitin combo improves knee OA pain. Nature reviews. Rheumatology, 2015, Volume: 11, Issue:3 Topics: Celecoxib; Chondroitin Sulfates; Cyclooxygenase 2 Inhibitors; Edema; Female; Glucosamine; Humans; Ma	2015
Synthesis, cyclooxygenase inhibition, anti-inflammatory evaluation and ulcerogenic liability of new 1-phenylpyrazolo[3,4-d]pyrimidine derivatives. Journal of enzyme inhibition and medicinal chemistry, 2016, Volume: 31, Issue:sup2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Celecoxib; Cyclooxygenase 1; Cyclooxy	2016
Synthesis and Evaluation of Anti-inflammatory N-Substituted 3,5-Bis(2-(trifluoromethyl)benzylidene)piperidin-4-ones. ChemMedChem, 2017, 02-20, Volume: 12, Issue:4 Topics: Animals; Anti-Inflammatory Agents; Bone Marrow Cells; Carrageenan; Celecoxib; Cell Survival; Dinopro	2017
In Vitro and In Vivo Evaluation of DMSO and Azone as Penetration Enhancers for Cutaneous Application of Celecoxib. Current drug delivery, 2017, Volume: 14, Issue:7 Topics: Administration, Cutaneous; Animals; Azepines; Celecoxib; Cyclooxygenase 2 Inhibitors; Dimethyl Sulfo	2017
Etodolac attenuates mechanical allodynia in a mouse model of neuropathic pain. Journal of pharmacological sciences, 2009, Volume: 109, Issue:4 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Celecoxib; Cyclooxygenase 2 Inhibitor	2009
The importance of brain PGE2 inhibition versus paw PGE2 inhibition as a mechanism for the separation of analgesic and antipyretic effects of lornoxicam in rats with paw inflammation. The Journal of pharmacy and pharmacology, 2009, Volume: 61, Issue:5 Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Cel	2009
The analgesic and anti-inflammatory effect of WIN-34B, a new herbal formula for osteoarthritis composed of Lonicera japonica Thunb and Anemarrhena asphodeloides BUNGE in vivo. Journal of ethnopharmacology, 2010, Sep-15, Volume: 131, Issue:2 Topics: Analgesics; Anemarrhena; Animals; Anti-Inflammatory Agents; Behavior, Animal; Capillary Permeability	2010
A novel COX-2 inhibitor pyrazole derivative proven effective as an anti-inflammatory and analgesic drug. Basic & clinical pharmacology & toxicology, 2011, Volume: 108, Issue:4 Topics: Analgesics; Animals; Anti-Inflammatory Agents; Benzenesulfonamides; Carrageenan; Celecoxib; Chronic	2011
["Rheumatic pain". Joint is painfully swollen overnight]. MMW Fortschritte der Medizin, 2010, Dec-16, Volume: 152, Issue:51-52 Topics: Acute Disease; Adult; Allopurinol; Ankle Joint; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia;	2010
Synthesis and anti-inflammatory activity of celecoxib like compounds. Journal of enzyme inhibition and medicinal chemistry, 2013, Volume: 28, Issue:5 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carrageenan; Celecoxib; Cel	2013
Tulsi oil as a potential penetration enhancer for celecoxib transdermal gel formulations. Pharmaceutical development and technology, 2014, Volume: 19, Issue:1 Topics: Acrylic Resins; Administration, Cutaneous; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Car	2014
Physician-reported management of edema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension. Clinical therapeutics, 2002, Volume: 24, Issue:6 Topics: Celecoxib; Cross-Sectional Studies; Cyclooxygenase Inhibitors; Diuretics; Edema; Humans; Hypertensio	2002
Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation. British journal of pharmacology, 2002, Volume: 137, Issue:6 Topics: Animals; Carrageenan; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhib	2002
Role of endogenous glucocorticoids in hyperalgesia and edema in old arthritic rats. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2003, Volume: 36, Issue:1 Topics: Adrenalectomy; Age Factors; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal;	2003
Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation. Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2002, Volume: 51, Issue:12 Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Celecoxib;	2002
The anti-inflammatory effects of the phosphodiesterase inhibitor pentoxifylline in the rat. Pharmacological research, 2003, Volume: 47, Issue:4 Topics: Animals; Anti-Inflammatory Agents; Carrageenan; Celecoxib; Dexamethasone; Dose-Response Relationship	2003
Blood pressure control and rates of edema following the administration of the cyclooxygenase-2 specific inhibitors celecoxib versus rofecoxib in patients with systemic hypertension and osteoarthritis. The American journal of cardiology, 2003, May-15, Volume: 91, Issue:10 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celecoxib; Cycloox	2003
A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population. Clinical therapeutics, 2003, Volume: 25, Issue:2 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Costs and Cost Analysis; C	2003
Effects of valeryl salicylate, a COX-1 inhibitor, on models of acute inflammation in mice. Pharmacological research, 2003, Volume: 48, Issue:5 Topics: Acute Disease; Animals; Arachidonic Acid; Carrageenan; Celecoxib; Croton Oil; Cyclooxygenase 1; Cycl	2003
4-substituted 1,5-diarylpyrazole, analogues of celecoxib: synthesis and preliminary evaluation of biological properties. Farmaco (Societa chimica italiana : 1989), 2003, Volume: 58, Issue:9 Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Celecoxib; Cyclooxygenase	2003
Studies on the anti-inflammatory effect of fluoxetine in the rat. Pharmacological research, 2004, Volume: 49, Issue:2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Carrageenan; Celecoxib; Cyc	2004
Gastric effects of the selective cyclooxygenase-2 inhibitor, celecoxib, in the rat. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2004, Volume: 36, Issue:4 Topics: Animals; Aspirin; Carrageenan; Celecoxib; Consciousness; Cyclooxygenase Inhibitors; Edema; Gastric M	2004
Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. The Journal of rheumatology, 2004, Volume: 31, Issue:6 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Blood Pressure; Celecox	2004
Lipopolysaccharide-induced paw edema model for detection of cytokine modulating anti-inflammatory agents. International immunopharmacology, 2004, Volume: 4, Issue:7 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Celecoxib; Cells, Cultured; Disease M	2004
Reduced sulfur mustard-induced skin toxicity in cyclooxygenase-2 knockout and celecoxib-treated mice. Toxicology and applied pharmacology, 2004, Oct-01, Volume: 200, Issue:1 Topics: Animals; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase	2004
Design, synthesis, and anti-inflammatory evaluation of a series of novel amino acid-binding 1,5-diarylpyrazole derivatives. Acta pharmacologica Sinica, 2005, Volume: 26, Issue:7 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyc	2005
Effects of the celecoxib on the acute necrotizing pancreatitis in rats. Inflammation, 2004, Volume: 28, Issue:5 Topics: Animals; Celecoxib; Ceruletide; Cyclooxygenase Inhibitors; Disease Models, Animal; Edema; Glycodeoxy	2004
CC 05, a novel anti-inflammatory compound, exerts its effect by inhibition of cyclooxygenase-2 activity. European journal of pharmacology, 2005, Sep-27, Volume: 520, Issue:1-3 Topics: Animals; Anti-Inflammatory Agents; Baculoviridae; Benzenesulfonamides; Carrageenan; Celecoxib; Cyclo	2005
Pharmacological separation between peripheral and central functions of cyclooxygenase-2 with CIAA, a novel cyclooxygenase-2 inhibitor. European journal of pharmacology, 2006, Jun-06, Volume: 539, Issue:1-2 Topics: Animals; Brain; Carrageenan; Celecoxib; Chlorobenzoates; Cyclooxygenase 1; Cyclooxygenase 2; Cycloox	2006
Celecoxib decreases prostaglandin E2 concentrations in nipple aspirate fluid from high risk postmenopausal women and women with breast cancer. BMC cancer, 2006, Oct-18, Volume: 6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Body Fluids; Breast Neoplasms; Car	2006
Ligand-based design, synthesis and primary in vivo screening of pyrrole derivatives as potential tricyclic anti-inflammatory agents. Arzneimittel-Forschung, 2006, Volume: 56, Issue:11 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Carrageenan; Celecoxib; Chromato	2006
Contributions of histamine, prostanoids, and neurokinins to edema elicited by edema toxin from Bacillus anthracis. Infection and immunity, 2007, Volume: 75, Issue:4 Topics: Animals; Antigens, Bacterial; Aprepitant; Bacillus anthracis; Bacterial Toxins; Capillary Permeabili	2007
Nanostructured lipid carrier (NLC) based gel of celecoxib. International journal of pharmaceutics, 2008, Jan-04, Volume: 346, Issue:1-2 Topics: Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Carriers; Edema; Gels; In Vitro Techniques; Li	2008
Multivesicular liposomes bearing celecoxib-beta-cyclodextrin complex for transdermal delivery. Drug delivery, 2007, Volume: 14, Issue:6 Topics: Administration, Cutaneous; Animals; beta-Cyclodextrins; Carrageenan; Celecoxib; Chemistry, Pharmaceu	2007
Design, development and evaluation of novel nanoemulsion formulations for transdermal potential of celecoxib. Acta pharmaceutica (Zagreb, Croatia), 2007, Volume: 57, Issue:3 Topics: Administration, Cutaneous; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; C	2007
Pro-inflammatory effect in mice of CvL, a lectin from the marine sponge Cliona varians. Comparative biochemistry and physiology. Toxicology & pharmacology : CBP, 2008, Volume: 147, Issue:2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chemotaxis, Leukocyte; Dexamethasone; D	2008
Niosomal gel for site-specific sustained delivery of anti-arthritic drug: in vitro-in vivo evaluation. Current drug delivery, 2007, Volume: 4, Issue:4 Topics: Acrylic Resins; Administration, Cutaneous; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrage	2007
Pharmacological analysis of cyclooxygenase-1 in inflammation. Proceedings of the National Academy of Sciences of the United States of America, 1998, Oct-27, Volume: 95, Issue:22 Topics: Animals; Arthritis, Experimental; Blood Platelets; Carrageenan; Celecoxib; Cyclooxygenase 1; Cycloox	1998
Topical application of a selective cyclooxygenase inhibitor suppresses UVB mediated cutaneous inflammation. Prostaglandins & other lipid mediators, 2000, Volume: 62, Issue:4 Topics: Administration, Topical; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxy	2000
Modulation of inflammatory paw oedema by cysteamine in the rat. Pharmacological research, 2002, Volume: 45, Issue:4 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Celecoxib; Corticotropin-Releasing Ho	2002

chemdatabank.com

celecoxib and Edema

Research Excerpts

Research

Studies (178)

Authors

Clinical Trials (6)

Trial Overview

Trial Outcomes

Change From Baseline in Percent Impairment While Working Due to Osteoarthritis at Week 24 Assessed Using Work Productivity and Activity Impairment Questionnaire- Specific Health Problem (WPAI-SHP): Baseline Observation Carried Forward (BOCF)

Change From Baseline in Percent Work Time Missed Due to Osteoarthritis at Week 24 Assessed Using Work Productivity and Activity Impairment Questionnaire- Specific Health Problem (WPAI-SHP): Baseline Observation Carried Forward (BOCF)

Change From Baseline in the Percent Activity Impairment Due to Osteoarthritis at Week 24 Assessed Using Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP): Baseline Observation Carried Forward (BOCF)

Change From Baseline in the Percent Overall Work Impairment Due to Osteoarthritis at Week 24 Assessed Using Work Productivity and Activity Impairment Questionnaire- Specific Health Problem (WPAI-SHP): BOCF

Number of Participants Who Had Discontinued Study Due to Lack of Efficacy

Number of Participants With Positive Urine or Serum Pregnancy Test

Time to Discontinuation Due to Lack of Efficacy

Amount of Rescue Medication Used

Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24: Baseline Observation Carried Forward (BOCF)

Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Weeks 12, 24, 40 and 56: Last Observation Carried Forward (LOCF)

Change From Baseline in Medial Minimum Joint Space Width of the Index Knee at Week 56

Change From Baseline in Minimum Joint Space Width of the Index Hip at Week 56

Change From Baseline in Neuropathy Impairment Score (NIS) at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)

Change From Baseline in Neuropathy Impairment Score (NIS) at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Observed Data

Change From Baseline in Percent Impairment While Working Due to Osteoarthritis at Week 24 and 56 Assessed Using Work Productivity and Activity Impairment Questionnaire- Specific Health Problem (WPAI-SHP): Last Observation Carried Forward (LOCF)

Change From Baseline in Percent Work Time Missed Due to Osteoarthritis at Week 24 and 56 Assessed Using Work Productivity and Activity Impairment Questionnaire- Specific Health Problem (WPAI-SHP): Last Observation Carried Forward (LOCF)

Change From Baseline in the Patient Global Assessment (PGA) of Osteoarthritis at Week 16

Change From Baseline in the Patient Global Assessment (PGA) of Osteoarthritis at Weeks 2, 4, 8, 12 and 24: Baseline Observation Carried Forward (BOCF)

Change From Baseline in the Patient Global Assessment (PGA) of Osteoarthritis at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)

Change From Baseline in the Percent Activity Impairment Due to Osteoarthritis at Week 24 and 56 Assessed Using Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP): Last Observation Carried Forward (LOCF)

Change From Baseline in the Percent Overall Work Impairment Due to Osteoarthritis at Week 24 and 56 Assessed Using Work Productivity and Activity Impairment Questionnaire- Specific Health Problem (WPAI-SHP): LOCF

Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 16

Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Weeks 2, 4, 8, 12 and 24: Baseline Observation Carried Forward (BOCF)

Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)

Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score at Week 16

Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score at Weeks 2, 4, 8, 12 and 24: Baseline Observation Carried Forward (BOCF)

Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score at Weeks 2, 4, 8, 12, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Average Score at Weeks 2, 4, 8, 12, 16 and 24: Baseline Observation Carried Forward (BOCF)

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Average Score at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Going Up or Down Stairs at Weeks 2, 4, 8, 12, 16 and 24: Baseline Observation Carried Forward (BOCF)

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Going Up or Down Stairs at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Walking on a Flat Surface at Weeks 2, 4, 8, 12, 16 and 24: Baseline Observation Carried Forward (BOCF)

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Walking on a Flat Surface at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale Score at Weeks 2, 4, 8, 12, 16 and 24: Baseline Observation Carried Forward (BOCF)

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale Score at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)

Number of Participants With Anti-Drug Antibody (ADA) Response

Number of Participants With Cumulative Reduction From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score: Baseline Observation Carried Forward (BOCF)

Number of Participants With Cumulative Reduction From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score: Last Observation Carried Forward (LOCF)

Number of Participants With Intravenous (IV) Doses of Study Medication

Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

Percentage of Participants Who Used Rescue Medication: Last Observation Carried Forward (LOCF)

Percentage of Participants Who Used Rescue Medication: Observed Data

Percentage of Participants With at Least 30 Percent (%), 50%, 70% and 90% Reduction in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score From Baseline at Weeks 2, 4, 8, 12, 16, and 24: BOCF

Percentage of Participants With at Least 30%, 50%, 70% and 90% Reduction in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score: Last Observation Carried Forward (LOCF)

Percentage of Participants With Improvement of At Least 2 Points in Patient's Global Assessment (PGA) of Osteoarthritis at Weeks 2, 4, 8, 12, 16, and 24: Baseline Observation Carried Forward (BOCF)

Percentage of Participants With Improvement of Atleast 2 Points in Patient's Global Assessment (PGA) of Osteoarthritis at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56: Last Observation Carried Forward (LOCF)

Percentage of Participants With Outcome Measures in Rheumatology - Osteoarthritis Research Society International (OMERACT-OARSI) Response: Baseline Observation Carried Forward (BOCF)

Percentage of Participants With Outcome Measures in Rheumatology - Osteoarthritis Research Society International (OMERACT-OARSI) Response: Last Observation Carried Forward (LOCF)

Plasma Trough (Pre-dose) Concentration of Tanezumab

Consumption of Rescue Medication

Number of Participants With at Least One Adverse Events

Percentage of Participants With Response as Defined by Outcome Variables for Osteoarthritis Clinical Trials - Osteoarthritis Research Society International (OMERACT-OARSI)

Percentage of Presence of Joint Effusion

Percentage of Presence of Joint Swelling

WOMAC Pain Subscale

Health Status According to EuroQoL

Huskisson's VAS

Number of Adverse Events Defined by Relationship With Treatment

Patient's and Investigator's Global Assessment of Response to Therapy

Patient's Global Assessment (PGA) and Investigator's Global Assessment (IGA) of Disease Activity

WOMAC Function Subscale

WOMAC Stiffness Subscale

Reviews

Trials

Other Studies